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Spinocerebellar ataxia type 7 (SCA7) is a dominantly-inherited neurodegenerative disease, resulting from a CAG 
trinucleotide repeat expansion in the ataxin-7 gene. The Ataxin-7 protein is known to play a role in transcriptional 
regulation through association with cellular histone acetylation complexes, and several studies have highlighted the role 
of transcriptional dysregulation, caused by the presence of mutant Ataxin-7, in the neuronal dysfunction that precedes the 
onset of disease symptoms.   
 
This study aimed to establish patient-derived cell models of SCA7, for use in the investigation of pathogenesis (with 
particular reference to transcriptional alterations), and in the evaluation of previously-developed therapies for the disease.  
The high prevalence of SCA7 in the South African population, as a result of a founder effect, makes this disease 
particularly amenable to allele-specific RNA interference (RNAi)-based therapy.  Thus, this study also evaluated the 
feasibility of these cell models as a vehicle to test previously-developed RNAi therapeutics, using the alteration of 
expression of key transcripts as a phenotypic marker. SCA7 patient and control dermal fibroblasts were reprogrammed to 
pluripotency by retroviral transduction.  The resultant induced pluripotent stem cell (iPSC) lines were characterised with 
respect to endogenous markers of pluripotency, differentiation capacity and transgene silencing.  These cells were then 
subjected to neuronal differentiation, the success of which was confirmed by the expression of early neuronal markers.  
 
The expression levels of key transcripts, previously demonstrated to be differentially regulated in SCA7 disease models, 
were compared between SCA7 and control fibroblasts, iPSCs and iPSC-derived neurons by means of quantitative real-
time PCR.  Significant differences in expression were observed, particularly with regard to genes involved in the heat 
shock protein and ubiquitin-proteasome pathways, which have been previously implicated in SCA7 pathology.  Using 
SCA7 patient fibroblasts, this study also demonstrated that allele-specific RNAi-mediated silencing of ataxin-7 may lead 
to a degree of amelioration of the disease-associated transcriptional phenotype. 
 
The development of these novel cell models for the South African SCA7 patient cohort offers the opportunity, for the 
first time, to study the molecular basis of SCA7 in disease-relevant cell types from human patients.  The identification of 
a transcriptional phenotype in these cells provides further evidence of the central role of transcriptional regulation in the 
aetiology and pathogenesis of the disease, and may serve as a valuable marker for the evaluation of population-specific 
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Chapter 1 Introduction 
Disorders of the nervous system represent a significant proportion of the global burden of non-
communicable diseases, largely due to the trend towards aging populations (Bergen and Silberberg, 
2002).  Although traditionally believed to be the concern of developed nations, improvements in 
healthcare and increased life expectancy could soon see this phenomenon spreading to developing 
countries.  Inherited neurodegenerative diseases in particular, characterised by progressive symptoms 
and a lengthy disease course, present a significant economic and psychological burden to affected 
families (de Villiers et al., 1997).   
 
A subset of these conditions, known collectively as the polyglutamine (polyQ) diseases, have a well-
defined genetic aetiology, making them attractive targets for research and therapeutic development.  
There are currently nine known inherited polyQ diseases, including Huntington’s Disease (HD), 
dentatorubral-pallidoluysian atrophy (DRPLA), spinal bulbar muscular atrophy (SBMA), and six of 
the spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17) (Watson and Wood, 2012).  All arise from a 
common type of mutation – an expanded trinucleotide CAG repeat within the coding region of the 
disease-causing gene, which is translated into an abnormally long polyglutamine tract in the mutant 
protein (Durr, 2010).  As a result, these disorders share many features, including late onset of disease 
symptoms, anticipation, and repeat instability during vertical transmission (Watson and Wood, 
2012). 
 
The number of CAG repeats required for presentation of disease symptoms varies according to gene, 
however, many of the polyglutamine disorders share similar CAG threshold levels, such that 37- 40 
repeats in most of these conditions results in neurodegeneration (Orr and Zoghbi, 2007).   Although 













disorder to the next, most lie in the 40-60 range, with numbers extending into the hundreds 
(Rosenblatt et al., 2001; Lindblad et al., 1996).  
 
The length of the CAG repeat tract is prone to expansion from one generation to the next (Stevanin et 
al., 1998), and shows a strong correlation with both the age of onset and disease severity (Globas et 
al., 2008; Garden and La Spada, 2008; Pulst et al., 2005; Lebre and Brice, 2003).  Most polyQ 
diseases exhibit the phenomenon of “anticipation”, whereby larger expansions in successive 
generations result in earlier, more severe phenotypes, and more rapid disease progression (Lebre and 
Brice, 2003). 
 
Symptoms, including chorea, dystonia and dementia (HD), ataxia and dysarthria (SCAs and 
DRPLA), seizures (SCA17) and motor weakness (SBMA), result from the selective degeneration of 
well-defined subpopulations of neurons (Shirendeb et al., 2011; Bichelmeier et al., 2007;  Saegusa et 
al., 2007; Helmlinger et al., 2006a; Goti et al., 2004; Li and Li, 2004; Huynh et al., 2003; Yoo et al., 
2003; Cemal et al., 2002; Watase et al., 2002; La Spada et al., 2001; Burright et al., 1995).  Although 
the precise mechanisms underlying this selectivity are not yet fully understood, the identification of 
common hallmarks of pathology suggests that many, if not all, of the polyQ diseases may be 
amenable to similar therapeutic approaches.   
 
1.1 Spinocerebellar Ataxia 7 
1.1.1 Phenotype  
Spinocerebellar ataxia type 7 (SCA7) is a late-onset, dominantly-inherited polyQ neurodegenerative 
disease, the major clinical manifestations of which include cerebellar ataxia, dysarthria, dysphagia, 
exaggerated deep tendon reflexes, and progressive macular degeneration (Horton et al., 2012; Lebre 













(ADCA), it is distinct from other polyQ diseases by virtue of the presence of an ocular phenotype, 
which results in severe visual impairment, in addition to the gait and speech difficulties characteristic 
of cerebellar degeneration (Garden and La Spada, 2008; Einum et al., 2001; Mauger et al., 1999).  In 
adult-onset SCA7, cerebellar symptoms tend to precede visual impairment, while earlier-onset cases 
often present with vision loss prior to the development of ataxia (Johansson et al., 1998).  Adolescent 
cases typically progress more rapidly than adult-onset forms of the disease, with a more severe 
clinical presentation.  Infantile SCA7 on the other hand, may be seen as a phenotypically distinct, 
rapidly-progressing multisystem disorder, presenting within the first two years of life with symptoms 
including weight loss, cardiac abnormalities, motor regression, wasting, hypotonia and failure to 
thrive (Whitney et al., 2007; van de Warrenburg et al., 2001; Johansson et al., 1998). 
   
1.1.2 Genetics  
The identification of linkage to the short arm of chromosome 3 in affected families (Benomar et al., 
1995) suggested strongly that SCA7 was genetically distinct from other ADCAs.  Fine-mapping of 
the region resulted in identification of the causative gene, dubbed “ataxin-7”, at position 3p12-21.1 
(Michalik et al., 1999; Del-Favero et al., 1998; David et al., 1996).  Shortly thereafter, an unstable 
CAG repeat region was identified within exon 3 of the gene and expansion of this region was 
demonstrated to co-segregate with the disease in several affected families, confirming the causative 
nature of the CAG expansion, and allowing the molecular classification of SCA7 as a polyQ disease 
(David et al., 1997; Lindblad et al., 1996).      
 
Non-pathogenic ataxin-7 alleles contain between 4 and 35 CAG repeats, with the most common 
allele being (CAG)10  (David et al., 1998; Johansson et al., 1998), although this may differ according 
to population group (Alluri et al., 2007). Alleles in the 28-35 CAG repeat range are classified as 
“mutable” or “expansion prone” and may undergo further expansion into the pathogenic range 













appearance of disease in the offspring of asymptomatic carriers (Lebre and Brice, 2003; Stevanin et 
al., 1998).  Pathological alleles range in length from 36 to over 400 repeats (Lebre and Brice, 2003; 
Einum et al., 2001), although the lower threshold is not precisely defined (Nardacchione et al., 
1999). 
 
The CAG repeat tract in ataxin-7 shows the greatest propensity for expansion upon vertical 
transmission of any of the polyQ disorders, particularly through the paternal line, indicating a 
predisposition towards instability during spermatogenesis (Monckton et al., 1999).  This bias towards 
expansion via paternal transmission is not unique to SCA7 (Mandel, 1994; Trottier et al., 1994), and 
may reflect the high mitotic turnover of spermatocytes in comparison to oocytes (Yoon et al., 2003).  
However, the extreme cases of instability of the ataxin-7 CAG repeat greatly surpass those of the 
other polyQ disease genes, with a report of a (CAG)49 allele expanding to (CAG)460 in a single 
generation (van de Warrenburg et al., 2001).  This may be due, at least in part, to the genomic 
context within which the ataxin-7 expansion is situated – a theory supported by findings in SCA7 
mice, in which removal of ataxin-7 flanking sequences reduces the instability in transmission to 
offspring (Libby et al., 2003); while mutations in binding sites for the regulatory factor CTCF, 
situated in close proximity to many genomic repeat sequences, significantly enhance the instability 
of the ataxin-7 CAG repeat (Libby et al., 2008). 
 
1.1.3 Pathology  
The neuropathology of SCA7 (namely, the marked degeneration of cerebellum and retina in affected 
individuals) shows a strong correlation with the disease phenotype.  Cerebellar atrophy is often 
preceded by significant atrophy of the pons, a feature characteristic of SCA7 (Fig. 1a-c) (Garden and 
La Spada, 2008; Bang et al., 2004; Michalik et al., 2003).  Within the cerebellum, SCA7 patients 













granule layer (Fig. 1g-h) (Garden and La Spada, 2008; Einum et al., 2001).  In the brainstem, atrophy 
of the olivocerebellar, spinocerebellar and pyramidal tracts has been observed, with the inferior olive 
undergoing substantial neuronal loss together with gliosis. Additional pathologies include neuronal 
loss in the brainstem cranial nerve motor nuclei, demyelination of pyramidal tracts and posterior 
columns of the spinal cord, and, in some patients, degeneration of the substantia nigra, globus 
pallidus and subthalamic nucleus (Garden and La Spada, 2008). 
 
A pathogenic hallmark of SCA7 shared by many of the polyQ diseases is the formation of nuclear 
inclusions (NIs), aggregates of mutant ataxin-7 which sequester numerous key proteins, including 
ubiquitin-proteasome components and transcription factors (Zander et al., 2001; Chai et al., 1999a; 
Chai et al., 1999b; García-Mata et al., 1999; Cummings et al., 1998a).  The role of these NIs in the 
molecular pathogenesis of the disease remains controversial, however, particularly since their 
presence is not limited to vulnerable neuronal populations, but extends to unaffected areas of the 
brain (for example, the cerebral cortex) (Lindenberg et al., 2000; Holmberg et al., 1998). 
 
The retinal phenotype in SCA7 results primarily from the dysfunction of the cone, and later, rod 
photoreceptors, hence its classification as a cone-rod dystrophy (Hugosson et al., 2009). The initial 
impairment of central vision, caused by dysfunction of cone cells in the foveal region, is followed by 
the progressive dysfunction of rods and cones throughout the retina, leading ultimately to total 
































Figure 1 Cerebellar and retinal pathology in SCA7. (a-c) Magnetic resonance imaging of a control individual (a) and 
two SCA7 patients (b), (c). The patient depicted in (b) has severe cerebellar atrophy (Cb), while the pons (P) is almost 
completely spared. The patient in (c) shows severe atrophy of the cerebellum, as well as marked atrophy of the pons (P). 
(d-f) Fundoscopy images of a control individual (d) and two SCA7 patients (e, f). In the control individual, the macula 
(black arrow) and optic disk (arrowhead) appear normal, and vasculature (white arrow) is well-developed (d). By 
contrast, the retina of patient (e) displays macular atrophy (black arrow), very pale optic disk (arrowhead), and poor 
vasculature (white arrow). The retina of patient (f) shows an extremely pale optic disc (arrowhead), and degeneration of 
the pigmentary epithelium and choroid (arrow). (g, h) Calbindin staining of the cerebellar cortex of a control individual 
(g) and a SCA7 patient (h), to visualise Purkinje neurons. The control displays strongly labelled bodies of Purkinje cells 
(PC), and dendritic extensions within the molecular layer (ML) (g). The cerebellum of a SCA7 patient (h) on the other 
hand, shows a dramatic loss of Purkinje neurons. (i, j) Histology of the retina of a control individual (i) and a SCA7 
patient (j). The control individual (i) shows proper organization of the retinal layers: the pigment epithelium (P), nuclei of 
photoreceptors within the outer nuclear layer (ONL), nuclei of bipolar neurons within the inner nuclear layer (INL), and 
the ganglion cell layer (G). By contrast, the SCA7 patient (j) displays severe retinal degeneration, with complete demise 
of photoreceptor segments and nuclei, disorganization of the INL (arrowhead), and migration of melanin into the atrophic 
retina (arrows). Adapted by permission from Macmillan Publishers Ltd: European Journal of Human Genetics (Michalik 














1.1.4 Wildtype ataxin-7 function   
The ataxin-7 gene encodes an 892 amino-acid protein, Ataxin-7 (David et al., 1997), comprising 
several known functional domains, including the disease-associated polyQ repeat, a phosphate 
binding site (Mushegian et al., 2000), a nuclear localization signal (NLS) (Kaytor et al., 1999), and a 
nuclear export signal (NES) (Taylor et al., 2006).   Studies of cell models transfected with truncated 
and full-length ataxin-7 constructs have demonstrated the ability of the NLS to shuttle both wildtype 
and mutant Ataxin-7 into the nucleus (Kaytor et al., 1999).  Nuclear export, mediated by the leucine-
rich NES, occurs via the CRM-1/exportin pathway in a polyQ length-dependent manner, with longer 
repeats inhibiting the cytoplasmic trafficking of the protein (Taylor et al., 2006). 
 
Wildtype Ataxin-7 is widely expressed in the brain and retina, and peripheral tissues including testis, 
thyroid, striated muscle, lymphoblasts, kidney and pancreas (Jonasson et al., 2002; Einum et al., 
2001; Cancel et al., 2000).  Within the CNS, Ataxin-7 is preferentially expressed in neurons, 
although low levels have also been detected in astrocytes (Cancel et al., 2000).  The distribution of 
Ataxin-7 does not, however, correlate with the selective neuronal loss observed in SCA7 pathology – 
highly vulnerable Purkinje cells, for example, have been shown in some cases to express relatively 
low levels of the protein (Cancel et al., 2000).   
 
In normal human brains, Ataxin-7 is found in the cell bodies and processes of neurons, as well as the 
nucleus, with subcellular localization varying according to cell type (Einum et al., 2001; Cancel et 
al., 2000).   An age-dependent shift in subcellular compartmentalisation has also been postulated, 
based on observations in the brains of control individuals, which showed predominantly nuclear 
Ataxin-7 immunostaining at a young age, followed by cytoplasmic staining later in life (Jonasson et 
al., 2002).  This model should be viewed with caution, however, as the results represent a collation of 













Ataxin-7 co-localises with the endoplasmic reticulum (ER), but not with mitochondria or the Golgi 
network (Cancel et al., 2000). 
 
Early studies of Ataxin-7 protein function identified two interacting proteins – R85, a splice variant 
of Cbl-associated protein (Lebre et al., 2001),  and the ATPase subunit S4 of the proteasomal 19S 
regulatory complex (Matilla et al., 2001).  The former provided a potential mechanism for the 
ubiquitination of Ataxin-7; while the latter interaction, inversely correlated with the length of the 
polyQ tract, suggested a role for the proteasome in SCA7 pathogenesis (see Section 1.2.1) (Lebre et 
al., 2001; Matilla et al., 2001). 
 
The high degree of homology between human and mouse Ataxin-7 (88.7%) (Ström et al., 2002), and 
between human and vertebrate Ataxin-7 (Taylor et al., 2006), point to an evolutionarily conserved 
function for the wildtype protein.  Indeed, the identification of a yeast orthologue predicted to be a 
component of the histone acetyltransferase Spt/Ada/Gcn5/acetylase (SAGA) complex – a key 
modulator of yeast transcription – has provided valuable insight into the role of Ataxin-7 as a 
transcriptional regulator (Scheel et al., 2003).  Subsequent studies of mammalian Ataxin-7 have 
confirmed its role in the SAGA-like complexes, the  TATA-binding protein-free TAF-containing 
complex (TFTC) and the SPT3/TAF9/GCN5 acetyltransferase complex (STAGA), where it interacts 
directly with the Gcn5 histone acetyltransferase subunit to activate gene transcription via the 
acetylation of histone H3 (Palhan et al., 2005; Helmlinger et al., 2004a).  The incorporation of 
mutant expanded Ataxin-7 inhibits the histone acetylation function of Gcn5 in a dominant-negative 
fashion, possibly accounting for the transcriptional dysregulation frequently observed in SCA7 
(Palhan et al., 2005). 
 
Further evidence for the role of Ataxin-7 in transcriptional regulation has come from the observation 













(CRX) protein (La Spada et al., 2001), mutations in which are known to result in retinal degenerative 
disorders and dysregulated expression of photoreceptor genes (Sohocki et al., 1998).   The 
interaction, mediated by the glutamine regions of both proteins, is required for the transactivation of 
CRX-dependent genes in vivo, and may be disrupted by the expansion of the Ataxin-7 polyQ tract 
(Chen et al., 2004). 
 
The aforementioned hypotheses account, at least in part, for the function of Ataxin-7 in the nucleus.  
However, the ability of the protein to shuttle between the nucleus and the cytoplasm via its NLS and 
NES suggests that Ataxin-7 may also perform certain cytoplasmic functions.   In a recent study by 
Nakamura and colleagues, the expression levels, nuclear:cytoplasmic ratio and intracytoplasmic 
distribution of fluorescent-tagged Ataxin-7 in transfected HeLa cells were found to change 
dramatically during the cell cycle (Nakamura et al., 2012).  Data from immunofluorescence and 
immunoprecipitation experiments were used to confirm that the filamentous structures formed by 
Ataxin-7 during mitosis overlapped with the spindle, the result of a physical interaction between 
Ataxin-7 and α-tubulin which occurred independently of repeat length (Nakamura et al., 2012).  
Reduced sensitivity of Ataxin-7 transfected cells to nocodazole, an inhibitor of microtubule 
polymerisation, served as further confirmation of the role of Ataxin-7 in the stabilisation of the 
microtubule network; although it is possible that the interaction of Ataxin-7 and α-tubulin may be a 
reflection of the transport of excess protein to aggresomes – a significant limitation of 
overexpression models of disease (Nakamura et al., 2012). 
 
1.2 Pathogenic mechanisms of PolyQ disease  
1.2.1 Protein aggregation and impairment of the ubiquitin-proteasome pathway  
Nuclear inclusions (NIs), containing aggregates of proteolytically-cleaved mutant protein, have long 













and human brain tissue have confirmed the presence of intra- and perinuclear fibrillar aggregates of 
Ataxin-7, particularly in models in which truncated, polyQ-containing fragments of the protein are 
expressed (Zander et al., 2001).  These aggregates have been shown to contain key cellular 
components including transcription factors, ubiquitin-proteasome components, heat shock proteins 
(such as HSP40 and HSP70), and activated caspase-3, in addition to other polyQ proteins, suggesting 
that their formation may disrupt important biological processes (Fig. 2) (Zander et al., 2001; Chai et 
al., 1999a; Chai et al., 1999b; García-Mata et al., 1999; Cummings et al., 1998a).  However, these 
findings have not been robustly reproduced in animal models, with several studies failing to 
demonstrate any deleterious effects of NIs on transcription factor function (Sadri-Vakili et al., 2006; 
Yu et al., 2002).  Wildtype Ataxin-7 has also been shown to be recruited to NIs, suggesting that a 
loss-of-function may contribute to disease manifestation (Jonasson et al., 2002; Zander et al., 2001). 
 
Proteolytic cleavage by caspase-7, which generates an amino-terminal fragment containing the 
polyQ tract but not the NES (Garden and La Spada, 2008; Young et al., 2007), has been found to be 
an important modulator of SCA7 aggregation and toxicity (Young et al., 2007; Garden et al., 2002).  
The resultant truncated fragments demonstrate enhanced nuclear localisation (Taylor et al., 2006), 
and may be more prone to aggregation, increasing the likelihood of NI formation (Young et al., 
2007). 
 
The sequestration of molecular chaperones and proteasome components into NIs, together with the 
presence of elevated levels of ubiquitin conjugates associated with deposits of aggregated mutant 
Ataxin-7, are indicative of a link between dysfunction of the ubiquitin proteasome system (UPS) and 
SCA7 pathogenesis (Bence et al., 2001; Chai et al., 1999b), particularly given the essential role of 
the UPS in the turnover of both mutant and wildtype Ataxin-7 (Yu et al., 2012).  Indeed, 
overexpression of two aggregation-prone proteins has been shown to directly impair the UPS in vitro 





























Figure 2 Mechanisms of polyQ toxicity. The expansion of CAG trinucleotide repeats within the coding region of 
several genes results in the expression of proteins containing pathologically expanded polyglutamine (polyQ) tracts. 
Pathogenesis has largely been attributed to the effects of the mutant protein, although a role for RNA toxicity in the 
development of disease has also been proposed. The mechanism by which polyQ proteins exert their toxic effects varies 
according to protein context, and may include proteolytic cleavage (leading to the production of toxic fragments), 
impairment of the ubiquitin–proteasome pathway, formation of aggregates of mutant protein (involving the sequestration 
of wild-type polyQ protein and other important cellular components such as transcription factors), dysregulation of 
transcription, either directly or as a result of aggregate formation, and mitochondrial dysfunction, all of which result in 
deleterious downstream consequences.  Adapted by permission from Expert Reviews in Molecular Medicine (Watson 














Early theories for the inhibition of the UPS in polyQ disease included the saturation of molecular 
chaperones required for UPS function, and direct interaction of “indigestible” polyQ tracts with the 
proteasome (Bence et al., 2001).  In the latter case, proteasomes could theoretically become blocked 
by degradation-resistant, ubiquitinated aggregates, thereby limiting their availability for degrading 
other cellular substrates (Bence et al., 2001).  This hypothesis was supported by the observation that 
eukaryotic proteasomes appeared unable to process polyQ sequences, resulting in direct blockage of 
the 20S core proteasome in a length-dependent manner (Venkatraman et al., 2004).  Protein 
aggregates, such as the NIs observed in SCA7, were thus assumed to function as both inhibitors of 
the UPS pathway and the products resulting from its inhibition – a decrease in UPS activity resulting 
in the further accumulation of misfolded proteins, leading in turn to a further decrease in UPS 
function – a positive feedback mechanism thought to account for the progressive loss of neuronal 
function that characterises neurodegenerative diseases (Bence et al., 2001).  Considering the central 
role of the UPS in regulating cellular events such as cell division and apoptosis, this link provided a 
mechanism by which protein aggregation might result in cellular dysregulation and cell death (Bence 
et al., 2001). 
 
More recent evidence has revealed a vastly different relationship between polyQ proteins and the 
UPS.  The discovery of UPS impairment in the absence of protein aggregates, together with lack of 
discernible effects of aggregation on the 26S proteasome observed in several models, indicate that 
UPS impairment is unlikely to result from the choking of proteasomes by aggregated proteins 
(Bennett et al., 2005; Michalik and Van Broeckhoven 2004).  Instead, analyses of single cells 
suggest that UPS dysfunction precedes inclusion body formation, and may actually be ameliorated 
by the formation of inclusions (Mitra et al., 2009).  An investigation into the temporal and 
mechanistic relationship between N-terminal HTT aggregation and UPS function by Hipp et al. 
(2012) further supported these findings, leading the authors to propose a model whereby the 













direct impairment by polyQ tracts.  In this model, UPS components become gradually overwhelmed 
by folding-impaired, aggregation prone proteins, resulting in a disruption of protein homeostasis 
(Hipp et al., 2012; Finkbeiner 2011). 
 
The role of NIs in polyQ pathogenesis therefore remains controversial (Watson et al., 2012; Michalik 
and Van Broeckhoven, 2003).  The presence of aggregates in unaffected tissues (Ansorge et al., 
2004; Jonasson et al., 2002), together with the observed lack of NIs in at least one SCA7 affected 
individual (Einum et al., 2001), suggest that their formation does not entirely coincide with disease 
pathology.  A protective role for the aggregation of mutant Ataxin-7 has even been suggested, based 
on an observed inverse correlation between neuropathology and the presence of NIs in the vulnerable 
neurons of a SCA7 knock-in mouse model (Bowman et al., 2005). 
 
Autophagy, literally “self-eating”, refers to the lysosomal enzymatic mechanism employed by cells 
to degrade long-lived cytosolic proteins (Duncan et al., 2010).  The discovery of an association 
between mutant HTT and the accumulation of autophagic vacuoles in HD patient brain tissue, 
lymphoblasts and mouse models provided the first concrete link between autophagy and polyQ 
disease (Fig. 2) (Nagata et al., 2004; Petersén et al., 2001; Kegel et al., 2000; Sapp et al., 1997).  
Hallmarks of autophagy have subsequently been reported in other polyQ diseases, including SBMA, 
SCA1 and SCA7 (Montie et al., 2009; Vig et al., 2009; Zander et al., 2001).   
 
The presence of accumulating autophagosomes in degenerating neurons suggested at first that 
autophagy could contribute to the demise of these cells, particularly in light of the established role 
for autophagy in programmed cell death (Duenas et al., 2006; Yue et al., 2002).  This hypothesis has 
been refined over time to reflect the current understanding of the role of basal autophagy in normal 













in polyQ diseases may reflect a defect in autophagic flux, rather than the induction of the pathway 
(Atwal et al., 2007). 
 
The rate of basal autophagy differs between different tissues, with a particularly high demand for 
protein turnover in the liver, and in post-mitotic cells such as neurons (Komatsu et al., 2007; Hara et 
al., 2006; Komatsu et al., 2006).  Neurons in particular are highly vulnerable to perturbations in the 
autophagy-lysosomal system, due to their highly metabolically active state, and their unique cellular 
architecture, which requires that autophagosomes produced in dendrites, axons or synaptic terminals 
travel substantial distances in order to fuse with lysosomes, located adjacent to the nucleus (La Spada 
and Taylor, 2010).  The importance of basal autophagy in the CNS is further highlighted by the 
observation that conditional knockout of certain key autophagy genes results in neurodegeneration 
and accumulation of ubiquitinated inclusions, similar to those seen in human neurodegenerative 
diseases (Hara et al., 2006). 
 
Although autophagic impairment in polyQ diseases has yet to be convincingly demonstrated, it is 
hypothesised to arise in one of two ways: either through the over-burdening of the autophagy-
lysosomal pathway with aggregated, misfolded proteins which are resistant to degradation, or 
through direct impairment, in cases where the disease protein plays an important role in the process 
of autophagy (as is the case in HD) (Atwal et al., 2007; Shibata et al., 2006). 
 
The potential neuroprotective function of autophagy should, however, also be noted.  Indeed, the 
upregulation of autophagy genes, and sequestration of the autophagic inhibitor mammalian target of 
rapamycin (mTOR) observed in polyQ diseases results in activation of autophagy and enhanced 
clearance of mutant polyQ proteins (Ravikumar et al., 2004).  This effect has been mimicked with 
some success in animal models of polyQ disease, in which pharmacological or genetic augmentation 













neurodegeneration, offering a potential avenue for therapy for these diseases (Sarkar et al., 2008; 
Pandey et al., 2007; Sarkar et al., 2007; Davies et al., 2006; Ravikumar et al., 2004; Tanaka et al., 
2004). Most recently, results from a stable, inducible SCA7 cell model have provided strong 
evidence for the importance of autophagy in the clearance of proteolytically cleaved Ataxin-7 
fragments, providing further confirmation that enhancement of this key pathway could serve as a 
valuable therapeutic strategy (Yu et al., 2012). 
 
1.2.2 Altered protein-protein interactions and post-translational mechanisms  
The expanded polyQ tract imparts a conformational change to the mutant protein, thereby directly 
affecting native protein-protein interactions (Matilla et al., 2001).   In addition, post-translational 
modifications such as phosphorylation, SUMOylation and acetylation of specific residues in several 
polyQ proteins may be altered in the presence of the mutation, affecting interactions with their 
natural binding proteins (reviewed by La Spada and Taylor, 2010).  Post-translational mechanisms 
may also influence the stability and rate of turnover of the mutant protein, as is the case in SCA7, in 
which acetylation of lysine 257 (K257) has been shown to regulate caspase-7-mediated cleavage of 
Ataxin-7 in a repeat length-dependent manner (Mookerjee et al., 2009).  SUMOylation of Ataxin-7 
at K257 has also been observed, and is believed to decrease the aggregation propensity and cellular 
toxicity of the mutant protein (Janer et al., 2009). 
  
1.2.3 Transcriptional alterations  
Transcriptional dysregulation is a common feature of polyQ diseases (Fig. 2) (Helmlinger et al., 
2006b).   Many polyQ proteins play a role in transcriptional regulation,
 
and several reports have 
identified transcriptional changes in molecular chaperones and genes involved in neuronal 
differentiation, prior to cellular dysfunction, suggesting that transcriptional alteration may be one of 













differences in transcriptional phenotypes of different polyQ diseases are likely to reflect the specific 
function(s) of the disease-causing proteins (Helmlinger et al., 2006b). 
 
Transcriptional dysregulation in polyQ disease is hypothesised to result either from the recruitment 
and sequestration of transcription factors in NIs (thereby interfering with their normal function), or 
via direct interactions between the mutant protein and transcription factors (that is, an alteration of 
wildtype function, or a gain of function resulting from the expansion of the polyQ tract).  These 
proposed mechanisms are supported by the detection of numerous transcription factors capable of 
interaction with polyQ-containing proteins, including the cAMP response element binding protein 
(CREB), the TATA-binding protein associated factor 4 (TAF4) and specificity protein 1 (Sp1) 
(Dunah et al., 2002; McCampbell et al., 2000; Shimohata et al., 2000; Steffan et al., 2000; Kazantsev 
et al., 1999).  Although many of these proteins have been shown to localise in NIs, evidence from 
mouse models suggests that direct interactions between mutant protein monomers or oligomers and 
transcription factors may have a more profound effect on gene expression than their sequestration 
into protein aggregates (Sadri-Vakili et al., 2006; Schaffar et al., 2004). 
 
In most cases, the precise causes of transcriptional changes, and their relationship to the polyQ 
disease phenotype have proved difficult to elucidate (Helmlinger et al., 2006b).  However, the 
discovery of a role for wildtype Ataxin-7 in the mammalian STAGA/TFTC complexes (Helmlinger 
et al., 2006c; Palhan et al., 2005; Helmlinger et al., 2004a) has provided valuable insights into the 
role of transcriptional dysregulation in the development of SCA7.  
 
The TFTC and STAGA complexes are members of an important class of transcriptional co-activators 
– multi-protein complexes recruited to gene promoters by specific co-activators, where they facilitate 
the assembly of the general transcriptional machinery and the acetylation of histones, via the 












immunoprecipitation studies have confirmed that Ataxin-7 is required for transcriptional activation 
by TFTC/STAGA, and that this activation is mediated by CRX, a photoreceptor-specific 
transcriptional co-activator.  These results have led to extensive investigations of the effects of 
mutant Ataxin-7 on transcriptional regulation in SCA7 mouse models (Helmlinger et al., 2006a). 
As retinal degeneration is a unique feature of SCA7, most studies have focused on retinal
photoreceptors in order to gain insight into the function of mutant Ataxin-7, with several groups
reporting severe transcriptional dysregulation in the retinas of SCA7 transgenic and knock-in mouse
models (Carlson et al., 2009). In all cases, the expression of mutant Ataxin-7 induced dramatic,
early downregulation of most photoreceptor-specific genes, including many of those encoding 
components of the phototransduction cascade (Abou-Sleymane et al., 2006; Helmlinger et al., 2006a;
Yoo et al., 2003; La Spada et al., 2001). Downregulation of Rhodopsin expression, the earliest
molecular abnormality detected, correlated with a decrease in rod electrophysiological responses and
thinning of rod photoreceptor segments, observed well before the onset of cell death in the mouse
retina (Helmlinger et al., 2004b; Yoo et al., 2003). Transcriptomic analysis provided further
confirmation of the preferential downregulation of genes whose expression is both restricted to the
retina, and required for normal photoreceptor function (Abou-Sleymane et al., 2006). These findings 
indicated strongly that the retinopathy observed in SCA7 mice and patients may result from the
decreased expression of photoreceptor genes (Helmlinger et al., 2006b). This was further
corroborated by significant reduction in expression in SCA7 mouse retina of three photoreceptor-
specific activators – CRX, NRL (a basic motif leucine zipper transcriptional activator) and Nr2E3
(an orphan nuclear receptor) – suggesting that photoreceptors in SCA7 mice may lose their ability to














The effect of mutant Ataxin-7 on TFTC/STAGA function remains controversial.  Evidence from 
transfected cell models, yeast and SCA7 transgenic mice has confirmed that polyQ-expanded 
Ataxin-7 incorporates into TFTC/STAGA as efficiently as the wildtype protein (Helmlinger et al., 
2006c; McMahon et al., 2005; Palhan et al., 2005; Helmlinger et al., 2004a).  However, in vitro 
studies suggest that the polyQ-expanded protein may affect the assembly of the transcriptional 
complexes, by interfering with recruitment of SPT3, ADA2b and TAF12 (Balasubramanian et al., 
2002; Grant et al., 1999; Grant et al., 1998; Grant et al., 1997).  Mutant Ataxin-7 has also been 
shown to interfere with Gcn5 histone H3 activity and CRX-mediated recruitment of TFTC/STAGA 
to promoters, in a dominant-negative manner in transfected HEK293T cells (Palhan et al., 2005). 
 
In contrast to these in vitro findings, studies of SCA7 mice have failed to demonstrate a direct 
interaction between CRX and Ataxin-7 or TFTC/STAGA (Helmlinger et al., 2006a; La Spada et al., 
2001).  In addition, the presence of polyQ-expanded Ataxin-7 in vivo was found to induce a global 
downregulation of all rod-specific genes, rather than just those regulated by CRX, leading 
researchers to question the role of CRX in the recruitment of TFTC/STAGA (Yoo et al., 2003).   
 
Analysis of the composition of purified TFTC/STAGA from the retinas of R7E transgenic mice 
revealed normal levels of all components, including mutant Ataxin-7, as well as normal levels of 
histone acetylation activity (Helmlinger et al., 2006a).  However, incorporation of the polyQ-
expanded mutant protein into TFTC/STAGA in vivo resulted in a gain of function of these 
complexes, inducing histone H3 hyperacetylation, leading to severe chromatin decondensation in the 
rod photoreceptors of SCA7 transgenic and knock-in mice (Helmlinger et al., 2006a).  Surprisingly, 
the hyperacetylated genes were transcriptionally downregulated, a counterintuitive finding proposed 
to result from an increase in photoreceptor nuclear volume, leading to the “dilution” of retina-
specific transcription factors and hence to the downregulation of strongly-expressed retina-specific 












packaging in the control of gene expression and cell type determination (Francastel et al., 2000).  
Indeed, photoreceptor dysfunction, measured electrophysiologically, histologically and by a decrease 
in Rhodopsin expression, was directly correlated with the degree of chromatin decondensation in 
R7E and knock-in mouse models (Helmlinger et al., 2006a).  
The discrepancies in TFTC/STAGA HAT activity observed between in vitro and in vivo models of
SCA7 may be partly explained by the different model systems used in each study. For instance, the
effect of incorporation of mutant human Ataxin-7 into the yeast SAGA complex may not accurately
reflect its effects on the mammalian version of the complexes, while the absence of transcriptional 
alterations in transfected HEK293T cells makes it difficult to correlate the observed HAT
impairment with SCA7 pathology. Results from transgenic SCA7 mice on the other hand, are
affected by the tissue-specific expression patterns of the transgene, and by its massive
overexpression, which limit extrapolations of these findings to other affected tissues. The
advantages, limitations and future prospects for SCA7 disease models are discussed in more detail in 
Section 1.5.
With the role of transcriptional dysregulation as an early marker of SCA7 retinopathy firmly
established, recent studies hav been expanded to include investigations of transcriptional patterns in 
the CNS. Chou et al. investigated the involvement of transcriptional dysregulation in cerebellar
dysfunction using a transgenic mouse model of adult-onset SCA7, expressing polyQ-expanded 
Ataxin-7-Q52 in brain regions implicated in SCA7 neurodegeneration, including the cerebellum and
inferior olivary nucleus (Chou et al., 2010). Microarray analysis of cerebellar gene expression in 10-
11 month old mice revealed downregulation of genes encoding proteins responsible for 
glutamatergic transmission, myelin formation, signal transduction, deubiquitination, axon transport, 
neuronal differentiation or glial functions, and heat shock proteins (Chou et al., 2010). Upregulation 












The role of transcriptional changes in initiating SCA7 pathology was confirmed by the observation 
that 6-month-old transgenic mice, which did not exhibit a measurable ataxic phenotype, exhibited a
similar pattern of transcriptional dysregulation. The most notable difference between the two age
groups was found in the expression levels of heat shock proteins, which were upregulated in 6-
month-old mice. This biphasic expression pattern is likely to reflect the induction of the HSP
response during the early stages of disease as part of a misfolded protein response, followed by the
impairment of HSP gene transcription by accumulation of toxic mutant Ataxin-7 as the disease
progresses (Chou et al., 2010). Downregulation of HSP expression is a common hallmark of 
advanced polyQ pathogenesis, having been identified in affected neurons in HD, SBMA, SCA3 and
SCA17 transgenic mice (Chou et al., 2010; Chou et al., 2008; Katsuno et al., 2005; Hay et al., 2004).
Based on these findings, it is evident that transcriptional dysregulation plays a significant role in the
development of SCA7 pathology, making it both an important early marker of disease and a
promising therapeutic target.
1.2.4 Loss-of-function and additional pathogenic mechanisms
Although polyQ diseases are generally accepted to result from a toxic gain-of-function of the mutant
protein, it is possible that a loss of function may contribute to pathogenesis, particularly since
knockout models of some polyQ diseases show neurodegeneration, and NIs have been shown to 
recruit the native protein, possibly leading to impairment of its normal function (Watson and Wood, 
2012).  Lessons learnt from the role of Ataxin-7 in the TFTC/STAGA complex further emphasise the
importance of understanding normal protein function in the elucidation of disease pathogenesis.
A number of additional polyQ disease mechanisms have been reported, including mitochondrial 
dysfunction, enhanced apoptosis and excitotoxicity caused by glutamate receptor overactivation 













activating the mitochondrial apoptotic pathway in SCA7 transgenic mice, via p53-mediated 
upregulation of pro-apoptotic BAX mRNA (Wang et al., 2010).  Most recently, a role for polyQ-
expanded Ataxin-7 in the development of oxidative stress has also been proposed, based on its 
effects on NADPH oxidase complex activity and Catalase levels (both of which are key regulators of 
the levels of reactive oxygen species) in a SCA7 inducible cell model (Ajayi et al., 2012).  
 
Given the multitude of cellular insults triggered by expanded polyQ tracts, developing an effective 
therapy appears a daunting prospect. However, based on current theories of pathogenesis, several 
proof-of-principle treatments have already been demonstrated.  These are discussed in more detail in 
Section 1.4. 
 
1.3 SCA7 in South Africa  
SCA7 is one of the rarer polyQ disorders, with a prevalence of less than 1 per 100 000 worldwide 
(Durr, 2010; Storey et al., 2000).  In South Africa, however, the situation is vastly different, with a 
recent report identifying SCA7 as the second most prevalent dominantly-inherited ataxia, after SCA1 
(Smith et al., 2012).  This unusual pattern was first described by Bryer et al., who reported an 
increased prevalence of SCA7 in the South African population, as compared to the rest of the world 
(22.2% of total dominant ataxia cases, compared with a frequency of less than 5% in countries such 
as China, India, the United States of America, Korea, Australia, and Spain) (Bryer et al., 2003).   
 
Similar to their counterparts in other regions of the world, South African SCA7 patients present with 
either ataxia, visual impairment, or both symptoms simultaneously, with a mean age at onset of 20.3 
years.  Families display significant anticipation, and affected individuals die within 5 to 30 years of 














The disease occurs almost exclusively in individuals of Black African origin, hypothesised to have 
resulted from a founder event (Greenberg et al., 2006) similar to those reported in Mixed Ancestry 
and Caucasian SCA1 patients in South Africa (Ramesar et al., 1997).  South African SCA7 patients 
are thus presumed to have descended from a common ancestor, and should, as a result, share a 
common haplotype surrounding the ataxin-7 gene, including alleles of common SNPs within the 
region.  Indeed, the observation that over 50% of South African SCA7 patients are heterozygous for 
a common SNP (rs3774729) in the 3’ region of ataxin-7, such that the A and G alleles of the SNP are 
associated with the mutant and wildtype transcripts, respectively, has provided much of the impetus 
for the development of RNA interference (RNAi)-based therapy for this patient population 
(Scholefield et al., 2009; Greenberg et al., 2006). 
 
1.4 Therapeutic approaches for polyQ diseases  
(Adapted from Watson and Wood, 2012; and Watson et al. 2012) 
Historically, treatment for polyQ diseases has focused on symptomatic management. However, with 
greater understanding of the molecular basis of these diseases has come the opportunity to prevent or 
delay onset of disease symptoms, through the identification of targets within the disease pathway 
which may be amenable to therapy. Current experimental therapies may be classified into two 
categories - those aimed at alleviating the burden of accumulated mutant protein, and those targeting 
its downstream effects. 
 
1.4.1 Therapies targeting polyglutamine proteins  
1.4.1.1 Oligonucleotide-based therapies  
Given the complexities of polyQ pathogenesis, one logical approach to therapy is to suppress 
production of the mutant protein upstream of its deleterious effects. Several lines of evidence support 













models of disease in particular have shown that neuropathological features, which develop over time 
in response to the presence of mutant polyQ protein, are rapidly improved upon attenuation of 
mutant gene expression. These findings provide proof-of-principle that inhibition of disease-causing 
genes represents an effective avenue for therapy in patients already exhibiting a disease phenotype 
(Zu et al., 2004; Yamamoto et al., 2000).   Attention has therefore turned in recent years to the 
development of effective transcriptional and post-transcriptional gene silencing therapies, mediated 
for the most part by small non-coding RNA molecules (Fig. 3). 
 
The most straightforward method of RNA-based gene silencing involves indiscriminate suppression 
of both the normal and pathological alleles of the gene – termed “non allele-specific silencing” (Fig. 
3b).  Although technically less challenging, this approach is based on the assumption  that the 
wildtype gene function is either non-essential or functionally redundant, since silencing of genes 

















Figure 3 Principles of allele-specific, non-allele-specific, and gene knockdown and replacement therapies. (a) 
Translation of wild-type and pathologically expanded alleles of a CAG repeat results in the production of both mutant 
(red) and wild-type (green) protein. (b) Non-allele-specific post-transcriptional gene silencing (PTGS) therapy (shown in 
blue) prevents translation of both transcripts, leading to a reduction in wild-type and mutant polyglutamine protein levels. 
(c) In the case of gene knockdown and replacement, the introduction of an exogenous wild-type transcript, which is 
resistant to silencing as a result of modifications to the nucleotide sequence, results in restoration of wild-type protein 
expression despite the suppression of both endogenous transcripts in a non-allele-specific manner. (d) Allele-specific 
gene silencing (shown in red), based on discrimination between single-nucleotide polymorphism genotypes or 
differences in CAG repeat lengths, results in selective suppression of mutant protein production, while wildtype protein 
levels remain relatively unchanged. Effectors may be either RNA interference-based or antisense oligonucleotides 
Adapted by permission from Expert Reviews in Molecular Medicine (Watson and Wood, 2012), copyright 2012. 
 
In cases where wildtype protein function is indispensable, an allele-specific approach may be 
required.  Allele-specific silencing relies on the availability of targetable sequence differences that 
enable discrimination between the normal and mutant transcripts of a gene; for example, single 













differences in the CAG repeat length itself (Fig. 3d) (Rodriguez-Lebron and Paulson, 2005).  In 
theory, an allele-specific strategy represents the preferred therapeutic mechanism for the majority of 
polyQ diseases, as it enables selective silencing of the mutant copy of the gene, while maintaining 
wildtype expression.  However, in practice it is not always feasible – polymorphisms linked to the 
disease allele in a small number of affected individuals may not justify the development of a therapy, 
and may not be amenable to targeting due to their location within the gene (Scholefield and Wood, 
2010).  In such cases, alternative approaches such as gene knockdown and replacement may be 
employed.  This method combines non allele-specific silencing with gene replacement therapy, in 
which an RNAi or antisense oligonucleotide (AON)-resistant transgene is delivered to the targeted 
tissues together with the therapeutic effector (Fig. 3c) (Kubodera et al., 2010; Kubodera et al., 2005). 
 
The decision regarding which silencing method to apply to a given polyQ disease depends both on 
the degree to which loss of wildtype protein expression is tolerated, and the feasibility of allele-
specific silencing.  To date, answers to these questions have largely been based on the phenotypes 
observed in knockout and transgenic animal models of disease.  In the case of HD, for instance, HTT 
knockout results in embryonic lethality (Nasir et al., 1995), while conditional knockout mice display 
a neurodegenerative phenotype and significantly shorter lifespan (Dragatsis et al., 2000).  Ablation of 
wildtype function in transgenic HD mice results in an exacerbation of disease symptoms (Van 
Raamsdonk et al., 2005).  Since HTT is known to play a role in several key pathways in brain 
development, retention of wildtype expression appears necessary, although the absence of a 
phenotype in heterozygous conditional knockout mice and in an individual expressing HTT at only 
50% of normal levels suggests that a single functional copy may be sufficient (Persichetti et al., 
1996; Ambrose et al., 1994) – a strong argument in favour of the allele-specific silencing approach. 
 
The absence of a knockout model for SCA7 makes it difficult to determine the effect of a loss of 












gene expression (Helmlinger et al., 2006a; Palhan et al., 2005; La Spada et al., 2001) has prompted 
the suggestion that an allele-specific approach be adopted until further information becomes 
available. 
1.4.1.1.1 Principles and mechanisms of gene silencing 
Therapeutic strategies based on the principle of RNAi make use of the endogenous mammalian gene
silencing pathway, in which primary microRNA (miRNA) hairpins, transcribed from non-coding 
regions of the genome, are processed sequentially by a series of enzyme complexes to yield short
double-stranded RNAs (Fig. 4a) (Weinberg and Wood, 2009). In the final step, the antisense or 
“guide” strand of the duplex is loaded into the RNA-induced silencing complex (RISC) which, in the
case of post-transcriptional silencing, directs either cleavage or translational suppression of the 
complementary target mRNA, depending on the accuracy of base-pairing (Castanotto and Rossi, 
2009; Zamore et al., 2000). 
The pathway may be harnessed for therapeutic gene silencing through cytoplasmic delivery of
synthetic short interfering RNAs (siRNAs), double-stranded molecules 21-22 nucleotides in length, 
which are designed to be perfectly complementary to the mRNA targeted for silencing (Fig. 4c)
(Rodriguez-Lebron and Paulson, 2005). Short hairpin RNAs (shRNAs) represent a modification of
this strategy in which the basic siRNA sequence is incorporated into a stem-loop construct,
expressed at high levels from a PolIII promoter (Fig. 4b) (Boudreau et al., 2008a). However, since
both siRNAs and shRNAs bind obligatorily to components of the RNAi pathway, large doses may
result in saturation of the cellular RNAi processing machinery, disrupting endogenous miRNA
biogenesis and function (Grimm et al., 2006). Additionally, the risk of off-target effects as a result
of partial complementarity to unintended transcripts represents an important caveat to the clinical




























Figure 4 RNA interference-based therapies make use of the endogenous mammalian gene silencing pathway.      
(a) Endogenous primary microRNAs (pri-miRNAs), transcribed from genomic DNA, are processed in the nucleus by 
Drosha (an RNase III enzyme) and its interaction partners to yield pre-miRNAs. These are exported to the cytoplasm by 
means of exportin-5 (XPO5), where they are recognised and cleaved by the Dicer enzyme complex, resulting in the 
production of ∼22 bp staggered duplexes. The guide strand (depicted in red) is loaded into the RNA-induced silencing 
complex (RISC), which, in the case of posttranscriptional silencing, directs cleavage or translational suppression of the 
cognate mRNA, depending on the accuracy of base pairing between the guide strand and the target mRNA (Castanotto 
and Rossi, 2009). (b) The pathway may be manipulated for therapeutic gene silencing through the introduction of 
artificial miRNA or short hairpin RNA (shRNA) constructs complementary to the gene or allele targeted for repression. 
These effectors are expressed under the control of PolII and PolIII promoters, respectively, and enter the pathway 
upstream of Dicer processing. (c) Alternatively, short interfering RNAs (siRNAs) that target the gene of interest can be 
incorporated directly into RISC. (d) Long-term suppression of gene expression may be accomplished through TGS, in 
which siRNAs complementary to the promoter region of the target gene induce epigenetic changes. Delivery is usually 
mediated by integrating lenti- or episomally-expressing (rAAV) viruses (in the case of shRNAs and miRNAs) or by 
direct injection or lipid-mediated transfection (in the case of siRNAs) (Adapted by permission from Expert Reviews in 













One method to avoid saturation involves the incorporation of synthetic siRNA sequences into 
artificial miRNAs under the control of a PolII promoter, allowing for regulated, cell-specific 
expression of the gene silencing molecules (Fig. 4b) (Boudreau et al., 2008b).  The result is a 
decrease in accumulation of unprocessed precursors leading to a reduction in cellular immune 
response, and hence to an improvement in non-specific, toxic effects (Bauer et al., 2008; Boudreau et 
al., 2008b; McBride et al., 2008). 
 
Another method that has been proposed involves circumvention of the RNAi pathway altogether, 
through the use of antisense oligonucleotides complementary to the mRNA targeted for silencing.  
AONs are short synthetic molecules, 15-25 nucleotides in length, which hybridise to their target 
mRNA by means of Watson and Crick base pairing (Smith et al., 2006).  Posttranscriptional gene 
silencing is achieved through RNAse H-mediated intranuclear degradation of the target transcript 
(Crooke, 2004), or steric blocking of translation (Gagnon et al., 2010).   
 
1.4.1.1.2 Allele-specific gene silencing  
Allele-specific silencing is accomplished through the exploitation of differences in nucleotide 
sequence between wildtype and mutant alleles, making it particularly applicable to dominantly 
inherited disorders such as the polyQ diseases, in which only one copy of the mutant gene is required 
for the disease to manifest.  The aim is thus to achieve maximum selectivity for the mutant transcript, 
while ensuring that the wildtype allele is spared the effects of gene silencing (Rodriguez-Lebron and 
Paulson, 2005).  Since the sequence of the effector must match the target exactly to elicit RISC- or 
RNase H-mediated degradation, it is vital that the mutant and wildtype transcripts of the gene to be 
targeted differ by at least one nucleotide, in order to facilitate discrimination.  In many diseases 
caused by point mutations, insertions or deletions, the targetable sequence difference is offered by 
the mutation itself (Xia et al., 2006; Abdelgany et al., 2003; Gonzalez-Alegre et al., 2003).  













a challenge, as the polymorphic nature and ubiquitous presence of the repeat tract throughout the 
genome make it difficult to target specifically, particularly since effectors <25 nucleotides in length 
are unlikely to be able to distinguish between wildtype and pathologically expanded CAG tracts 
(Scholefield and Wood, 2010). 
 
Most efforts have therefore focused on targeting sequence differences created by the presence of 
SNPs linked to the CAG repeat expansion in a specific patient group (Rodriguez-Lebron and 
Paulson, 2005), using RNAi-based technologies. Once a suitable SNP has been identified, several 
additional mechanistic issues must be taken into account when designing siRNAs capable of optimal 
discrimination between transcripts that differ at a single nucleotide (reviewed in greater detail in 
Watson and Wood, 2012).  Of critical importance, the allele of the SNP linked to the mutant copy of 
the gene should be identified, in order to determine the correct siRNA sequence required. This may 
be accomplished through studies of conserved haplotypes within patient cohorts, or through more 
direct methods such as allele-specific reverse trancriptase PCR (Van Bilsen et al., 2008).  In addition 
to design, the concentration of effector administered is also important, as allele-specificity has been 
shown to be concentration dependent (Zhang et al., 2009). The most successful allele-specific 
treatment is therefore likely to be that for which adequate discrimination is achieved at a 
concentration sufficient to effect a clinically significant level of mutant protein inhibition (Lombardi 
et al., 2009; Schwarz et al., 2006). 
 
SNP-based allele-specific approaches have been successfully demonstrated at the preclinical level in 
SCA3 and HD models, including patient fibroblasts (Alves et al., 2008; Van Bilsen et al., 2008; Li et 
al., 2004; Miller et al., 2003; Cattaneo et al., 2001; Gaspar et al., 1996).  This approach has also been 
used to achieve allele-specific silencing of mutant ataxin-7 in HEK293 cells, targeting the A-allele of 
a SNP in linkage disequilibrium with the pathogenic expansion (Scholefield et al., 2009).  These 













of RNAi to successfully discriminate between endogenous single nucleotide mismatches present in 
patient DNA, rather than relying on sequence differences between species to selectively silence 
mutant genes, as is often the case in transgenic animal models of disease.  However, it should be 
noted that the cost and effort required to develop large numbers of effectors for low-frequency 
disease-linked SNPs are likely to hinder the progress of allele-specific therapy towards clinical trials 
(Zhang et al., 2009; Van Bilsen et al., 2008).  
 
In order to address this issue, large-scale studies of polymorphic sites within the HTT gene have been 
conducted in the European and North American HD patient populations (Lombardi et al., 2009; 
Pfister et al., 2009).  The finding that as few as five allele-specific siRNAs, targeting three SNP sites 
could be used to treat 75% of these patients should greatly simplify the development of therapy 
(Pfister et al., 2009).  Including a further four SNPs increases the proportion of eligible patients to 
85.6%, although targeting these additional sites would require the design of a significantly greater 
number of siRNAs (Lombardi et al., 2009; Pfister et al., 2009).  It is difficult to extrapolate these 
results from the European Caucasian patient sample to other patient populations around the world. 
However, a similar investigation into targetable polymorphisms in Venezuelan HD patients has 
revealed six SNPs, which would provide options for allele-specific silencing for up to 63.5% of the 
patient population (Lombardi et al., 2009).  Thus, it may be theoretically possible to develop a 
relatively small number of effectors to deliver effective allele-specific RNAi therapy to the majority 
of polyQ disease patients. 
 
1.4.1.1.3 CAG repeat targeting, antisense oligonucleotides and additional therapeutic 
approaches   
Innovations in the field of antisense oligonucleotide technology offer the opportunity to develop 
therapies applicable to all patients across the polyQ disease spectrum, through the discovery of 













(Gagnon et al., 2010; Hu et al., 2009a).  Discrimination is thought to be based either on differences 
in secondary structure or number of binding sites, depending on the size of the CAG repeat tract, 
with larger repeats demonstrating increased susceptibility to AON binding (Gagnon et al., 2010; Hu 
et al., 2009a).  The result is steric blocking of translation, rather than RNase H-mediated cleavage of 
the target mRNA (Gagnon et al., 2010). 
 
Allele-specific targeting of the CAG repeats is not limited to AONs, however. Artificial miRNAs – 
mismatch-containing duplexes complementary to the CAG expansion – have also been proposed to 
offer a potent and versatile silencing mechanism, capable of >31-fold selectivity in vitro despite the 
introduction of up to four mismatched bases into the guide strand (Hu et al., 2010a). 
 
There are still some concerns regarding the use of CAG-targeting AONs, which may limit their 
efficacy in vivo.  In particular, the presence of CAG tracts throughout the genome suggests the 
potential for deleterious off-target effects, although no silencing of repeat-containing genes 
(including TBP, ATN1 and FOXP2) has yet been observed in vitro (Gagnon et al., 2010; Hu et al., 
2010a).  The fact that more common smaller CAG expansions appear to be less amenable to 
silencing using this approach, compared to rarer large expansions also presents a challenge to the 
clinical utility of this method, which must be addressed before such approaches can progress to 
clinical trials (Gagnon et al., 2010). 
 
One alternative to sequence-based allele-specific silencing, which still results in retention of 
wildtype protein function, is the gene knockdown and replacement method.  Silencing of both mutant 
and wildtype alleles of the disease gene is accomplished through the use of non-allele-specific RNAi.  
This is accompanied by the introduction of a full-length, codon-optimised “replacement” copy of the 
wildtype gene, whose nucleotide sequence is altered in such a way as to retain the amino acid 













In SCA6, the CAG repeat length of mutant alleles falls within the normal range of other polyQ 
diseases, making allele-specific approaches based on repeat-length targeting inappropriate. In a cell 
model of SCA6, transfection of an siRNA capable of silencing both the mutant and wildtype 
CACNA1A, together with an exogenous copy of the gene which is resistant to the gene silencing 
effector, resulted in restoration of wildtype protein function (Kubodera et al., 2005).  A similar 
approach has subsequently been tested in vivo, to restore wildtype SOD1 function in a mouse model 
of amyotrophic lateral sclerosis (ALS) (Kubodera et al., 2010).   
 
This method has the distinct advantage of being able to circumvent the laborious process of 
identification and validation of allele-specific siRNAs targeting disease-linked polymorphisms, 
particularly in diseases where no single sequence change can be targeted in a large number of 
patients (Kubodera et al., 2010). However, the expression of the restored wildtype protein would 
need to be tightly regulated, to prevent the development of side effects. In addition, delivery methods 
would need to be optimised to ensure that every cell treated receives both the RNAi effector and the 
modified replacement gene, suggesting that this method may not be as straightforward as originally 
believed (Kubodera et al., 2005). 
 
1.4.1.2 Clearance of misfolded mutant protein and inhibition of aggregate formation  
In addition to post-translational suppression, a decrease in mutant protein levels may be achieved by 
enhancing the rate of polyQ protein clearance, through upregulation of the two main cellular 
pathways responsible for degradation of misfolded proteins – the ubiquitin-proteasome system (UPS) 
and autophagy.  Impairment of the UPS has been observed in several of the polyQ diseases.  
However, therapeutic upregulation of this pathway is technically challenging, particularly since 














Thus, attention has shifted to the enhancement of autophagy.  In the case of HD, activation of 
autophagy using the mTOR inhibitor rapamycin has been shown to reduce mutant HTT toxicity in 
both Drosophila and mouse models, suggesting that small molecules capable of inducing the 
autophagic cascade may be of therapeutic benefit (Renna et al., 2010).  Similar results have since 
been achieved in transgenic mice expressing full-length ataxin-3, suggesting that induction of 
autophagy may also be effective in the treatment of SCA3 (Menzies and Rubinsztein, 2010).  Phase I 
clinical trials of this therapeutic approach are due to commence in 2012. 
 
Another approach to the clearance of mutant polyQ proteins is to upregulate the activity of molecular 
chaperones capable of promoting the refolding of misfolded proteins.  Overexpression of heat shock 
proteins HSP27 and HSP104 have both been shown to suppress neurotoxicity in HD mouse and rat 
models
 
(Perrin et al., 2007), while global induction of the heat shock response (HSR) has been found 
to rescue a subset of HD phenotypes in mice.  The effects of HSR induction are transient, however, 
suggesting that impairment of the HSR may occur during polyQ disease progression (Labbadia et al., 
2011).  These findings emphasise the complexities of targeting the HSR pathway, and provide strong 
motivation for the development of combinatorial therapies to circumvent impairment of the HSR, 
such as the use of histone deacetylase (HDAC) inhibitors capable of enhancing HSR gene 
transcription. 
 
Direct methods of preventing polyQ protein aggregation have also been attempted, using molecules 
such as Congo red, trehalose, polyQ-binding peptide 1 and cystamine, which act to stabilise the 
native non-toxic conformation of the protein, prevent crosslinking of the mutant isoform, or promote 
clearance from the cell via the mechanisms described above.  All have demonstrated some 
therapeutic benefit in vivo, although questions regarding efficacy and delivery across the blood-brain 















1.4.2 Therapies targeting downstream effects of polyQ proteins  
1.4.2.1 Transcriptional dysregulation  
A key feature of many of the polyQ diseases is the alteration of gene transcription, either through 
direct interaction of the mutant protein with DNA, or via the action of molecular mediators such as 
CREB binding protein (CBP).  The inhibition of HDACs, repressors of transcription, has been 
proposed as a method for mitigating transcriptional dysregulation.  A variety of small molecule 
inhibitors of HDACs have previously been tested as anti-cancer drugs, several of which – including 
phenyl butyrate, and pimelic diphenylamide – have been shown to rescue disease phenotypes in HD 
mouse models (Ross and Tabrizi, 2011).  In particular, the discovery that R6/2 mice engineered to be 
deficient in HDAC4 show an improvement in survival, motor phenotype and transcriptional 
dysregulation suggests that HDAC suppression may be a promising therapeutic route for future 
exploration.   
 
Upregulation of specific genes known to play a role in neuroprotection (such as Brain Derived 
Neurotrophic Factor in the case of HD), either indirectly, through HDAC inhibitors, or directly, by 
overexpression of the gene itself, have also shown beneficial effects in animal models of disease.  
However, this approach requires a thorough understanding of the functions of downstream targets of 
transcriptional regulation by polyQ proteins, in order to identify the most promising therapeutic 
targets.  
 
1.4.2.2 Additional therapeutic approaches  
A number of additional therapeutic approaches have been proposed, which aim to reverse the 
downstream cellular effects of mutant polyQ proteins.  These include compounds capable of 
alleviating energy metabolism defects or mitigating oxidative stress, such as creatine, antioxidants 













mitochondrial complexes II and III, all of which have demonstrated a level of efficacy in alleviating 
the mitochondrial dysfunction observed in some models of polyQ disease. 
 
Compounds such as riluzole and remacemide, which mitigate excitotoxicity by intercepting 
excessive glutamate release, have achieved some success in preclinical studies in R6/2 HD 
transgenic mice, although these results have not been successfully reproduced in clinical trials 
(Landwehrmeyer et al., 2007).  Anti-apoptotic drugs, such as minocycline and caspase inhibitors 
have also shown promise, resulting in significant improvements in survival in polyQ animal models, 
although data from long-term studies will be required in order to rule out possible side effects 
associated with suppression of these key cellular pathways. 
 
1.5 Models of polyQ disease  
The use of model systems is a vital step in understanding the molecular and cellular consequences of 
human disease mutations.  This is particularly true of inherited neurodegenerative conditions with a 
well-defined genetic aetiology, for which (CNS-derived) biological material is not readily available 
(Marsh et al., 2009).  A considerable number of animal models mimicking the phenotypes of polyQ 
diseases have become available in recent years (Ingram et al., 2011; Manto and Marmolino, 2009), 
enabling the identification of pathways affecting disease onset and progression, as well as the genetic 
and pharmacological validation of therapeutic agents proposed to affect pathogenic processes (Marsh 
et al., 2009).  Among these are C. elegans and D. melanogaster models of HD, SCA3 and pure 
polyQ tracts (reviewed in Brignull et al., 2006; Marsh and Thompson, 2006), which have greatly 
contributed to the growing understanding of the molecular basis of disease (Bilen and Bonini, 2005).  
Mouse models have been generated for each of the polyQ diseases (Ingram et al., 2011), which 
recapitulate disease pathology, and display characteristic behavioural phenotypes amenable to 













reported (Yang et al., 2008).  In vitro, transfected commercially-available cell lines such as HEK293 
and the neuroblastoma line SH-SY5Y (Zander et al., 2001), and patient-derived non-neuronal cells, 
including fibroblasts (Garden et al., 2002) and lymphoblasts (Tsai et al., 2005) have also provided 
valuable insights. 
 
These models have been used to identify and validate therapeutic targets, to screen for disease 
modifiers (Bilen and Bonini, 2007; Marsh and Thompson, 2006), and to investigate the effects of 
post-translational modifications of disease proteins (Orr and Zoghbi, 2007).  Studies in worms, flies 
and mice have also enabled the dissection of cellular pathways, in order to test their relevance to 
pathology. For example, the roles of chaperones (Orr and Zoghbi, 2007; Marsh and Thompson, 
2006; Landles and Bates, 2004), modifiers of polyQ protein aggregation (Brignull et al., 2006; Marsh 
and Thompson, 2006), global disruption of the UPS and lysosomal pathways, and miRNA pathways 
(Bilen et al., 2006), in polyQ pathogenesis have all been identified through the use of model systems. 
 
The choice of disease model depends primarily on the accuracy with which the model reflects the 
human phenotype and disease processes; and to a lesser extent, on the cost- and time-effectiveness of 
the model as a therapeutic screening tool (Marsh et al., 2009).  Most investigations into the 
pathogenesis of SCA7 have focused on mouse models of disease, although patient-derived cells 
models have shown increasing promise as an in vitro alternative. 
 
1.5.1 SCA7 mouse models  
A number of SCA7 transgenic mouse models have been generated in recent years, many of which 
have focused primarily on the retina (Ingram et al., 2011).  These models have enabled the 













downregulation of rod-specific gene expression via histone H3 hyperacetylation (Abou-Sleymane et 
al., 2006; Helmlinger et al., 2006a). 
 
Transgenic models of SCA7 affecting the mouse CNS may be divided according to whether 
transgene expression is restricted to Purkinje cells, or more widely distributed (summarised in Table 
1).  A single knock-in mouse model of the disease has been created to date, carrying a 266Q-repeat 
(Yoo et al., 2003).  These animals developed a severe neurological phenotype as early as 5 weeks of 
age, despite relatively mild cerebellar pathology.  NIs were detected, following the onset of motor 
symptoms.  Downregulation of retinal photoreceptor genes was also observed, together with UPS 
impairment, with the latter found to be inversely correlated with the presence of NIs (Yoo et al., 
2003; Bowman et al., 2005). 
 
There are a number of challenges inherent in modelling human neurodegenerative diseases in mice.  
Human cases of SCA7, for instance, may have an adult onset, and progress over years or even 
decades (Ingram et al., 2011).  In order to reproduce the disease within the short lifespan of a mouse 
therefore, additional genetic manipulations may be required, such as the use of abnormally long 
polyQ repeat tracts (associated with a very distinct phenotype in human patients (Ansorge et al., 
2004)), often coupled with overexpression of multiple copies of the disease-causing transgene 
(Ingram et al., 2011).  The result is a severe phenotype, which may not accurately reflect the slow 
progression of the disease.  Thus, animals that overexpress non-mutant alleles should be viewed as 


















Table 1 SCA7 Transgenic Mouse Models 
Transgenic 
Line 




Cellular Phenotype Behavioural 
Phenotype 
Reference 
P7E Pcp-2 90Q Purkinje cells NI in Purkinje cells, 
dendritic 
simplification of 
Purkinje cells at 16 
months 
Rotarod deficit at 11 
months 
(Yvert et al., 
2000) 
R7E Rhodopsin 90Q Rod 
photoreceptors 

















nuclei, not restricted 
to degenerating 
neurons;   
transcription factors 
sequestered in NIs 










with NIs; somatic 
atrophy of Purkinje 
cells; NI in cerebellar 
granular neurons 
Early onset ataxia (Garden et 
al., 2002; La 
Spada et al., 
2001) 
Gfa2-SCA7 Gfa 2 92Q Bergmann glia Decreased glutamate 
transporter activity; 
ultrastructural 
changes in Purkinje 
cells 
Rotarod deficit at 12 
months 






52Q Neuronal and 
glial 
Mild somatic and 
dendritic atrophy of 
Purkinje cells by 11 
months; altered gene 
expression; increased 
apoptosis 
Motor problems at 7 
months; rotarod 
deficit at 9 months 
(Chou et al., 
2010; Wang 
et al., 2010) 
Q: glutamine residues 
 
Cellular targeting of transgene expression is also an important consideration.  Knock-in models, in 
which the mutant gene remains under the control of the endogenous promoter, are more likely to 
show involvement of all neuronal populations affected in the human disease.  However, in many 
cases such models have failed to robustly mimic the human phenotype.  Nonetheless, they remain 














Transgenic models offer the opportunity to target mutant gene expression to particular tissues of 
interest, such as the Purkinje cells.  Targeting expression to a particular cell type is advantageous, as 
it allows all observable phenotypes to be correlated with the dysfunction of a distinct cellular 
population.  However, such lines are often unsuitable for biochemical studies, due to the relatively 
small proportion of cells expressing the transgene, which may result in diluted effects within a tissue 
sample (Ingram et al., 2011).  Since Purkinje cell-specific targeting fails to fully recapitulate human 
ataxia pathology, such models are less beneficial in evaluating therapeutic strategies, and may only 
be useful in proof-of-principle and screening experiments (Ingram et al., 2011).  More generalised 
targeting has therefore been used in a number of transgenic models in recent years, often employing 
the prion protein (PrP) promoter.  However, care should be taken when designing and choosing the 
transgenic construct, as many have been shown not to be expressed in Purkinje cells (Boy et al., 
2009; Borchelt et al., 1996; Fischer et al., 1996). 
 
A final consideration in the generation of transgenic models is the use of full-length versus truncated 
versions of the protein.  Although a role for the full-length protein in pathogenesis has been shown 
for several of the polyQ diseases, studies have also demonstrated the enhanced pathogenicity of 
shorter fragments, consisting mainly of the polyQ tract (Helmlinger et al., 2006a), again emphasising 
the importance of the choice of construct in understanding the disease process. 
 
Perhaps the most valuable application of mouse models to date has been to assess therapeutic 
strategies, including RNAi-based gene silencing (Xia et al., 2004).  Such investigations have also 
enabled the development of sophisticated and effective delivery systems. One such example is the 
use of recombinant adeno-associated viral vectors capable of sustained suppression of mutant HTT 
expression both in vitro and in vivo, which have been shown to partially ameliorate both cellular and 
behavioural manifestations of HD in R6/1 and HD-N171- 82Q transgenic mice (Harper et al., 2005; 













The use of transgenic mice in evaluating RNAi therapies is, however, limited by the nature of the 
models, in which an exogenous mutant gene or gene fragment has been introduced into a model 
system in which two normal endogenous copies of the gene of interest are already present (Boudreau 
et al., 2009). In these cases, gene silencing efficacy is evaluated based on the ability of the effector to 
selectively target the transgene sequence, rather than its ability to distinguish between endogenous 
pathogenic and normal alleles (Harper et al., 2005).  As suppression of a transgene against the 
background of sustained endogenous gene expression provides little information about the effect of 
non-allele-specific silencing on the wildtype copy of the gene and hence, of the potential need for 
allele-specific approaches, the use of transgenic models as a screening tool is currently limited to the 
evaluation of non-allele-specific gene silencing therapies. 
 
1.5.2 In vitro models of SCA7  
While lacking the cellular context and measurable behavioural phenotype offered by animal models, 
in vitro disease models offer the unique opportunity to test and develop allele-specific therapeutic 
modalities.  In addition, patient-derived cell models provide the advantage of examining the 
pathogenic mutation against the patient’s own genetic background, in order to identify additional 
modifiers of disease. 
 
The most rudimentary of in vitro models are those derived from commercially-available cell lines, 
into which constructs containing the disease-causing gene have been transiently transfected.  Zander 
et al. developed two such models for SCA7, using HEK293 and SH-SY5Y cells, respectively 
(Zander et al., 2001). Both formed Ataxin-7-positive, fibrillar inclusions, and displayed 
ultrastructural signs of autophagy and nuclear indentation, indicative of a major stress response, in 
the presence of mutant Ataxin-7.  When compared to autopsy samples of SCA7 human brain tissue, 













profile of transcription factors recruited to the NIs differed.  The composition of the aggregates also 
differed in composition with regards to Ataxin-7, with the full-length protein detectable in cell 
model, but not patient, aggregates.  Although the truncated forms of the protein appeared more prone 
to aggregation in transfected cells, this could be partially explained by differences in expression 
levels of the truncated versus full-length constructs - an important caveat of this study, and of the use 
of transfected cell models in general (Zander et al., 2001). 
 
The recent development of stable, inducible cell PC12 cell lines expressing N-terminal FLAG- and 
C-terminal GFP-tagged Ataxin-7 containing either ten (FLQ10) or 65 (FLQ65) glutamines, under the 
control of the Tet-off system, represents a distinct improvement over transiently transfected models 
(Yu et al., 2012).  These cell lines, which express wildtype or mutant Ataxin-7 at similar levels 
following the removal of doxycycline from the culture medium, can be readily manipulated to 
explore the effects of mutant protein levels on cellular toxicity.  Indeed, these models have already 
provided valuable insights into the aggregation and turnover of polyQ-expanded Ataxin-7, as well as 
its role in the induction of oxidative stress (Ajayi et al., 2012; Yu et al., 2012).  They have also been 
used to evaluate the efficacy of existing therapies for polyQ disease, such as antioxidants and 
pharmacological activators of autophagy (Ajayi et al., 2012; Yu et al., 2012).   
 
Transfected cell models have also proven extremely useful in the development of allele-specific 
RNAi-based therapy for SCA7.  A study by Scholefield et al. in 2009 demonstrated the ability of an 
allele-specific shRNA to selectively suppress expression of mutant ataxin-7 in transfected HEK293 
cells, based on the presence of a disease-linked SNP, resulting from a founder effect in the South 
African SCA7 patient population (Scholefield et al., 2009; Greenberg et al., 2006).  Expression of the 














Such studies provide a valuable proof-of-concept regarding the efficacy of allele-specific RNAi 
therapy for SCA7.  However, they offer little information about the restoration of wildtype function, 
or the alleviation of other cellular markers of disease, emphasising the need for further studies in 
more physiologically relevant models (Scholefield et al., 2009). 
 
Patient-derived primary cells are well-established as models of disease pathogenesis and as screening 
tools for potential therapies.  Neurodegenerative diseases, however, face a choice between readily-
available cells from “unaffected” tissues (such as dermal fibroblasts and peripheral blood 
lymphoblasts), and the disease-relevance afforded by CNS tissues, infrequently harvested at autopsy 
from consented individuals.   
 
A key breakthrough has been the identification of a cellular phenotype in cells previously believed to 
be unaffected in neurodegenerative disease.  In HD in particular, the discovery of proteasome 
impairment (Seo et al., 2004) and RNA toxicity (de Mezer et al., 2011) in patient fibroblasts has 
strengthened the argument in favour of their use for RNAi screening (Gagnon et al., 2010; Van 
Bilsen et al., 2008; Zhang et al., 2009).   
 
In SCA7, patient fibroblasts have been shown to express an N-terminal truncated fragment of mutant 
Ataxin-7, similar to that found in patient brain tissue, and in PrP-SCA7-c92Q transgenic mice 
(Garden et al., 2002).  Most recently, SCA7 fibroblasts have been used to confirm the presence of a 
regulatory antisense transcript associated with CTCF-mediated regulation of ataxin-7 gene 
expression (Sopher et al., 2011).  To date, however, there have been no investigations into the 
presence of transcriptional dysregulation in these patient cells.  (The role of fibroblasts in 













1.5.2.1 Induced pluripotent stem cell-derived models  
Since the first derivation of human embryonic stem cells (ESCs), the inherent properties of 
pluripotent cells, namely their ability to propagate indefinitely without commitment in vitro, and 
their capacity to differentiate into cell lineages belonging to the three germ layers, have made them 
an attractive source of cells for basic research, as well as regenerative medicine (Drews et al., 2012; 
Thomson et al., 1998).   However, ethical and immune rejection concerns arising from the use of 
stem cells derived from human blastocysts have prompted research into alternative sources of 
pluripotent cells. 
 
Although once believed to arise through the progression of distinct developmental stages in strict 
temporal order, mammalian development is now widely regarded as being epigenetically regulated 
and thus, reversible (Yu et al., 2007).  The results of seminal somatic cell nuclear transfer 
experiments demonstrated that nuclei from differentiated amphibian and mammalian cells could be 
reprogrammed to an undifferentiated state by trans-acting factors present in the cytoplasm of the 
recipient oocyte (Wilmut et al., 1997; Gurdon 1962).  This led to a search for factors which might 
mediate similar reprogramming without the need for nuclear transfer. 
 
The generation of embryonic stem cell (ESC)-like cells, termed “induced pluripotent stem cells” 
(iPSCs), from mouse and human fibroblasts using the defined factors OCT3/4, SOX2, c-MYC and 
KLF4, or OCT4, SOX2, NANOG and LIN28, was first described in 2006 and 2007 (Takahashi et al., 
2007; Yu et al., 2007; Takahashi and Yamanaka, 2006).  These findings have subsequently been 
replicated in several studies, confirming the ability of both four-factor combinations of transcription 
factors to reprogram differentiated human cells to a pluripotent state, and opening up exciting new 
opportunities in the field (Maherali et al., 2007; Okita et al., 2007; Park et al., 2007; Wernig et al., 












exploited; notably in the derivation of neurons from patients with a variety of neurodegenerative 
conditions (Koch et al., 2011; Zhang et al., 2010; Dimos et al., 2008; Ebert et al., 2008).   
 
Dimos et al. (2008) provided the first evidence that iPSCs could be generated directly from elderly 
patients with chronic disease – in their case, an 82-year old female patient with familial ALS.  
Patient fibroblasts were retrovirally transduced with the reprogramming factor combination 
OCT4/SOX2/KLF4/c-MYC, and gave rise to colonies with a distinctive ESC-like morphology after 
approximately three weeks in culture.  Colonies displayed typical ESC markers, and could 
spontaneously differentiate into representative phenotypes of the three embryonic germ layers, a 
hallmark of pluripotency.  Furthermore, using an established protocol which recapitulates aspects of 
spinal motor neuron differentiation, iPSCs could be differentiated to a spinal motor neuron 
phenotype, expressing key motor neuron markers such as HB9.  However, the cells failed to display 
any disease-associated phenotypic changes (Dimos et al., 2008). 
 
A similar approach was followed by Ebert et al. (2008), who sought to address the major spinal 
motor neuron disease of childhood, spinal muscular atrophy (SMA), caused by a genetic mutation in 
the survival motor neuron-1 gene (SMN1).  In this case, fibroblasts from a single patient and his 
unaffected mother were transduced with lentiviral constructs containing the reprogramming factors 
OCT4/SOX2/NANOG/LIN28, resulting in the generation of iPSCs which could be differentiated into 
a variety of different cell types, including cells with a spinal motor neuron phenotype.  Over time, 
these iPSC-derived motor neurons were shown to reduce in size and number in patient cultures 
versus controls.  In addition, patient iPSCs showed a deficiency in nuclear SMN protein aggregates 
similar to that observed in the disease, which could be ameliorated by treatment with VPA or 













At the time of initiation of this study, no iPSC-derived models were available for SCA7.  The 
generation of iPSC-derived neurons from a single adult SCA7 patient in China, carrying 45 CAG 
repeats, has subsequently been reported (Luo et al., 2012).  However, there is currently no data 
available concerning the presence of a cellular phenotype in these neurons.  Furthermore, no iPSC-
derived models have yet been generated from patients in South Africa, a country with a uniquely 
high number of SCA7 affected individuals, and a disease-linked SNP ideally suited to therapeutic 
targeting.  Indeed, the importance of iPSC-based research in African populations cannot be 
overstated, as the high degree of structural and population genetic diversity provide a unique 
opportunity to dissect genetic risk for both infectious and complex diseases through the generation of 
iPSC lines which represent a vast spectrum of human genetic variation (Fakunle 2012). 
 
(The importance of iPSC-derived models for neurodegenerative disease is addressed in more detail 













1.6 Aims and objectives  
This project aimed to establish and evaluate patient-derived cell models of SCA7, to be used in the 
investigation of the molecular pathogenesis of SCA7 (with particular reference to transcriptional 
dysregulation), and in the evaluation of previously-developed therapies for the disease.   
 
1.6.1 Objectives  
The objectives of the investigation were as follows: 
1. To investigate the presence of disease-associated transcriptional changes in SCA7 patient 
fibroblasts, using a candidate gene approach. 
2. To evaluate the efficacy of a previously-designed siRNA therapy for SCA7 in patient 
fibroblasts, with particular reference to the restoration of observable transcriptional changes. 
3. To establish and characterise induced pluripotent stem cell (iPSC) lines derived from SCA7 
patient fibroblasts. 
4. To differentiate these iPSCs into neurons using established protocols. 













Chapter 2 Materials and Methods 
2.1 Ethics approval and patient recruitment  
Ethics approval for the study was granted by the University of Cape Town (UCT) Faculty of Health 
Sciences Human Research Ethics Committee (REC REF. 380/2009 and 460/2010), and was renewed 
annually, incorporating amendments to the project protocol where necessary.  Confirmation of ethics 
approval, together with an example of a patient information sheet and consent form, can be found in 
Appendix 1.  
 
Suitable patients were identified from the UCT Division of Human Genetics DNA database, based 
on a positive diagnosis for SCA7, and the availability of contact details.  Two patients were enrolled 
in the study once they had given written informed consent to participate.   
 
Patient 1518 is a 44-year old affected female of Black African origin, with a recorded CAG repeat 
expansion length of 42 at diagnosis, and a reported age of onset of approximately 29 years.  Patient 
1519 is the son of patient 1518, a 25 year old male of Black African origin, with a recorded CAG 
repeat expansion of approximately 51 repeats, and an age of onset of approximately 14 years. 
 
2.2 Establishment of primary fibroblast cultures  
Primary fibroblast cultures were established from punch skin biopsies taken from the two patients 
who had consented to participate in the study, as previously described (Freshney, 2010).  Control 
fibroblast lines were obtained from Lonza (Basel, Switzerland).   The control designations are as 
follows: “SC Con”: Lonza CC-2511, lot 0000086510, a 44 yr old female of Caucasian origin; “JS 
Con”: Lonza CC-2611, lot 0000160309,  a 51 year old female of Caucasian origin; “BA Con”: Lonza 












fibroblast line was obtained from the cell repositories of the Coriell Institute for Medical Research 
(Camden, New Jersey, USA), and was designated “SCA7 Coriell” (GM03561, a 22 year old female 
of Black African origin).  A summary of the fibroblast cell lines used in this study can be found in 
Table 2. 
Table 2 Summary of patient and control fibroblast cell lines used in this study 
Fibroblast line (CAG)exp Age  Sex Ethnicity Age at Disease 
Onset 
Clinical data 
1518 42 44yrs F Black African 29yrs Impaired mobility from 22yrs 
1519 51 25yrs M Black African 14yrs Ocular symptoms from 14yrs 
SCA7 Coriell 55 22yrs F Black African Unknown Positive family history 
JS Con N/A 44yrs F Caucasian N/A N/A 
SC Con N/A 51yrs F Caucasian N/A N/A 
BA Con N/A 22yrs F Black African N/A N/A 
(CAG)exp: Number of CAG repeats on expanded (mutant) allele; N/A: not applicable 
 
Cells were cultured in GIBCO Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, 
Carlsbad, California, USA), supplemented with 10% (v/v) Foetal Calf Serum (Life Technologies), 
and 1X Antibiotic/Antimycotic containing Penicillin, Streptomycin and Amphotericin B (Life 
Technologies) (hereafter referred to as DMEM+10% FCS+1X antibiotic/antimycotic).  Cells were 
maintained at 37°C in a humidified atmosphere with 5% CO2.  Media was replaced every 3-5 days.  
General protocols and reagents for cell culture can be found in Appendix 2. 
 
2.3 DNA isolation  
DNA used for the confirmation of disease status was extracted from whole fresh blood samples using 
the PUREGENE Genomic DNA Isolation Kit (Gentra Systems, Minneapolis, Minnesota, USA).  
DNA extraction from cultured cells was performed using the DNeasy Blood and Tissue Kit 
(QIAGEN, Hilden, Germany), following the manufacturer’s instructions.  After extraction the 
quality and quantity of DNA was assessed using a NanoDrop spectrophotometer (Thermo Scientific, 
Wilmington, Massachusetts, USA).  Samples with an A260/A280 absorbance ratio of 1.8 to 2.0 were 












2.4 RNA isolation and cDNA synthesis  
RNA was isolated from cultured cells using the HighPure RNA Isolation Kit (Roche Diagnostics, 
Basel, Switzerland), as per the manufacturer’s instructions.  The quality and quantity of RNA was 
assessed using a NanoDrop spectrophotometer (Thermo Scientific).  Samples with an A260/A280 
absorbance ratio of 1.8 to 2.0 were stored at -80°C for further experiments. 
 
Synthesis of cDNA was performed using the Applied Biosystems High Capacity cDNA Reverse 
Transcription Kit (Life Technologies) as per the manufacturer’s instructions, using 500ng-1µg 
template RNA, together with 1X reverse transcriptase (RT) Buffer, 4mM dNTPs, 1X random RT 
primers and 1µl MultiScribe reverse transcriptase, in a final reaction volume of 20µl.  The reaction 
conditions were as follows: 10min at 25°C, 2hrs at 37°C, and 5min at 85°C. 
 
2.5 CAG repeat length determination   
The length of the disease-causing CAG repeat in ataxin-7 was determined from DNA by means of 
polymerase chain reaction (PCR) and automated fluorescent genotyping.  The PCR reaction mix 
consisted of 0.4µM each, forward and reverse primer (Appendix 3, A3.1), 0.6units of GoTaq DNA 
polymerase (Promega, Madison, WI, USA), 100ng of DNA, and Failsafe buffer J (Epicentre 
Biotechnologies, Madison, WI, USA) at a final concentration of 1X, made up to a final reaction 
volume of 10µl.  Cycling conditions were as follows: 95°C for 5min; followed by 30 cycles of 95°C 
for 30 seconds, 53°C for 6 seconds and 72°C for 40 seconds; and a final elongation step at 72°C for 
7min.  To confirm the presence of a product, an aliquot (usually 5µl) of each PCR reaction was 
resolved on a 2% (w/v) agarose gel, containing 500ng/ml Ethidium Bromide (Sigma-Aldrich, St 
Louis, MO, USA), for approximately 40min, at 160V, before visualisation under UV light, using the 
UVIPro Gel Documentation System (UVITec, Cambridge, UK).  Images were acquired using 












molecular mass of the bands observed, 500ng of the Gene Ruler 100bp DNA Ladder Plus Molecular 
Weight Marker Improved (Fermentas International Inc., Burlington, Canada) (Appendix 3, A3.2) 
was included as a size standard. 
 
Automated fluorescent genotyping was performed using the ABI PRISM 3100xl Genetic Analyzer 
(Applied Biosystems by Life Technologies).  Samples were prepared by mixing 1µl of PCR product 
with 8µl HiDi formamide (Applied Biosystems) and 0.4µl of the size standard GeneScan 500 ROX 
(Applied Biosystems), and denatured for 5min at 95°C, before snap-cooling on ice.  Genotyping 
results were collected using ABI PRISM 3100 Data Collection software (Applied Biosystems) and 
analysed using the ABI PRISM GeneMapper software v3.0 (Applied Biosystems).   
 
The length of the CAG repeat [(CAG)n] was approximated using the following equation, adapted 
from Dorschner et al. (2002): 
 
n = (0.3063 x Length of major PCR product in base pairs) – 76.475bp 
                  3 
 
where the major PCR product was defined as the product generating the highest fluorescent peak, as 
detected using the ABI PRISM 3100xl Genetic Analyzer.  A repeat in the pathogenic range was 
defined as any allele with a repeat length >36 (Lebre and Brice, 2003; Einum et al., 2001). 
 
2.6 SNP genotyping  
To determine the alleles of the disease-linked SNP (rs3774729) present in each patient, PCR was 
performed using the standard reaction mix and conditions outlined in Appendix 3 (A3.3 and 3.4), 












3 (A3.1).  An aliquot of the resultant PCR product was electrophoresed on a 1% (w/v) agarose gel as 
described in Section 2.5. 
 
Depending on the efficiency of PCR, between 3 and 8µl of PCR product was then subjected to cycle 
sequencing using the ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems), following the manufacturer’s instructions outlined in the Automated DNA Sequencing 
Chemistry Guide (Applied Biosystems, Copyright 1998).  The reaction mix consisted of 0.5µM of 
the reverse primer, 2µl BigDye Terminator Mix (Applied Biosystems), and 4µl BigDye Sequencing 
Dilution Buffer, made up to a final volume of 20µl.  Reaction conditions were as follows: 96°C for 
5min; followed by 30 cycles of 96°C for 30 seconds, 50°C for 15 seconds and 60°C for 4min. 
 
Following cycle sequencing, the amplified DNA was purified from contaminating reagents (such as 
dNTPs, excess primer or DNA polymerase) by subjecting the reaction mixture to ethanol 
precipitation.  Two microlitres of 1.5M Sodium Acetate (pH>8, 250mM EDTA) (Atria Genetics, San 
Francisco, California, USA) and 2.5 volumes of 100% ethanol were added to the reaction mixture, 
which was then incubated at -20°C for at least 2 hours.  This mixture was centrifuged for 10min at 
10 000rpm using a standard benchtop microcentrifuge.  The supernatant was discarded, and the pellet 
resuspended in 20µl 70% ethanol, followed by a second centrifugation step for 10min at 10 000rpm.  
The supernatant was again discarded, and the pellet left to air dry for at least 1 hour at room 
temperature.  Finally, the pellet, containing purified, amplified DNA for sequencing, was 
resuspended in 10µl Hi-Di formamide. 
 
Automated sequencing was performed on the ABI PRISM
®
 3100 Genetic Analyzer (Applied 
Biosystems) at 60°C, using the POP-7 separation polymer (Applied Biosystems).  Sequencing results 












analysed initially using Sequencing Analysis v3.7 software (Copyright 1989-2001, Applied 
Biosystems). The sequences generated for each sample were edited, reverse complemented, and 
aligned with the reference sequence (obtained from NCBI) using the ClustalW Multiple Alignment 
accessory application available in BioEdit Sequence Alignment Editor v7.0.0 (Hall, 1999). 
 
2.7 Neon transfection (RNAi)  
Transfection of control and patient (1519) fibroblasts with siRNA was performed using the Neon 
Transfection System (Life Technologies), following manufacturer’s instructions.  Briefly, aliquots of 
three siRNAs – siR-atxn7 (targeting both alleles of the ataxin-7 transcript), siR-p16 (targeting the 
mutant allele) and siR-NS (a non-specific siRNA kindly provided by Dr Christopher Sibley, 
University of Cambridge) – were prepared, at concentrations of 20nM, 5nM and 1nM, in sterile 
distilled water.  The siRNA sequences can be found in Appendix 3 (A3.5).  Fibroblasts, cultured as 
described in Section 2.2, were dissociated in TrypLE (Life Technologies), centrifuged at 1500rpm 
for 5min in a standard benchtop centrifuge, and resuspended in phosphate buffered saline (PBS) 
(Life Technologies) at a concentration of 6x10
5 
cells/ml. One millilitre aliquots of the cell suspension 
were decanted into microcentrifuge tubes and centrifuged for a further 3min at 1000rpm, in a 
standard benchtop microcentrifuge.  The upernatant was aspirated, and cells were resuspended in 
Buffer R before being mixed with aliquotted siRNA immediately prior to electroporation.  
Electroporation was performed in triplicate at the following settings: Volts: 1700, Width: 20; Pulse 
Number: 1.  Transfected fibroblasts were seeded onto poly-L-lysine (Life Technologies) coated 6-
well plates in antibiotic-free DMEM + 10% FCS and incubated at 37°C, 5% CO2  for 24 hours, 
before being changed to DMEM+10% FCS+1X antibiotic/antimycotic.  RNA was harvested seven 













2.8 Real-time quantitative PCR  
Real-time quantitative PCR (qPCR) was performed on the Applied Biosystems StepOne Plus Real-
time PCR System (Life Technologies), using the Power SYBR Green PCR Master Mix (Applied 
Biosystems).  Primers (listed in Appendix 3, A3.6) were obtained from PrimerDesign Ltd 
(Southampton, UK), IDT (Leuven, Belgium), or Sigma-Aldrich.   
 
The reaction mix for all qPCRs was as follows:  10µl of Power SYBR Green PCR Master Mix 
(Applied Biosystems), 1µl of PrimerDesign Primer Mix (if PrimerDesign primers were used), or 
125nM each of forward and reverse primer (if IDT primers were used), and 10ng of sample cDNA, 
made up to a final volume of 20µl with sterile distilled water. 
 
Relative quantities of target mRNA were determined using the relative standard curve method. 
Standard curves were prepared for each primer pair, from serial dilutions of pooled sample cDNA.  
Universal cycling conditions were used (95°C for 10min, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1min).  PCRs were per ormed in technical duplicate or triplicate, on at least 
three biological replicates, and results analysed using the StepOne Software v2.1 (Applied 
Biosystems). Gene of interest expression was normalised to β-Actin expression in each case. 
 
The design and reporting of qPCR experiments aimed to comply with the Minimum Information for 
publication of Quantitative real-time PCR Experiments guidelines (Taylor et al., 2010; Bustin et al., 
2009) as far as possible. 
 
2.9 Generation and characterisation of patient-derived iPSCs 
The iPSC lines used in this study were generated in collaboration with Dr Sally Cowley and Ms Jane 












Oxford), and Dr Janine Scholefield (Gene Expression and Biophysics Laboratory, CSIR, Pretoria/ 
Department of Physiology, Anatomy and Genetics, University of Oxford).  Their kind provision of 
protocols for this section is hereby acknowledged. 
 
2.9.1 Bulk preparation of plasmids containing reprogramming and viral 
packaging genes  
The pMXs-hKlf4 (plasmid # 17219), pMXs-hSox2 (# 17218), pMXs-hOct3/4 (# 17217) and pCMV-
VSV-G (# 8454) plasmids, as well as pMXs-hc-Myc (# 17220) and pMXs-Nanog (# 13354) (in the 
case of iPS SC NHDF),  were obtained from Addgene (Cambridge, MA, USA) (Takahashi et al., 
2007; Takahashi and Yamanaka, 2006; Stewart et al., 2003).  Bulk stocks of each plasmid were 
obtained by transformation into competent DH5α Escherichia coli cells grown on ampicillin 
selective agar plates, followed by preparation using the EndoFree Plasmid Maxi Kit (QIAGEN), 
following manufacturer’s instructions. 
 
2.9.2 Preparation of retroviral vectors 
The Platinum-GP (Plat-GP) retroviral packaging cell line (Cell Biolabs, San Diego, California, USA) 
was used in the production of retroviral vectors for reprogramming.  For routine cell culture, Plat-GP 
cells were maintained in DMEM+10% FCS+1X antibiotic/antimycotic (all Life Technologies), 
containing 10µg/ml blasticidin (Sigma-Aldrich), at 37°C, 5% CO2. 
 
At Day 0, Plat GP cells were seeded at a density of approximately 14 million per T175 flask, in 
DMEM+10% FCS+1X antibiotic/antimycotic (all Life Technologies), and incubated overnight at 














On Day 1, the following transfection mix was prepared for each of the pMXs plasmids: 
Tube A: 
42µg pMXs plasmid (i.e. pMXs-hKlf4, -hSox2 -hOct3/4, -hc-Myc or -Nanog) 
28µg pCMV-VSV-G (envelope plasmid) 
Made up to 8.1ml with DMEM (containing no serum or antibiotic/antimycotic) 
 
Tube B:  
191ul 10µM polyethylenimine (PEI) (Sigma-Aldrich) 
7.98ml DMEM 
 
The contents of tube B were added to tube A in a dropwise fashion with constant mixing, and 
incubated for 20min at room temperature.  The media on the Plat-GP cells, which were by then 70-
80% confluent, was replaced with the transfection mix, and the cells were incubated for four hours at 
37°C, 5% CO2.  The transfection mix was then aspirated and replaced with blasticidin-free culture 
media, and the cells incubated for 48hrs at 37°C, 5% CO2. 
 
Supernatant from the cultured Plat-GP cells was harvested at 48 and 72 hrs post-transfection, pooled, 
and centrifuged at 1500rpm for 5min in a standard benchtop centrifuge, to remove cellular debris.  
The supernatant was then filtered through a 0.45µm low-protein binding filter (Millipore, Billerica, 
MA, USA). 
 
To concentrate the virus, pooled supernatants were decanted into sterile 25mm x 99mm Ultraclear 
ultracentrifuge tubes (Beckman Coulter, Fullerton, California, USA), and centrifuged for 90min at 
25 000rpm, at 4°C, in a Beckman L8-80M ultracentrifuge (Beckman Coulter, SW28 rotor).  The 












concentration of greater than 100X, and incubated for 1 hour on ice before aliquotting for storage at  
-80°C. 
 
2.9.3 Determination of viral titre 
To determine viral titre, HEK293 cells (seeded at 30 000 cells/well in a 24-well format, and 
incubated overnight at 37°C, 5% CO2) were infected with a virus cocktail consisting of 10μl 
concentrated virus stock and 5μg/ml polybrene (Sigma-Aldrich) in a total volume of 1ml 
DMEM+10% FCS+1X antibiotic/antimycotic (all Life Technologies).  Plates containing infected 
cells were centrifuged at 1200xg for 45min at 15°C, and incubated for 72hrs at 37°C, 5% CO2.  In 
parallel, HEK293 cells transfected with 430ng of each plasmid (pMXs-hKlf4, -hSox2, -hOct3/4or     
-hc-Myc), mixed with 6µl PEI (Sigma-Aldrich) were included as positive controls.  Medium was 
changed 4hrs after transfection. 
 
After 72hrs, the infected and transfected cells were washed with PBS, and fixed in 4% (w/v) 
paraformaldehyde in FACS buffer (Appendix 3, A3.7) at room temperature for 10min.  The cells 
were then permeabilised in FACS buffer + 0.1% (v/v) saponin (Sigma-Aldrich) + 10% serum 
(specific to the species in which the secondary antibody was raised), at room temperature for 40min.  
Cells were incubated with primary antibody (10µg/ml in FACS buffer+0.1% (v/v) saponin) at room 
temperature for 1-2hrs, washed, and incubated with secondary antibody (10µg/ml in FACS 
buffer+0.1% (v/v) saponin) for 1hr at room temperature, protected from light.  Following 
counterstaining with DAPI, cells were washed and fixed in 4% formaldehyde in FACS buffer (Fig. 














Viral titre was calculated using the following equation: 
Number of infectious particles per ml = (% of infected cells x total number of HEK293 cells seeded 






Figure 5 Immunostaining to calculate retroviral titre.  (a) HEK293 cells infected with 10µl of concentrated pMXs-
hKlf4-retrovirus stock were subjected to immunostaining for Klf4 (green) 72hrs post-infection to determine the viral titre 
for subsequent reprogramming experiments.  (b) Cells transfected with the reprogramming gene plasmid were used as a 
positive control. (c) Untransfected cells served as a negative control.  Nuclei are stained with DAPI (blue). Scale bar: 
100µm. 
 
2.9.4 Reprogramming fibroblasts to iPSCs  
Reprogramming of patient and control fibroblasts to iPSCs was based on the protocol outlined by 
Takahashi et al., 2007.  The SCA7 and iPS George (control) iPSC lines used in this study were 
generated using the method described below.  The control line iPS SC NHDF was generated by 
collaborators Dr Sally Cowley and Ms Jane Vowles following a similar protocol, using a 
combination of five reprogramming factors – OCT4, SOX2, KLF4, c-MYC and NANOG. 
 
Primary fibroblasts from either patient or control individuals were plated at a concentration of 50 000
 
cells/well in a 6-well format (Day 0).  After 24hrs (i.e. on Day 1), fibroblasts were infected with the 
concentrated virus stock (Section 2.9.3), at a multiplicity of infection (MOI) of approximately 1, 












diluted in DMEM+10% FCS+1% antibiotic/antimycotic (all Life Technologies), containing 5µg/ml 
polybrene (Sigma-Aldrich).  A second infection was performed 24hrs later (Day 2). 
 
On Day 3 (48hrs after the first infection), virus-containing medium was replaced with DMEM+10% 
FCS+1X antibiotic/antimycotic (all Life Technologies), and cells were incubated for a further 48hrs.  
On Day 5, infected fibroblasts were trypsinised, and re-seeded onto a previously-prepared inactivated 
mouse embryonic fibroblast (iMEF) feeder layer (Appendix 4, A4.2 and 4.3) at a concentration of 
approximately 8 000 cells/well, in DMEM+10% FCS+1X antibiotic/antimycotic (all Life 
Technologies).  An aliquot of fibroblasts from each line was seeded in iMEF-free conditions to 
determine the efficiency of infection, using the immunostaining protocol outlined in Section 2.9.3. 
 
On Day 6, media on the fibroblast/iMEF plates was removed and replaced with human embryonic 
stem cell medium (huESC medium – see Appendix 4, A4.1).  From Day 7 to Day 13, a half-medium 
change (i.e. removal of half the volume of culture medium and replacement with half the volume of 
fresh medium) was performed every second day.  Valproic acid (VPA), at a final concentration of 
2mM, was included in the medium for the first 10 days post-infection.  Thereafter, medium was 
replaced every day with fresh, sterile-filtered iMEF-conditioned huESC medium (Appendix 4, A4.4), 
supplemented with 10ng/ml basic fibroblast growth factor (bFGF, R&D Systems, Minneapolis, 
Minnesota, USA).  In most cases, iPSC colonies were observed approximately 20 to 40 days post-
infection, whereupon they were manually dissected using a pulled-glass pipette, and subcultured as 
described in Section 2.9.5. 
 
2.9.5 iPSC maintenance culture  
In the case of iPSC colonies grown on an iMEF feeder layer, manual dissection was performed 












huESC medium (Appendix 4, A4.1) at 37°C, 5% CO2.  A detailed protocol for the preparation of 
iMEF feeders can be found in Appendix 4 (A4.2 and 4.3). 
 
In preparation for DNA or RNA isolation or the formation of embryoid bodies (see Section 2.9.6.4), 
iPSCs were transitioned from growth on an iMEF feeder layer to growth in feeder-free conditions, on 
the commercially-available growth matrix, Matrigel (BD Biosciences, Franklin Lakes, New Jersey, 
USA).  Matrigel-coated plates were prepared according to the manufacturer’s instructions. Details of 
the conversion of iPSCs from growth on iMEF feeders to feeder-free culture can be found in 
Appendix 4 (A4.5). 
 
Where iPSCs had been grown on Matrigel (BD Biosciences), cells were dissociated every 5-7 days 
using TrypLE (Life Technologies) and re-plated at a concentration of approximately 5x10
5
 cells/well 
in supplemented mTeSR medium (Stem Cell Technologies, Vancouver, Canada), containing 10µM 
Rho-Kinase inhibitor Y-27632 (Sigma Aldrich), as described in Appendix 4 (A4.6).   
 
Half (in the case of iPSCs on iMEF feeders) or full (in the case of iPSCs grown in feeder-free 
conditions) medium changes were performed every day. 
 
2.9.6 iPSC characterisation 
2.9.6.1 Expression of exogenous and endogenous pluripotency genes  
The expression levels of exogenous and endogenous pluripotency genes were measured by endpoint 
RT-PCR, using the primers listed in Appendix 4 (A4.7 and 4.8).  The reaction mix in each case was 
as follows: 200nM each of forward and reverse primer, 200µM PCR Nucleotide Mix (Roche), 1 unit 












England Biolabs) and 50ng template cDNA, made up to a final volume of 25µl with sterile distilled 
water.  No RT controls were included where necessary. 
 
The standard PCR cycling conditions (Appendix 3, A3.4) were used, and expression was determined 
by electrophoresis of the PCR product on a 1% (w/v) agarose gel incorporating 500ng/ml Ethidium 
Bromide, as described in Section 2.5. 
 
2.9.6.2 Expression of pluripotency markers  
The expression of pluripotency markers was determined by subjecting iPSC colonies grown on 
iMEF feeder layers to immunofluorescence staining as follows:  
 
Cells were fixed in 4% paraformaldehyde for 15min at room temperature.  Blocking was performed 
in a solution of 10% (v/v) serum (specific to the species in which the secondary antibody was raised) 
in PBS + 0.1% (v/v) Triton X-100 for 1-3hrs at room temperature.  Cells were then incubated with 
primary antibody (see Appendix 3, A3.8), at a dilution of between 1:100 and 1:500 in 1% (v/v) 
serum + PBS+ 0.1% (v/v) Triton X-100, overnight at 4°C.  After washing three times for 10min each 
in PBS+ 0.1% (v/v) Triton X-100, cells were incubated with secondary antibody (Appendix 3, A3.8), 
diluted 1:500 in 1% (v/v) serum + PBS+ 0.1% (v/v) Triton X-100, for 1hr at room temperature, 
protected from light.  This was followed by a further three washes for 10min each in PBS.  Where 
used, a nuclear stain (either DAPI or Hoechst, at 500ng/ml) was added to the PBS during the second 
wash.  In the case of cells fixed to coverslips, coverslips were mounted onto microscope slides using 
FluoroMount G (Southern Biotech, Birmingham, Alabama, USA), and sealed with clear nail varnish, 














2.9.6.3 Genomic integrity  
The genomic integrity of iPSC lines generated in Section 2.9.4 was assessed using the Infinium HD 
assay, on HumanCytoSNP-12v2.1 bead-chips (Illumina, San Diego, California, USA), at the 
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.  DNA extracted 
from iPSCs, and the fibroblast lines from which they had been derived, was quantified using the 
Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies), following the manufacturer’s 
instructions. The final concentration of DNA was adjusted to 50ng/μl in TE (10mM Tris, 1mM 
EDTA) solution, and 200 to 500 ng of high quality genomic DNA with an A260/280 ratio of 1.65-2.1 
was subjected to array analysis.  
 
Genomestudio software (Illumina) was used to carry out quality control checks of the procedure, and 
Karyostudio software (Illumina) was used to provide final reports.   
 
Standard G-banding chromosome analysis was performed for a single control iPSC line (iPS 
George), and its parental fibroblast line (JS Con), at Unistel Medical Laboratories (Cape Town, 
South Africa). 
 
2.9.6.4 In vitro differentiation from embryoid bodies  
Embryoid bodies (EBs) were generated from using 5x10⁶ iPSCs cultured on Matrigel (BD 
Biosciences) in mTeSR medium (Stem Cell Technologies) using Aggrewell 800 plates (Stem Cell 
Technologies), following the manufacturer’s instructions,.  EBs were cultured in mTeSR medium + 
10mM Rho-Kinase Inhibitor (Sigma-Aldrich), and a 75% medium change was performed daily for 
three days. For undirected differentiation, EBs were harvested on day 4 using a 40µm cell strainer, 
and transferred to ultra low attachment plates in mTeSR  medium (Stem Cell Technologies). Media 












gelatin-coated plates and cultured for a further 8 days.  RNA was isolated from each cell line in 
triplicate (as described in Section 2.4), and expression of germ-layer specific markers (endoderm: 
FOXA2 and AFP, mesoderm: MSX1, ectoderm: PAX6 and MAP2) was assessed by endpoint RT-
PCR, as described in Section 2.9.6.2.  Primers are listed in Appendix 4 (A4.9).  
 
Directed differentiation was performed as follows (protocol adapted from the Barcelona Stem Cell 
Bank):  For endoderm, mTeSR medium was replaced with EB medium (Appendix 4, A4.1) after 
24hrs of EB formation, and EBs were cultured for a further 2-3 days in suspension.  EBs were then 
seeded into gelatin-coated slide flasks in EB medium, and cultured for a further 15-20 days, with 
medium changed every 2-3 days. 
 
For mesoderm, mTeSR medium was replaced with EB medium supplemented with 0.5mM ascorbic 
acid, after 24hrs of EB formation, and EBs were cultured for a further 2-3 days in suspension.  EBs 
were then seeded into gelatin-coated slide flasks in EB medium supplemented with 0.5mM ascorbic 
acid, and cultured for a further 15-20 days, with medium changed every 2-3 days. 
 
Differentiation into ectoderm was assessed by the ability of the iPSC lines to differentiate into 
neuronal cells, as described in Section 2.10. 
 
To confirm the expression of germ-layer specific markers, EBs were subjected to 
immunofluorescence staining for germ layer-specific markers as described in Section 2.9.6.3.  













2.10 Neuronal differentiation from iPSCs  
The differentiation of iPSCs into neurons has been previously described (Dottori and Pera, 2008).  
Briefly, iPSCs were cultured on an iMEF feeder layer as described in Section 2.9.5.  At the time of 
manual dissection and transfer onto a fresh feeder layer, 500ng/ml human recombinant Noggin 
(R&D Systems) was added to the huESC culture medium.  The iPSC colonies were cultured for 14 
days without passage, with replacement of Noggin-containing media every second day. 
 
After 14 days of Noggin treatment, colonies were manually dissected in PBS, and single patches 
transferred to individual wells of a non-adherent 96-well plate, to allow neurosphere formation (the 
preparation of non-adherent plates is described in Appendix 5, A5.2).  Neurospheres were cultured in 
suspension in Neurobasal Medium A (NBM-A) (Life Technologies) supplemented with 10ng/ml 
human recombinant epidermal growth factor (EGF) (Millipore) and 10ng/ml bFGF (R&D Systems) 
(Appendix 5, A5.1) for approximately seven days.  For long-term culture, neurospheres were 
subcultured by manual dissection. 
 
To promote differentiation into neurons, whole neurospheres were seeded onto plates coated with 
10µg/ml poly-D-lysine (Sigma Aldrich) and 5µg/ml natural mouse laminin (Sigma-Aldrich) in 
NBM-A without bFGF and EGF supplements, and maintained at 37°C, 5% CO2 (Appendix 5, A5.3). 
Medium was changed every second day.   
 
2.10.1 Expression of neuron-specific markers 
The expression of neuron- and glial-specific markers, including βIII-tubulin, gamma-aminobutyric 
acid (GABA), and glial fibrillary acidic protein (GFAP) was assessed by immunofluorescence as 













2.11  Statistical analysis 
In cases where data from two groups were compared, statistical analysis was performed using the 
Mann-Whitney test for unpaired samples.  A two-tailed distribution, assuming unequal variances, 
was used to analyse the data.  In cases where comparisons were made between three or more groups, 
the Kruskal-Wallis test was used, followed by the Dunn’s post-test for multiple comparisons.  
Analysis was performed in GraphPad Prism v.5.0 (GraphPad Software, San Diego, CA, USA). 
 













Chapter 3 Fibroblasts as a Model for Testing RNA interference-
based Therapy for SCA7  
3.1 Introduction 
The selection of appropriate models of disease which are easy to access and manipulate, and which 
recapitulate the human phenotype, remains one of the major challenges in the development of 
effective therapies for neurodegenerative conditions.  The plethora of SCA7 transgenic mouse 
models developed over the past decade has yielded many valuable insights into the mechanisms 
underlying cellular pathology (see Section 1.5.1).  However, as the focus of neurodegenerative 
disease research shifts from understanding disease mechanisms towards the development of allele-
specific gene silencing therapies, the development of models in which both the mutant and wildtype 
alleles of a particular disease gene are present, is becoming increasingly necessary. 
 
Mounting evidence from polyQ disease patients suggests that peripheral tissues display a cellular 
phenotype in the presence of the mutant protein, including the formation of intranuclear inclusions 
(de Mezer et al., 2011; Squitieri et al., 2010; Seo et al., 2004; Giuliano et al., 2003; Sathasivam et al., 
1999).  Although not generally associated with clinical pathology, such phenotypes may nonetheless 
prove useful as measures of therapeutic efficacy in vitro. 
 
3.1.1 A polyQ disease phenotype in non-neuronal cells 
Of the peripheral cell types, cultured skin fibroblasts and Epstein Barr Virus (EBV)-transformed 
lymphoblastoid cell lines (LCLs) have been the subjects of extensive study, and have yielded many 
valuable insights into the molecular pathogenesis of polyQ diseases, including the discovery of 












an observation which may prove valuable in predicting the age of onset in presymptomatic 
individuals (Swami et al., 2009). 
 
Similar to observations in autopsied brain tissue, polyQ patient fibroblasts show nuclear localization 
(De Rooij et al., 1996) and proteolytic cleavage of the mutant protein to yield toxic N-terminal 
truncated fragments (Garden et al., 2002).  At the ultrastructural level, fibroblasts from HD 
homozygotes display numerous morphological abnormalities when compared to age-matched 
controls, including vacuolization, structural derangements of the mitochondria and endoplasmic 
reticulum, and multiple autophagic vacuoles similar to those occurring in neurons within affected 
brain regions (Squitieri et al., 2010).  Indeed, despite cell-type specific variations in pathology, 
arising as a result of differential patterns of gene expression dysregulation, the influence of specific 
microenvironments, and differences in kinetics of polyQ aggregation (and hence, in the timing of 
protein aggregation), fibroblasts appear, at least at the ultrastructural level, to most closely mimic the 
neuronal pathological phenotype (Squitieri et al., 2010).  
 
In HD and SCA2 fibroblasts, the identification of markers of DNA damage and repair pathways 
suggests that expanded polyQ proteins may activate the ataxia telangiectasia mutated kinase/ATM 
and Rad3-related kinase (ATM/ATR)-dependent DNA damage response through the accumulation of 
reactive oxygen species (Giuliano et al., 2003); while a reduction in glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) activity in HD and Alzheimer’s disease fibroblasts provides a potential 
mechanism for the hypometabolism and programmed cell death which are key features of these 
diseases (Mazzola and Sirover, 2003; Mazzola and Sirover, 2002; Mazzola and Sirover, 2001).  
Studies of fibroblasts have also provided evidence for the role of HTT in the trafficking of secretory 
and endocytic vesicles, revealing co-localisation of mutant HTT with clathrin in the Golgi network 













Non-neuronal cells have also offered insights into the most prominent manifestations of polyQ 
pathogenesis, including autophagy (Nagata et al., 2004), RNA toxicity (de Mezer et al., 2011), and 
the effects of polyQ protein on the UPS and heat shock protein pathways.   
 
UPS dysfunction in HD fibroblasts has been used as a model to understand why certain cells and 
tissues are able to cope with the effects of abnormal gene products, while others dysfunction and die 
(Davies et al., 2007; Seo et al., 2004).  HD patient fibroblasts display a similar degree of UPS 
inhibition to affected brain regions.  However, since other factors known to contribute to HD 
pathology are not affected in HD fibroblasts, it is possible that an impaired UPS alone is not 
sufficient to induce cell degeneration in HD.  Instead, it may be viewed as one of several markers of 
polyQ disease progression, resulting in severe pathology only when coupled with other catastrophic 
cellular events, such as the decreases in ubiquitin, BDNF and mitochondrial complexes observed in 
the caudate putamen of HD patients (Seo et al., 2004).   
 
Indeed, UPS inhibition appears to be compensated for in most cell types by protein quality control 
mechanisms capable of regulating the turnover of the misfolded protein, or by rapid dilution of the 
mutant protein by cell division (Zijlstra et al., 2010; Seo et al., 2004).  This is further supported by 
the observation that SCA3 patient fibroblasts, which express mutant Ataxin-3, show no sign of 
protein aggregation.  One mechanism proposed to account for this phenomenon is the significant 
upregulation of heat shock proteins HSPB1 (HSP27) and DNAJB (HSP40) family members in the 
fibroblasts of these SCA3 patients, with levels of the latter showing a correlation with age of onset, 
and hence a possible modifying role in disease progression (Zijlstra et al., 2010).  However, a study 
of similar markers of the HSR in SCA7 patient LCLs suggests that the role of these molecular 













Tsai et al. used LCLs from two SCA7 patients, with 100 and 41 CAG repeats, respectively, to 
examine the effects of polyglutamine expression on the HSR (Tsai et al., 2005).  Under basal 
conditions, levels of HSP27 and HSP70 proteins were significantly reduced in cells containing 
expanded Ataxin-7, when compared to normal LCLs.  Results from semiquantitative PCR analysis 
confirmed that the reduction in HSP70, but not HSP27, was a result of a transcriptional defect.  
Despite these defects in expression, however, mutant LCLs were still capable of heat shock protein 
induction in response to heat stress, suggesting that the HSR may remain intact (Tsai et al., 2005).  
Taken together with the observations of HSR function in SCA3 fibroblasts, these results suggest that 
HSP levels may vary according to disease, patient age and stage of progression, as well as cell type.  
Nevertheless, it appears that alterations of HSP expression in peripheral cells may also serve as 
useful markers of polyQ disease pathogenesis. 
 
These data together provide strong motivation for the use of peripheral cells in investigating the 
molecular mechanisms of polyQ disease.  In addition to subcellular pathology comparable to that of 
affected neurons, non-neuronal cells offer the advantages of easy accessibility, as well as the 
potential to harvest and culture sufficient cells for statistical analysis of pathogenic effects (Squitieri 
et al., 2010; Zijlstra et al., 2010).  Unlike patient brain tissue, obtained at autopsy, peripheral cells 
allow for the monitoring of early-stag  modifiers of disease, without the confounding effects of post-
mortem artefacts (Zijlstra et al., 2010).  
 
Most recently, the discovery in fibroblasts of a novel antisense non-coding RNA, SCAANT1, which 
represses ataxin-7 transcription in a cis-dependent fashion, has underscored the importance of non-
neuronal cells in understanding polyQ pathogenesis (Sopher et al., 2011).  Based on observations in 
SCA7 patient fibroblasts carrying 55 and 150 CAG repeats respectively, it appears that SCAANT1 
expression is dependent on ataxin-7 CAG repeat length, with an expansion resulting in decreased 












turn, to significantly elevated Ataxin-7 protein levels, creating a feed-forward effect which 
accelerates the SCA7 disease pathway by promoting increased production of the mutant protein 
(Sopher et al., 2011). 
 
3.1.2 A cellular phenotype for SCA7 in non-neuronal cells 
A strong case has been made for the role of transcriptional dysregulation as an early marker of SCA7 
pathogenesis (see Section 1.2.3).  However, to date, limited data is available regarding transcriptional 
dysregulation in patient peripheral cell types.  Since non-neuronal cells such as skin fibroblasts have 
been shown to be valuable tools in understanding disease progression and evaluating therapies, this 
study sought to identify a pattern of disease-associated transcriptional alterations in SCA7 patient 
fibroblasts, using a pool of candidate genes encoding proteins implicated in the pathogenesis of 
SCA7, which had been previously shown to be differentially expressed in SCA7 models of disease 
(Chou et al., 2010; Tsai et al., 2005). All of the genes investigated had previously shown 
approximately 1.5-fold (or greater) up- or downregulation in SCA7 mouse cerebellum or retina, 
validated by qPCR and/or western blot. 
.  
3.1.3 Fibroblasts as a tool for evaluating therapies 
In addition to their role in elucidating pathogenic mechanisms, patient-derived fibroblasts have been 
used increasingly in the evaluation of allele-specific gene silencing therapies for polyQ disease.  In 
HD in particular, a series of studies have determined the efficacy of silencing molecules targeting the 
disease-causing CAG repeat.  These silencing effectors, which include chemically modified 
antisense oligonucleotides, as well as siRNAs and microRNA mimics, demonstrated robust, allele-
specific silencing of mutant HTT (based on cumulative binding of multiple silencers to the expanded 
CAG repeat), with reports of >30-fold selectivity for the mutant transcript in some cases (Hu et al., 












Allele-specificity was reportedly enhanced by oligonucleotide modifications (Hu et al., 2009a), and 
by shifting the mechanism of silencing from mRNA cleavage to translational suppression (Hu et al., 
2010a; Fiszer et al., 2011). Although enhanced selectivity was observed in cell lines with larger 
disease-causing repeat lengths, allele discrimination was still possible in fibroblast lines containing 
minimal CAG repeats representative of most HD patients (Fiszer et al., 2011; Gagnon et al., 2010; 
Hu et al., 2010a; Hu et al., 2009a). 
 
While preferable to CAG-targeted effectors due to the reduced risk of off-target effects, SNP-based 
gene silencing molecules are subject to a number of design constraints, some of which have been 
identified and refined within the context of fibroblast disease models.  Critically, the disease-linked 
allele of the SNP must be ascertained, in order to determine the correct siRNA sequence required.  
Additional design constraints include the selection of purine:purine mismatches as targets where 
possible, as these result in the greatest disruption of the siRNA-mRNA helix, and hence confer the 
greatest degree of discriminatory power (Pfister et al., 2009).  In cases where purine:purine 
mismatches are unavailable, the introduction of additional mismatches (particularly in the seed 
region of the siRNA, which directs binding and recognition of the target mRNA) has been suggested 
to enhance selectivity of SNP sites predicted to be poor candidates for the development of allele-
specific siRNAs (Ohnishi et al., 2008).  In general, however, mismatches in the 5’ seed region offer 
only moderate discrimination, whereas mismatches 3’ to the seed region – in particular at positions 
10 and 16 of the siRNA – promote robust allele selectivity (Lombardi et al., 2009). This is likely due 
to the functions of the different regions, since allele-specificity is enhanced when the conformation 
of the siRNA-target complex blocks catalysis and RISC-mediated cleavage, rather than siRNA 
binding (Schwarz et al., 2006).  
 
In addition to design considerations, allele-specificity has been shown to be concentration dependent 











discrimination is achieved at a concentration sufficient to elicit clinically significant inhibition of the 
mutant protein (Lombardi et al., 2009; Schwarz et al., 2006). 
Fibroblasts have been instrumental in evaluating the silencing efficiency of allele-specific effectors 
designed to target disease-linked SNPs. In the case of HD, for example, an siRNA was successfully
designed to specifically target the mutant HTT transcript in a patient heterozygous for the rs363125 
SNP, in which the C-allele was found to be linked to the expansion (Van Bilsen et al., 2008).
Transfection of cultured patient fibroblasts with the siRNA resulted in an approximate 80%
reduction in mutant mRNA and protein expression, while wildtype levels were not significantly
altered (Van Bilsen et al., 2008). A similar study (Zhang et al., 2009) evaluated the efficacy of
allele-specific siRNAs in patient fibroblasts carrying the three base-pair Δ2642 deletion, present in
38% of mutant HD, but only 7% of wildtype HD alleles (Ambrose et al., 1994).  SiRNAs designed to 
target the deletion reduced expression of mutant HTT by up to 50% in patient fibroblasts, and
showed similar potent, dose-dependent effects in HeLa- and SH-SY5Y-based luciferase reporter
systems, suggesting that RNAi-based therapy is likely to be effective in a range of different cell
types. Allele-specific knockdown of the mutant allele also resulted in partial correction of HD-
associated nuclear abnormalities in patient fibroblasts, while avoiding the activation of caspase-3 
associated with silencing of both copies of the gene (Zhang et al., 2009). 
Such approaches are likely to be effective in other polyQ disorders in which disease-linked SNPs 
have been identified, including SCA3 (Miller et al., 2003) and SCA7 (Scholefield et al., 2009). 
3.1.4 RNAi-based therapy for SCA7 in South Africa 
The concept of allele-specific RNAi-based therapy for the South African SCA7 patient cohort was 












fluorescently-conjugated ataxin-7 constructs containing  10 (wildtype) or 100 (mutant) CAG repeats, 
using an shRNA designed to target a disease-linked SNP within the ataxin-7 transcript (rs3774729) 
(Scholefield et al., 2009).  The A allele of the SNP had been previously shown to co-segregate with 
the ataxin-7 CAG expansion, as a result of a founder effect in the South African population 
(Greenberg et al., 2006).  Almost complete ablation of mutant expression (to less than 10% of 
control levels) was observed when the allele-specific single nucleotide mismatch was located at 
position 16 of the shRNA guide strand (p<0.044), with a minimal effect on the wildtype target.  
Silencing resulted in a decrease in the number of Ataxin-7 aggregates, as well as a release of 
wildtype protein from sequestration (Scholefield et al., 2009). 
 
Although the abovementioned study served as proof-of-principle of the feasibility of allele-specific 
silencing as a therapeutic avenue for SCA7, the model employed provided very little information 
regarding the restoration of wildtype function, or the reversal of other cellular markers of disease, 
such as transcriptional dysregulation or loss of wildtype protein function.  In order for such a therapy 
to progress to clinical trials, it will therefore be necessary to further evaluate its efficacy in a model 
which more closely resembles the patient genetic background.  Since the applicability of transgenic 
models to the study of allele-specific silencing to date has been limited, this study has focused on the 














The aims of the experiments described in this chapter were thus: 
1. to ascertain the presence of a cellular phenotype (transcriptional dysregulation) in SCA7 
patient fibroblasts 
2. to validate the allele-specificity of a previously-designed siRNA targeting the mutant allele of 
ataxin-7 (Scholefield et al., 2009) and 
3. to determine whether siRNA-mediated silencing of ataxin-7 was sufficient to ameliorate any 
observed cellular phenotype,  
with the ultimate goal of evaluating SCA7 patient fibroblasts as a model for testing RNAi-based 
therapies. 
 
This work was completed in collaboration with Dr Janine Scholefield (Department of Physiology, 
Anatomy and Genetics, University of Oxford), and Ms Danielle Smith (Division of Human Genetics, 















3.2.1 Altered expression of transcripts in SCA7 patient fibroblasts 
In order to evaluate differences in gene expression between SCA7 patient and control dermal 
fibroblasts, six candidate transcripts were chosen, based on their relevance to known polyQ disease 
pathways.  These included genes encoding proteins involved in cellular stress such as HSP27, -70, -
105 and DNAJ/HSP40 homologue, Subfamily A, member 1 (DNAJA1) as well an RNA chaperone, 
RNA Binding Motif protein 3 (RBM3); and the ubiquitin carboxy-terminal hydrolase L1 (UCHL1), 
involved in deubiquitination.  All of these genes had previously been shown to be differentially 
expressed in SCA7 disease models (Chou et al., 2010; Tsai et al., 2005). 
 
Comparison of transcript levels of these six genes between control and SCA7 patient fibroblasts was 
performed by means of qPCR (Fig. 6). Consistent with the SCA7 models previously described, a 
two-fold increase in DNAJA1 expression (p=0.03), as well as a two-fold decrease in UCHL1 
expression (p=0.04), was observed in SCA7 patient fibroblasts relative to control lines. No 














Figure 6 Transcriptional changes in SCA7 patient fibroblasts. Expression of endogenous transcripts in SCA7 
fibroblasts relative to controls is shown, normalised to β-Actin. Values are mean ± SEM. Control fibroblasts, n = 2, 
SCA7 fibroblasts, n = 3. UCHL1, Ubiquitin carboxy-terminal hydrolase LI; HSP-, heat shock protein -27; -70; -105; 
DNAJA1 (HSP40), DNAJ homolog, subfamily A, member 1; RBM3, RNA-binding motif protein 3. * indicates a p value 
< 0.05. 
 
3.2.2 Validation of a previou ly-designed allele-specific siRNA targeting ataxin-7 
One of the key challenges to be addressed when designing RNAi-based therapies is the question of 
whether or not an allele-specific approach is required (see Section 1.4.1.1.2).  The feasibility of 
allele-specific silencing for SCA7 has been previously demonstrated in an artificial cell model, using 
an siRNA targeting a common SNP linked to the mutation in the South African patient population 
(Scholefield et al., 2009; Greenberg et al., 2006).  
 
In order to evaluate the efficacy of this allele-specific therapy in patient-derived cells, the expression 
of the wildtype and mutant alleles of ataxin-7 were evaluated in fibroblasts from a SCA7 patient 
heterozygous for the SNP (patient 1519) (Fig. 7a), following treatment with either siR-atxn7, or siR-













P16. siR-atxn7 is a non-allele-specific siRNA which targets the 3’ untranslated region (3’ UTR) of 
both wildtype and mutant ataxin-7, while siR-P16 was designed to specifically silence the A allele 
linked to the mutant transcript, with reduced activity against the G allele linked to the wild-type 
transcript (Scholefield et al., 2009; Greenberg et al., 2006) (Fig. 7b).  
 
To determine the relative abundance of each transcript following siRNA treatment, allele-specific 
qPCR was performed, using a method developed by Ms Danielle Smith.  A common reverse primer, 
located 3’ of the SNP was used in combination with one of two forward primers, complementary to 
either the A or G allele of the SNP, to amplify the mutant or wild-type cDNA, respectively. The 
specificity of the qPCR reaction had been previously validated for each allele, using cDNA samples 
of known genotype, to confirm the absence of a detectable product when using G allele primers on 
homozygous AA samples, or when using A allele primers on homozygous GG samples (Smith, 
2011). 
 
Results indicated that siR-atxn7 was capable of effecting silencing of both the mutant and wild-type 
transcripts with similar efficacy across all three doses (Fig. 7c). In contrast, siR-P16 mediated 
silencing of the mutant transcript by as much as 34% (p<0.05) at a 1nM dose, with no effect on the 
wildtype transcript (Fig. 7d). This allele-specificity was maintained at 5nM; resulting in silencing of 
the mutant transcript by 49%, with only modest silencing of the wild-type allele (by 25%). Only at 
the highest dose of siRNA (20nM) is this discriminating effect lost, possibly the result of a saturating 






























Figure 7 Allele-specific silencing of ataxin-7 in SCA7 patient fibroblasts.  (a) Chromatogram showing the sequence of 
the region surrounding the SNP rs3774729 (indicated by the arrow), confirming the heterozygous A/G genotype in 1519 
fibroblasts (above) compared to a homozygous G/G control (below). (b) Schematic diagram showing the allele-specific 
design of siR-P16 (green) targeting the A allele of the SNP, and a non-allele-specific siRNA, siR-atxn7 (blue), 
complementary to the 3’ UTR of both alleles of the transcript. The CAG repeat expansion, (CAG)ex, and the normal 
sized repeat, (CAG)n, are linked to the A and G allele of the SNP respectively.  (c) Levels of the wild-type allele do not 
differ significantly from levels of mutant allele transcript following treatment with siR-atxn7. (d) Treatment with siR-P16 
reduces the levels of mutant allele expression at a similar rate to that of siR-atxn7. However, wild-type allele levels are 
significantly unaffected by siR-P16 over low doses.  Transfection efficiency was calculated to be approximately 80%.  
Silencing was determined relative to a non-targeting siRNA, and gene expression was normalised to β-Actin. * indicates 
















3.2.3 Effect of RNAi-mediated silencing of ataxin-7 on transcriptional changes 
To determine the effect of ataxin-7 repression on the transcriptional alterations observed in SCA7 
fibroblasts, patient fibroblasts were transfected with either siR-atxn7 or siR-P16.  Total RNA was 
harvested seven days after the initial siRNA administration.  Both siRNAs silenced total ataxin-7 in a 
dose-dependent manner, ranging from 21% (at 1nM) to 77% knockdown (at 20nM) for siR-P16, and 
29% to 68% for siR-atxn7, as measured by qPCR (Fig. 8a).  
 
Following ataxin-7 silencing, levels of DNAJA1 and UCHL1 transcripts were also determined by 
qPCR. At low levels of silencing (less than 50%) no significant change in DNAJA1 levels was 
observed (Fig. 8b). However, repression of ataxin-7 expression to below 50% of normal transcript 
levels resulted in a significant reduction in DNAJA1 expression (p < 0.05) by up to 30% (siR-P16) or 
41% (siR-atxn7) – approaching the levels observed in control fibroblasts (Fig. 6). Of interest was the 
observation that robust silencing by both siRNAs did not have the same effect on levels of DNAJA1 
if assessed at a shorter time point of 96 hours (data not shown).  This may indicate a requirement for 
sustained inhibition of ataxin-7 expression, in order to sufficiently reduce mutant polyQ protein to 
allow for alleviation of the cell stress response, as measured by heat shock protein induction.  
 
At low levels of ataxin-7 knockdown (21- 48%), UCHL1 levels were elevated towards those 
observed in control samples, with an observed increase in UCHL1 expression of between 30 and 
59% (Fig. 8c). However, when total ataxin-7 expression was reduced by 68% (following treatment 
with 20nM siR-atxn7), UCHL1 expression reverted to levels similar to those observed in the absence 
of ataxin-7 silencing. In contrast, silencing of ataxin-7 by up to 77%, following treatment with the 




























Figure 8 siRNA-mediated silencing of ataxin-7 alters the levels of differentially expressed transcripts in SCA7 
patient fibroblasts towards those observed in controls. (a) Two siRNAs (siR-atxn7 and siR-P16) silence total ataxin-7 
transcript levels in a dose-dependent manner relative to a non-targeting siRNA (siR-NS). (b) Corresponding levels of 
DNAJA1 expression after treatment with increasing doses of siR-P16 and siR-atxn7.  Silencing of ataxin-7 reduces levels 
of DNAJA1 at high doses of both siRNAs. (c) Corresponding levels of UCHL1 expression after treatment with increasing 
doses of siR-P16 and siR-atxn7. Levels of UCHL1 increase across a wide range of ataxin-7 silencing, except at the 20nM 
dose of siR-atxn7. Concentrations of siRNAs are shown on the x-axis.  Gene expression was calculated relative to a non-
targeting control siRNA (siR-NS), and normalised to β-Actin.  Values are mean ± SEM.  * indicates a p value of < 0.05. 
 
In order to confirm that the effects of siRNA administration on expression of these transcripts were 
associated with removal of mutant ataxin-7, and to exclude the possibility of off-target effects, 
parallel silencing experiments were performed in control fibroblasts (JS Con line).  Dose-dependent 
silencing of ataxin-7 by both siRNAs was highly similar to results obtained in patient fibroblasts, 
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ranging from 30% to 64% knockdown (Fig. 9a). However, in contrast to the results obtained in 
SCA7 fibroblasts, no significant correlative decrease in DNAJA1 was observed (Fig. 9b). 
Furthermore, at low doses of siRNA, no concomitant elevation of UCHL1 expression was observed 
(Fig. 9c).  However, a 30% decrease in UCHL1 expression (p<0.05) was observed at 20nM siR-















Figure 9 Effects of siRNA-mediated silencing of ataxin-7 in control (JS Con) fibroblasts.  (a) Two siRNAs (siR-
atxn7 and siR-P16) silence ataxin-7 transcript levels in a dose dependent manner relative to a non-targeting siRNA (siR-
NS). (b) Corresponding levels of DNAJA1 expression after treatment with increasing doses of siR-P16 and siR-atxn7. 
Silencing of ataxin-7 has no effect on levels of DNAJA1. (c) Corresponding levels of UCHL1 expression after treatment 
with increasing doses of siR-P16 and siR-atxn7.  Levels of UCHL1 are reduced only at high doses of siR-atxn7. 
Concentrations of siRNAs are shown on the x-axis.  Gene expression was calculated relative to a non-targeting control 
siRNA (siR-NS), and normalised to β-Actin. Values are mean ± SEM. * indicates a p value of < 0.05.  
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The results of this study provided the first evidence of the presence of a disease-relevant 
transcriptional phenotype in SCA7 patient fibroblasts, which could be ameliorated by RNAi-
mediated silencing of ataxin-7, using both allele-specific and non-allele-specific siRNAs targeting 
the SCA7 disease-causing gene.  Furthermore, the use of a heterozygous SCA7 patient cell line 
provided the first confirmation of allele-specificity of the therapeutic effector, siR-P16, whose 
capacity for allele discrimination had previously only been demonstrated in an artificial cell model 
(Scholefield et al., 2009).   
 
3.3.1 A disease-relevant phenotype in SCA7 patient fibroblasts 
The role of transcriptional dysregulation in the early stages of polyQ pathogenesis has been widely 
documented (Helmlinger et al., 2006b).  In SCA7 in particular, the role of wildtype Ataxin-7 in the 
TFTC/STAGA transcriptional regulatory complexes has further emphasised the importance of 
transcriptional alterations in the development of the disease (Helmlinger et al., 2006a) with evidence 
from SCA7 mouse models revealing a spectrum of disease-associated transcriptional changes (Chou 
et al., 2010; Abou-Sleymane et al., 2006; Yoo et al., 2003; La Spada et al., 2001).  Although 
expression of many of the dysregulated transcripts is restricted to affected cells in the retina and 
CNS, studies of patient-derived lymphoblasts (Tsai et al., 2005) and fibroblasts (Zijlstra et al., 2010) 
suggest that patterns of transcriptional dysregulation in polyQ disease may extend to non-neuronal 
tissues.   
 
In order to investigate the presence of a transcriptional phenotype in SCA7 fibroblasts, six candidate 
transcripts were selected, in which robust changes had been previously demonstrated (Chou et al., 
2010; Tsai et al., 2005).  Transcripts which could be linked to a more general cell response that 












prioritised. These included genes encoding heat shock proteins, an RNA binding protein and a 
deubiquitinating enzyme. Of these six, the expression of four genes was not significantly affected by 
mutant ataxin-7, likely reflecting the tissue-specific nature of the cellular stress response. However, 
genes encoding one of the heat shock proteins, DNAJA1, and the deubiquitinating enzyme, UCHL1, 
were found to be differentially expressed in patient cell lines compared to control lines, 
corresponding to changes observed in a SCA7 mouse model (Chou et al., 2010).   
 
DNAJA1 encodes the heat shock protein DnaJA1 (also known as Hdj2/HDJ-2), a member of the 
family of proteins known as “J proteins”, which stimulate the catalytic activity of the HSP70 proteins 
via a conserved 70 amino acid signature region known as the J domain (Zhao et al., 2008a).  
Although the presence of DnaJA1 has been detected in NIs in HD, SCA1 and SCA7 (Michalik and 
Van Broeckhoven, 2003; Watase et al., 2002; Wyttenbach et al., 2000), the role of the protein in 
polyQ pathogenesis remains controversial.  Numerous studies have highlighted the potential of 
overexpression of DnaJA1 to reduce aggregation of the mutant protein in cell models of SCA1 
(Cummings et al., 1998), SBMA (Kobayashi et al., 2000; Stenoien et al., 1999), SCA3 (Chai et al., 
1999b) and SCA7 (Helmlinger et al., 2004b).  However, these findings have not been robustly 
replicated in animal models (Helmlinger et al., 2004c; Chan et al., 2000).  Moreover, results from 
three different HD cell models directly contradict these findings, suggesting instead that 
overexpression of DnaJA1 may even promote the formation of aggregates of mutant protein in COS-
7 cells (Wyttenbach et al., 2000).  It therefore appears that the net effect of DnaJA1 depends on the 
overall balance of HSR components, which varies between cell types. 
 
Chou et al. observed an approximately two-fold increase in DNAJA1 in the cerebellum of Ataxin-7-
Q52 transgenic mice at 6 months of age (p<0.01), which decreased as the mice approached 11 
months of age, in agreement with previous reports regarding the biphasic nature of the heat shock 












2004).  This phenomenon, in which an initially robust heat shock response becomes progressively 
impaired in polyQ diseased animals of advanced age, is thought to arise from hypoacetylation of 
histone H4, resulting in reduced chromatin accessibility across heat shock genes, and leading to a 
decrease in their transcription over time (Labbadia et al., 2011). 
 
The initial increase in DNAJA1 in SCA7 mouse cerebellum, and the observed increase in the patient 
derived fibroblasts reported here, is likely to represent a general response to cellular stress. Cellular 
stress caused by the accumulation of mutant polyQ protein is well established (reviewed in Huen et 
al., 2007), and is not restricted to affected neurons, having been demonstrated in several non-
neuronal cell types (Zijlstra et al., 2010; Tsai et al., 2005).  The results of the current study therefore 
support a model in which DNAJA1 is upregulated by non-neuronal cells expressing mutant ataxin-7, 
in an attempt to promote survival by facilitating protein folding and preventing aggregation (Chou et 
al., 2010).   
 
It may be argued that one of the patients studied here (patient 1518), with a disease course of 
approximately 22 years to date, represents an advanced stage of disease, and should thus exhibit a 
similar depression in HSR to that observed in aged polyQ mice.  However, it should be noted that 
mitotically active cells such as fibroblasts are capable of rapid dilution of polyQ-expanded Ataxin-7, 
resulting in greatly reduced levels of the mutant protein in comparison to affected neurons (Zijlstra et 
al., 2010; Seo et al., 2004).  This, together with the presence of additional compensatory mechanisms 
for the clearance of misfolded proteins, may explain why fibroblasts do not undergo a similar 
epigenetic silencing of the HSR to that observed in neurons at advanced stages of polyQ disease 
(Labbadia et al., 2011). 
 
The observed decrease in UCHL1 expression in SCA7 patient fibroblasts corresponds to changes 












protein, Ubiquitin C-terminal Hydrolase 1 (UCH-L1), a component of the UPS, which functions as a 
deubiquitinating enzyme (Wilkinson et al., 1989), a ubiquitin ligase (Liu et al., 2002) and stabiliser 
of mono-ubiquitin (Osaka et al., 2003).  UCH-L1 is predominantly expressed in the brain, where it is 
localised exclusively in neurons (Wilson et al., 1988).   
 
UCHL1 has been linked to several neurodegenerative disorders through the impairment of the 
ubiquitin proteasome pathway, including Parkinson’s disease, Alzheimer’s disease and HD (Gong et 
al., 2006; Metzger et al., 2006; Ardley et al., 2004).  Downregulation of UCHL1 mRNA and protein 
expression has been observed in the brains of Alzheimer’s and Parkinson’s disease patients, as well 
as in patients with dementia with Lewy bodies (Barrachina et al., 2006; Choi et al., 2004).  
Furthermore, amino acid changes in UCH-L1, which reduce the catalytic activity of the UPS in vitro, 
have been associated with parkinsonism, cognitive deficits and cortical Lewy pathology in autosomal 
dominantly-inherited cases of familial Parkinson’s disease (Barrachina et al., 2006; Nishikawa et al., 
2003).  These observations correlate strongly with early findings in mouse models lacking functional 
UCHL1, which develop ataxia and neurodegeneration (Saigoh et al., 1999).  When both UCHL1 and 
UCHL3 expression is suppressed, mice develop even more pronounced degeneration of the spinal 
cord, together with dysphagia, a clinical hallmark of human SCA patients (Kurihara et al., 2001).   
 
A role for UCH-L1 in the pathology of neurodegenerative diseases appears to be strongly 
substantiated.  Levels of UCHL1 expression have been postulated to influence neuronal life 
expectancy (Lombardino et al., 2005), and it appears that the precise regulation of UCHL1 is 
essential for the survival and correct functioning of neurons (Setsuie and Wada, 2007).  Since UCH-
L1 participates in the degradation of proteins via the UPS, abnormal UCH-L1 levels may interfere 
with protein processing, reducing the availability of monoubiquitin, and thereby contributing to the 
formation of protein aggregates (Barrachina et al., 2006), a hallmark of neurodegeneration.  












pathology, despite detection of the protein in Lewy bodies in some cases (Barrachina et al., 2006; 
Lowe et al., 1990). 
 
Although most research on UCHL1 function to date has focused on its role in neuronal degeneration, 
at least one study suggests that disease-associated changes in UCHL1 levels may also be detected in 
peripheral cells.  Hsu et al. used a proteomics approach in spinal muscular atrophy (SMA) patient 
fibroblasts to identify candidate proteins which distinguish them from normal fibroblasts.  Out of six 
differentially-expressed proteins, UCH-L1 was identified as a key regulator of the levels of SMN 
(survival of motor neuron) proteins, a decrease in which underlies the pathogenesis of SMA (Hsu et 
al., 2010).  It is not unsurprising, therefore, that downregulation of this key modulator of protein 
turnover should be observed in fibroblasts from patients with SCA7, a polyQ disease characterised 
by impairment of the UPS (See Section 1.2.1).   
 
It should, however, be noted, that additional mechanisms, including oxidative modifications of the 
UCH-L1 protein, have been shown to contribute to the development of neurodegenerative disease 
(Choi et al., 2004; Castegna et al., 2002).  Thus, the full extent of UPS disruption in SCA7 is 
unlikely to be captured by studies which focus exclusively on the levels of UPS-associated 
transcripts, without taking into account differences in protein levels or localisation.  Nonetheless, this 
finding, together with the observed increase in the heat shock protein gene, DNAJA1, provide 
evidence for a transcriptional phenotype in SCA7 fibroblasts, involving key pathways in the 
pathogenesis of polyQ disease. 
 
Despite these promising findings, it must be emphasised that a candidate gene study such as this is 
by definition limited, by the sample size, as well as by the pool of genes selected for study.  It is 
therefore possible that a larger cohort may yield more informative results regarding subtle changes in 












pathways, such as those mentioned in Section 1.2, or the use of non-hypothesis-driven methods such 
as whole genome expression analysis, may provide a more comprehensive picture of the disease-
associated transcriptional changes in SCA7. 
 
3.3.2 Fibroblasts as a model for therapeutic screening 
3.3.2.1 Validation of allele-specific silencing effectors 
The utility of RNAi-based therapies for neurodegenerative diseases caused by a toxic gain-of-
function of the mutant protein, such as the polyQ diseases, has been extensively demonstrated (Wang 
et al., 2008; Harper et al., 2005; Xia et al., 2004).  To date, however, relatively few studies have 
assessed silencing in patient-derived cells (Hu et al., 2011; Hu et al., 2010a; Hu et al., 2009b; Van 
Bilsen et al., 2008). This study sought to address the utility of SCA7 patient-derived fibroblasts as a 
model for assessing therapeutic strategies.  In particular, the identification of a patient heterozygous 
for a common disease-linked SNP (rs3774729) in the South African SCA7 patient population offered 
the opportunity to compare the efficacy of allele-specific and non-allele-specific silencing 
approaches in genetically accurate cells.  This represents a significant improvement over transfected 
cell models or transgenic animals, in which the background of endogenous ataxin-7 transcripts may 
confound results.  
 
Of the polyQ patient-derived cell line studies to date (Fiszer et al., 2011; Hu et al., 2011; Hu et al., 
2010a; Hu et al., 2009b; Lombardi et al., 2009; Van Bilsen et al., 2008) most have focused on the 
development of allele-specific silencing approaches targeting SNPs linked to the mutation and/ or the 
CAG repeat expansion itself, with increasingly promising results. In this investigation, an siRNA 
was used, which had been previously designed to target the A allele of SNP rs3774729 (Scholefield 
et al., 2009). The clinical relevance of allele-specific approaches which target disease-linked SNPs is 












effectors to be designed (Pfister et al., 2009).  However, recent studies employing haplogroup 
analyses suggest that target SNPs may be more prevalent than was originally believed.  Moreover, 
the high degree of linkage to the CAG expansion (100%) and heterozygosity (approximately 50%) of 
SNP rs3774729 in this case suggest that it is a promising candidate for therapy in the South African 
patient cohort (Scholefield et al., 2009). 
 
This investigation compared the efficacy of two siRNAs, one allele-specific (siR-P16), and one non-
allele-specific (siR-atxn7), by measuring the expression of endogenous mutant and wild-type 
transcripts in patient cells following administration of each siRNA. Results indicated that siR-P16 
silences the mutant transcript more efficiently than the wild-type transcript, in comparison to the 
consistent silencing of both alleles by siR-atxn7, particularly at low doses of siRNA.  The decrease in 
allele-specificity at high siRNA doses represents an important caveat of this approach, emphasising 
the importance of dose titration in the establishment of an allele-specific treatment regimen.  
Nonetheless, it may be reasonably concluded that siRNA-mediated targeting of rs3774729 represents 
an effective strategy for the allele-specific silencing of mutant ataxin-7.  This is of particular clinical 
significance, given the important role of wildtype ataxin-7 in the regulation of gene expression 
(Helmlinger et al., 2006a; Palhan et al., 2005; La Spada et al., 2001), and the absence of knockout 
model data regarding the effect of a loss of wildtype function, both of which motivate strongly for 
therapies which selectively silence mutant ataxin-7, while retaining wildtype gene expression. 
 
3.3.2.2 Amelioration of disease phenotype 
Given previous reports regarding the role of mutant ataxin-7 in transcriptional dysregulation (see 
Section 1.2.4), it was not surprising to observe alteration of DNAJA1 and UCHL1 transcript levels 
towards wildtype levels, following silencing of the disease-causing gene. The fact that these changes 












reported stability of mutant polyQ protein (Yvert et al., 2001); suggesting that improvements were 
noted only after a period of time sufficient to allow for degradation of residual protein.  The high 
concentration of siRNA required to effect a decrease in DNAJA1 expression indicates the presence of 
a threshold level of ataxin-7 expression, below which cellular stress is alleviated.  Although 
restoration of DNAJA1 levels towards normal occurs only at a concentration at which the allele-
specific effect of siR-P16 is no longer observed, the observation that silencing of ataxin-7 has no 
effect on DNAJA1 expression in control fibroblasts provides strong evidence that siRNA-mediated 
reduction of DNAJA1 expression in patient cells results from the removal of mutant ataxin-7, rather 
than a loss of normal ataxin-7 function, or off-target effects of the siRNAs. 
 
Ataxin-7 silencing in patient cells resulted in an initial restoration of UCHL1 levels towards that 
observed in control lines.  This is encouraging given that boosting UCHL1 levels has been suggested 
as a therapeutic strategy for Alzheimer’s disease (Gong et al., 2006).  However, this initial increase 
was mitigated at higher levels of ataxin-7 knockdown, after treatment with the non-allele-specific 
siR-atxn7.  In contrast, treatment with the allele-specific siR-P16 resulted in sustained elevated levels 
of UCHL1.  This suggested that loss of UCHL1 expression observed at high doses of non-allele-
specific silencing could have resulted in some way from the loss of wildtype ataxin-7 expression and 
hence, loss of normal function of the wild-type Ataxin-7 protein.  A similar loss of UCHL1 
expression was observed in control fibroblasts, following high doses of siR-atxn7, lending further 
weight to this assertion.  These findings suggest that, in the context of SCA7 pathogenesis, loss of 
UCHL1 expression may be caused by both the toxic gain-of-function of the mutant polyQ protein 
and by loss of wild-type ataxin-7 function.   Ataxin-7 functions as a critical component of the 
transcriptional co-activator complexes, STAGA/TFTC (Helmlinger et al., 2004a) and polyQ 
expanded Ataxin-7 has been shown to inhibit this function (Palhan et al., 2005). It is therefore 
possible that reduced UCHL1 expression may result from disruption of the STAGA complex, either 












which is thought to result from both gain-of-function (of the mutant protein), and loss of wildtype 
function.  These results also underscore the need for an allele-specific silencing approach for SCA7, 
as a loss of wildtype Ataxin-7 function appears to exacerbate the disease phenotype (as measured 
here) and may have broader implications for the functioning of key cellular pathways, such as the 
UPS.  However, given the gradual loss of allele-specificity of siR-P16 at increased doses, these 
conclusions are largely speculative, and do not preclude the involvement of additional mechanisms, 
as well as the possibility of off-target effects. 
 
3.3.3 Concluding remarks 
This study has shown that SCA7 patient derived cell lines, which are generated and manipulated with 
relative ease, display a disease-associated cellular phenotype, namely, alterations in expression of 
UPS and HSR genes.  As such, these cells are highly suitable for studies of therapeutic efficacy, 
including the evaluation of allele-specific versus non-allele-specific siRNAs demonstrated here. 
Results from a heterozygous SCA7 patient indicate that the allele-specific approach first proposed by 
Scholefield et al. is not only feasible for South African SCA7 patients, but may represent the 
preferred therapeutic strategy, in order to minimise the effects of loss of wildtype Ataxin-7 function 
(Scholefield et al., 2009).  In addition, siRNA-mediated rescue of the transcriptional phenotype 
provides insight into the pathogenic mechanisms of disease. Taken together, these findings suggest 
that although fibroblasts are not susceptible to the neuronal-specific degeneration exhibited in polyQ 
disorders, they may be a valuable tool for screening therapeutic molecules as well as providing 












Chapter 4 Generation and Characterisation of SCA7 Patient-Derived 
Induced Pluripotent Stem Cells 
4.1 Introduction 
Rapid developments in the field of stem cell technology offer the first opportunity to combine the 
genetic accuracy of patient-derived cell models with the disease-relevance of CNS cell types. 
Groundbreaking studies by Takahashi et al. and Yu et al. in 2006 and 2007 demonstrated the ability 
of virus-mediated overexpression of distinct sets of reprogramming factors to generate iPSCs from 
mouse and human dermal fibroblasts (Takahashi et al., 2007; Yu et al., 2007; Takahashi and 
Yamanaka, 2006).  Human iPSCs have since been generated from a wide variety of source tissues, 
including melanocytes (Utikal et al., 2009), cord blood-derived cells (Haase et al., 2009), adult 
peripheral blood cells (Loh et al., 2009), amniotic fluid (Li et al., 2009) and keratinocytes (Trond 
Aasen et al., 2008), to name a few. 
 
4.1.1 Techniques for generating iPSCs 
The choice of technique for generating iPSCs depends largely on the aims of the research to be 
conducted, and the downstream applications of the lines generated (Table 3).  Depending on 
priorities of the application for which the cells will be used, the appropriate protocol must take into 
account not only the efficiency, but also the quality and reproducibility of the reprogrammed cells 
(González et al., 2011).    
 
The generation of iPSCs from human cells using lenti- or retroviral-mediated overexpression of 
reprogramming factors has proven to be a robust method for inducing pluripotency, albeit with fairly 












although the use of increasing numbers of virally-encoded transcription factors has been advocated 
to enhance efficiency (Liao et al., 2008).   
 
Delivery of the OCT4/SOX2/KLF4/c-MYC combination of transcription factors was originally 
demonstrated using Moloney murine leukaemia virus (MMLV)-derived retroviruses, such as pMXs 
(Takahashi et al., 2007), pLib (Wernig et al., 2007) or pMSCV (Trond Aasen et al., 2008).  These 
vectors have cloning capacities of approximately 8kb, facilitate the insertion of genes into the 
genome of dividing cells, and are usually silenced in immature cells such as ESCs (Jähner et al., 
1982; Stewart et al., 1982).  The vector, into which the reprogramming cDNA has been cloned, also 
encodes a viral packaging signal, as well as transcription and processing components.  When 
transfected into a packaging cell line expressing a specific viral envelope protein, high-titre, 
replication-deficient viruses are produced, capable of infecting donor cells with efficiencies of up to 
90%. 
 
Lentiviral delivery vectors have also been used to express reprogramming factors in somatic cells 
(Yu et al., 2007).  These are generally derived from human immunodeficiency virus (HIV), have 
slightly higher cloning capacities (8-10kb), and are capable of higher infection efficiencies than 
MMLV-based retroviruses, although reprogramming efficiencies between the two types of virus are 
comparable.  Lentiviruses offer the advantage of infecting both dividing and non-dividing cells.  
However, compared with MMLV-derived vectors, lentiviruses are less effectively repressed in 
pluripotent cells (Yao et al., 2004). 
 
Although efficient and reproducible, virus-mediated reprogramming involves the generation of 
potentially harmful viral particles expressing potent oncogenes, such as c-MYC.  iPSCs generated 
using these vectors also carry randomly distributed transgene insertions (Varas et al., 2009), leading 












(Okita et al., 2007), all of which must be taken into account when establishing and characterising 
such lines.   As a result, attempts have been made to minimise or avoid integration of foreign DNA 
into reprogrammed cells using alternative methods of reprogramming.  To this end, a number of 
small molecule-based modifiers of signalling pathways involved in the process of reprogramming 
have been identified, which greatly enhance reprogramming efficiency while minimising the number 
of transcription factors required (Zhu et al., 2010; Lin et al., 2009).  Examples include vitamin C 
(Esteban et al., 2010), and the HDAC inhibitor valproic acid (VPA) (used in this study), which have 
been shown to enhance the efficiency of two- and three-factor mediated reprogramming (Huangfu et 
al., 2008).  
  
The use of different somatic cell types at distinct developmental stages has also been explored as a 
means of reducing the number of exogenous factors required for reprogramming.  Although 
fibroblasts remain the most popular donor cell type (accounting for 80% of all reprogramming 
experiments published), several studies have analysed the reprogramming capacity of alternative cell 
types, of particular interest due to their availability, ease of reprogramming or therapeutic relevance 
(González et al., 2011). The increase in reprogramming efficiency and/or decrease in factor 
requirement of certain cell types may be attributed to high endogenous levels of particular 
reprogramming factors, eliminating th  need for their trans expression, and/or an intrinsic epigenetic 
state which is more amenable to reprogramming.  One such example of the former is the high 
baseline level of SOX2 expression in neural precursor cells, allowing them to be reprogrammed in 
the absence of SOX2, or with OCT4 alone (Eminli et al., 2008).  In addition to efficiency, differences 
in reprogramming among cell types have also been shown to affect the quality of reprogrammed 
cells (Miura et al., 2009); thus, the choice of cell type is an important consideration, reflecting a 














Table 3 The choice of reprogramming method depends upon the downstream application  
Application Species of 
choice 








Mouse Cells from chimeric 
mice from iPSCs 
obtained using an 







Compare as many 



















Human/pig Reprogrammable cells 
easily available from 






Starting cell population 
may be limited, so 
efficient models 
required. Safety is not 






Human Reprogrammable cells 
easily available from 
patients, cell repository 
or HLA-matched 
iPSCs obtained from 
cord blood 
Need to avoid 
potent oncogenes 





Safety is the major 
issue. Non-integrative 
methods must be 




HLA: human leukocyte antigen; MEFs: mouse embryonic fibroblasts. OSK: OCT4, SOX2, KLF4; OSKM: OCT4, SOX2, 
KLF4, c-MYC (Takahashi et al., 2007). OSNL: OCT4, SOX2, NANOG, LIN28 (Yu et al., 2007). Adapted by permission 






Figure 10 Comparative efficiency and safety of currently available iPSC reprogramming methods.  Integrating 
viruses currently represent the most efficient method of reprogramming, while non-integrative methods are preferred 
when safety is a primary concern. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Genetics 












Alternative approaches to decrease the number of genomic integrations include the development of 
single vectors encoding all the necessary reprogramming factors, which may be excised from iPSC 
genomes following successful reprogramming, as well as the use of non-integrating viruses, 
expression plasmids, DNA mini-circles, transposons, recombinant proteins, synthetically modified 
mRNAs and miRNAs (Fig. 10) (reviewed in González et al., 2011).  Although effective in 
minimising or eliminating integration, these techniques present a number of additional technical 
obstacles, including the need for repeated transfection due to dilution of the reprogramming factors 
during cell division, leading to comparatively low reprogramming efficiencies (0.0001-0.001%); and 
the induction of aneuploidy, caused by the use of adenoviral vectors (Stadtfeld et al., 2008).  As 
several of the methods remain to be replicated (Drews et al., 2012), many proof-of-concept studies of 
iPSC generation, particularly for disease modelling, still rely on the well-established lenti- or 
retroviral methods (González et al., 2011) (see Section 4.1.4). 
 
4.1.2 Cell culture conditions 
Once an appropriate reprogramming technique has been selected, the culture conditions for 
reprogramming must be defined.  Cell culture conditions, medium composition and supportive (or 
feeder) cells have all been shown to modulate the efficiency of reprogramming.  For example, 
hypoxic conditions, particularly n combination with the addition of VPA, have been found to 
dramatically increase the reprogramming efficiency of both mouse and human cells (Yoshida et al., 
2010).  Supportive feeder cells, such as inactivated mouse embryonic fibroblasts, secrete growth 
factors that are required for stem cell survival, proliferation and inhibition of spontaneous 
differentiation, while serum-free medium allows iPSCs to be obtained at an earlier time point (Okada 
et al., 2010; Dravid et al., 2005). 












4.1.3 Molecular mechanisms of cellular reprogramming 
Studies of ESCs have led to a basic understanding of the role of the OCT4/SOX2/NANOG-regulated 
transcriptional network (Boyer et al., 2005).  Based on genome-wide analyses of binding sites and 
target genes, it has been suggested that OCT4, SOX2, and NANOG promote pluripotency and self-
renewal via positive regulation of their own genes, as well as genes encoding additional transcription 
factors, miRNAs and components of key pluripotency signalling cascades, such as the TGFβ and 
Wnt pathways (Boyer et al., 2005).  Analyses of the early events triggered by the introduction of 
exogenous pluripotency factors have revealed additional key steps in the reprogramming process, 
including promotion of the mesenchymal-to-epithelial transition (MET) (Mah et al., 2011; Eastham 
et al., 2007; Wong et al., 2004); elongation and epigenetic modification of telomeres (Marion et al., 
2009); and a reconfiguration of mitochondria and energy metabolism similar to that observed in 
cancer cells (Prigione et al., 2011a; Prigione et al., 2010; Warburg, 1956).  The latter, which results 
in a decrease in both mitochondrial number (Kelly et al., 2011; Armstrong et al., 2010; Prigione et 
al., 2010) and oxidative phosphorylation, leads to an increase in glycolysis (Varum et al., 2011; 
Zhang et al., 2011) and a decrease in levels of reactive oxygen species (Armstrong et al., 2010; 
Prigione et al., 2010).  These metabolic changes occur before the re-establishment of ESC-like 
properties (Mah et al., 2011), and are thus likely to play an instrumental role in reprogramming – a 
fact borne out by the observation that small-molecule-based alterations of energy metabolism 
enhance the efficiency of reprogramming (Yoshida et al., 2010; Zhu et al., 2010). 
 
Despite these insights, the distinct pathways and mechanisms underlying the conversion of somatic 
cells to a pluripotent phenotype remain incompletely understood (Drews et al., 2012).  To this end, a 
recent study analysed the early events triggered by retroviral transduction of OCT4, SOX2, KLF4 and 
c-MYC (Mah et al., 2011).  One of the key findings of this investigation was a significant increase in 
levels of reactive oxygen species upon viral transduction, resulting in DNA damage and ultimately, 












results support previous observations that downregulation of p53 enhances cellular reprogramming 
in both human and mouse somatic cells, suggesting that this may be a crucial hurdle to overcome in 
reprogramming experiments (Wang and Adjaye, 2011; Hong et al., 2009). 
 
Epigenetic remodelling, via alteration of histone modification and CpG methylation patterns, was 
highlighted in one of the first reports of human iPSCs (Takahashi et al., 2007), as a mechanism 
enabling access of the transcriptional machinery to pluripotency-associated genes, thereby 
facilitating major transcriptional changes during the process of reprogramming.  Global studies of 
mouse embryonic fibroblasts (MEFs) and MEF-derived iPSCs have revealed greater details 
regarding the kinetics of distinct histone modifications occurring throughout de-differentiation 
(Mattout et al., 2011).  These results support the finding that small molecules which influence 
chromatin remodelling, such as VPA or vitamin C, may enhance the efficiency of reprogramming, in 
conjunction with the overexpression of pluripotency transcription factors (Esteban et al., 2010; Zhu 
et al., 2010; Huangfu et al., 2008). 
 
4.1.4 Clinical applications 
Induced pluripotent stem cells may be useful for a range of applications, including the modelling of 
mono- and multigenic diseases, the investigation of complex genetic traits and allelic variation, 
autologous cell therapy, and as substrates for toxicity, drug, differentiation and therapeutic screens 
(González et al., 2011). 
 
4.1.4.1 Autologous cell replacement therapies  
The in vitro developmental potential and the success of iPSCs in animal models (Wernig et al., 2008; 
Hanna et al., 2007) suggest that iPSC-derived cells may be a viable regenerative source for 












first clinical trials using human ESC-derived cells, such as the recent cell replacement therapy trial 
by Advanced Cell Technology, which sought to assess the safety of treating macular dystrophy with 
transplanted human ESC-derived retinal pigment cells (Schwartz et al., 2012).  Despite initial 
successes, the emergence of long-term effects in patients remains to be determined, and several 
general and experimental obstacles must be overcome before differentiated cell types derived from 
iPSCs can be applied to humans.  These include the prohibitive cost of generating patient-specific 
iPSC-derived therapeutics, the poor survival of pluripotent cells following cryopreservation (Rizzino, 
2010), the necessity of using defined, xeno-free iPSC culture conditions (Takahashi et al., 2009), the 
development of alternatives to viral-mediated reprogramming, and the elimination of risks associated 
with teratoma formation, toxicity and immunological rejection, via efficient and reproducible 
derivation of a pure, lineage-defined cell population from iPSCs (Kriks et al., 2011).  The 
development of alternatives to overcome these hurdles, such as the establishment of HLA-
haplotyped iPSC banks (Nakatsuji et al., 2008), remains an ongoing challenge. 
 
4.1.4.2  “Disease in a dish” 
The successful conversion of human fibroblasts to iPSCs has generated new opportunities for the 
modelling of human disease, providing the unique possibility of investigating the molecular 
mechanisms underlying the aetiology of many monogenic and complex diseases (Drews et al., 2012).  
Despite the promise of this new technology, one particularly demanding task facing researchers in 
the field is the need to prove that iPSC-derived models accurately convey the main features of the 
disease under study.  This requires the recruitment of a suitable number of patients, the generation of 
multiple iPSC lines from each patient, and the establishment of efficient protocols for the 
differentiation of iPSCs into the disease-affected cell type.   Nonetheless, within the past few years, 












al., 2011) to Friedreich’s ataxia (Liu et al., 2011), affirming the ability of iPSCs to reconstruct 
disease phenotypes in vitro.   
 
These iPSC-derived disease models, which have given rise to the term “disease in a dish”, provide 
the means to investigate novel diagnostic markers, to identify drug targets and to screen therapeutic 
agents, such as small molecule drugs or RNAi.  Indeed, evidence from several disease models, 
including SMA (Ebert et al., 2008) and Rett’s syndrome (Marchetto et al., 2010) suggests that in 
vitro drug treatment successfully restores normal distribution of the affected protein. 
 
Perhaps most significantly, iPSCs offer the ability to study mechanisms of degeneration and recovery 
in conditions for which patient material is not readily available, through their directed differentiation 
into disease-relevant cell types, such as neurons.  In this way, iPSC technology has provided a 
breakthrough in the study of neurodegenerative disease (discussed in more detail in Chapter 5).  
 
4.1.5 Characterisation of iPSCs 
The inherent qualities of iPSCs have made them an attractive source of cells for the development of 
patient-derived models of disease.  However, the low rate of reprogramming, together with the high 
mutagenic risk associated with virus-mediated reprogramming have necessitated the establishment of 
criteria for the selection, propagation and cross-lab comparison of reproducible, pluripotent cell lines 
(Maherali and Hochedlinger, 2008).  These include the presence of characteristic features of ESCs, 
such as the presence of ESC-like morphology, the expression of cell surface markers that 
characterise undifferentiated human cells (for example, TRA-1-60 or TRA-1-81), and the ability to 
differentiate into representative cell types of each of the three embryonic germ layers (Thomson et 
al., 1998).   Teratoma formation in immune-deficient mice, once considered the gold standard for the 












when the iPSCs in question are to be used solely for in vitro purposes such as disease modelling or 
drug screening (Ellis et al., 2009).  In addition, iPSCs derived by integrating virus transduction 
should demonstrate reprogramming factor independence, characterised by the shutdown of viral 
transgene expression, and a concomitant upregulation of endogenous pluripotency gene expression 
(Ellis et al., 2009; Maherali and Hochedlinger, 2008).  Finally, the genomic integrity of the iPSC 
lines should be assessed, particularly when iPSCs are likely to be used in transplantation therapies, as 
chromosomal aberrations may enhance tumorigenicity and affect differentiation capacity (Mayshar et 
al., 2010).  
 
4.1.6 Aims 
The aims of the experiments described in this chapter were thus to generate iPSC lines through 
retrovirus-mediated reprogramming of SCA7 patient and control dermal fibroblasts, using a three-
factor combination (OCT4, SOX2 and KLF4), together with the HDAC inhibitor valproic acid, and to 
characterise the lines generated with respect to: 
1. repression of retroviral transgene expression, 
2. expression of endogenous pluripotency genes and cell-surface markers, 
3. genomic integrity, and 
4. the ability to differentiate into cells of each of the three embryonic germ layers (endoderm, 
mesoderm and ectoderm). 
 
This work was completed in collaboration with Dr Janine Scholefield (Department of Physiology, 
Anatomy and Genetics, University of Oxford), together with Dr Sally Cowley and Ms Jane Vowles 
(James Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford).  The 
control iPSC line iPS-NHDF-2, designated in this thesis as iPS SC NHDF, together with its 













4.2.1 Reprogramming fibroblasts to iPSCs 
Patient and control fibroblasts were transduced with retroviral vectors containing the three 
reprogramming factors, OCT4, SOX2, and KLF4.  In order to determine the success of infection, 
transduced fibroblasts were subjected to immunostaining for Klf4 protein approximately 10 days 
post-infection.  Infected fibroblasts showed intense nuclear staining for Klf4 (Fig. 11a), compared to 
the markedly lower levels of endogenous Klf4 expressed in uninfected controls (Fig. 11b), indicating 
efficient retroviral transduction.   
 
After approximately 20 to 40 days in culture, colonies exhibiting ESC-like morphology were 
observed (Fig. 11c), comprised of cells exhibiting a cobblestone appearance with high 
nuclear:cytoplasm ratio and pronounced individual cell borders, as has been previously described 
(Maherali and Hochedlinger, 2008) (Fig. 11d).  After successive passages, the colonies displayed a 
more uniform morphology, with well-defined borders (Fig. 11e), and appeared capable of unlimited 
self-renewal.  As is the case with ESCs, spontaneous differentiation was occasionally observed at the 
centre of iPSC colonies (Fig. 11f). 
 
A complete list of the iPSC lines generated from patient and control fibroblasts can be found in 
Table 4.  Six iPSC lines were generated from each of the SCA7 patient fibroblast lines, resulting in 




































     
 
Figure 11 Reprogramming of fibroblasts to iPSCs. (a) Fibroblasts transduced with retroviral vectors showed 
significantly elevated expression of Klf4 (green), compared to untransduced fibroblasts (b), 10 days post-reprogramming, 
indicating that they had been successfully infected. Nuclei are stained with DAPI (blue). (c) Colonies exhibiting ESC-
like morphology appeared after 20-40 days in culture. (d) iPS George at high magnification, showing a typical 
cobblestone appearance with pronounced individual cell borders. (e) Flat, uniform morphology of an established iPSC 
line at passage 6 (iPS George). (f) Spontaneously differentiated cells in the centre of an iPSC colony (indicated by white 



















Table 4 iPSC lines generated from SCA7 patients and controls. 
Fibroblast line of origin Derived iPSC lines Reprogramming factors 
Name  Disease status* 
JS Con  Control George OSK 
SC Con
†
 Control SC NHDF
†
 OSKMN 















*For further information, see Sections 2.1 and 2.2. 
†
Kindly provided by Dr Sally Cowley.  
‡
Each letter represents an 
individual colony identified on the original reprogramming plate, which was isolated and clonally expanded to generate 
an iPSC line. 
Key to reprogramming factors: O: OCT3/4 S: SOX2 K: KLF4 M: c-MYC N: NANOG 
 
4.2.2 iPSC characterisation 
Characterisation was performed on a subset of iPSC lines, which showed the most robust growth and 
proliferation on both iMEF feeder layers and in feeder-free conditions. 
 
4.2.2.1 Repression of transgene expression 
Human iPSCs have been found to silence expression of the retroviral transgenes used in 
reprogramming in some (Takahashi et al., 2007) but not all (Dimos et al., 2008; Takahashi et al., 
2007; Yu et al., 2007) cases.  Reverse transcriptase PCR, using primers specific to the retroviral 
transcripts (Appendix 4, A4.8), demonstrated nearly complete silencing of pMXs-hSox2 and pMXs-
hKlf4 at approximately passage 10 post-reprogramming (Fig. 12).  Persistent expression of pMXs-















Figure 12 RT-PCR analysis of transgene expression in iPSC lines. Primers specific to the retroviral transcripts were 
used to detect persistent transgene in the iPSC lines generated.  Both iPSC control lines (iPS George and iPS SC NHDF) 
appeared to have silenced expression of all transgenes, while persistent expression of pMXs-hOct3/4 was detected in four 
of the patient-derived iPSC lines (iPS 1519B and –C, and iPS 1518 A and –D).  HEK293 cells transfected with the 
relevant plasmid were used as a positive control in each case, while human ESCs served as a negative control.  Data for 
pMXs-hc-Myc and pMXs-Nanog expression in iPS SC NHDF courtesy of Dr Sally Cowley. 
 
4.2.2.2 Expression of e dogenous pluripotency genes 
The loss of transgene dependence, indicated by the induction of endogenous pluripotency genes, is a 
critical marker of complete reprogramming (Maherali and Hochedlinger, 2008).  RT-PCR indicated 
that genes expressed in pluripotent cells (OCT4, SOX2, NODAL, and c-MYC) were expressed in 
human ESCs as well as in the six iPSC lines and two control lines assessed here (Fig. 13; primers 
listed in Appendix 4, A4.7).  Moreover, these pluripotency marker genes were not expressed in the 






















Figure 13 Expression of endogenous pluripotency genes.  Primers specific for the endogenous transcripts were used to 
confirm that the iPSC lines generated expressed pluripotency-associated genes.  Human ESCs served as a positive 
control.  Expression of the pluripotency genes was not detected in the parental fibroblast lines, with the exception of c-
MYC, which was expressed in the 1518 line.  Data for iPS SC NHDF courtesy of Dr Sally Cowley. 
 
4.2.2.3 Expression of cell surface markers of pluripotency 
The expression of ESC-specific cell surface antigens is another key marker of pluripotency.  The 
levels of two such antigens, Tra-1-160 and Tra-1-81, were assessed in several of the iPSC lines.  All 
lines tested showed robust expression of the pluripotency markers, in contrast to the surrounding 






















Figure 14 Expression of cell surface markers of pluripotency.  All iPSC lines tested stained positive for cell surface 
markers of pluripotency including Tra-1-81 and Tra-1-60. (a) iPS SC NHDF (b) iPS George (c) iPS 1519A. Nuclei are 
stained with DAPI (blue). Images courtesy of Dr Sally Cowley and Ms Danielle Smith. Scale Bars: (a), 500µm; (b) and 
(c), 100µm. 
 
4.2.2.4 Genomic integrity 
The genomic integrity of five of the iPSC lines (iPS SC NHDF, 1518A, 1518D, 1519A and 1519C) 
was determined using the Infinium HD assay, on HumanCytoSNP-12v2.1 bead-chips (Illumina).  
The HumanCytoSNP-12 BeadChip contains approximately 300,000 genetic markers per sample, 
targeting all known cytogenetic abnormalities found in genes and pathways linked to mental 
retardation, autism, as well as additional common chromosomal anomalies.  It is therefore capable of 
detecting numerous types and sizes of structural variation in the human genome affecting 
phenotypes, including duplications, deletions, amplification, copy-neutral loss of heterozygosity and 
mosaicism.  An additional control line, iPS George, was karyotyped using traditional G-banding. 
 
The integrity of each iPSC line was assessed by comparison with its parental fibroblast line.  Small 
amplifications, deletions and regions of loss of heterozygosity occasionally appear in the parental 
fibroblasts.  Thus, iPSC lines which did not differ significantly from the parental fibroblasts were 
deemed acceptable for use, provided no gross structural abnormalities, such as large-scale 
duplications, deletions, rearrangements, or structural alterations affecting the gene-of-interest (in this 
case, ataxin-7) could be detected.  On this basis, the genomic integrity of the iPSC lines 1518D, 
1519A and –C, iPS SC NHDF and iPS George were all deemed sufficient for further experiments 













(Fig. 15 and Appendix 6).  The quality of DNA obtained for 1518A made assessment of the genomic 
integrity of the sample difficult, resulting in the exclusion of this sample from further analysis. 
 
In addition, SNP patterns for chromosome 1 could be used to match parental fibroblasts to their 
derived iPSC lines, confirming the origin of the reprogrammed cells, and eliminating the possibility 














Figure 15 Chromosomal analyses of SCA7 and control iPSC lines.  Representative result of the HumanCytoSNP-12 
BeadChip (results for the remaining iPSC lines can be found in Appendix 6), showing no gross structural abnormalities 
when comparing the SCA7 iPSC line 1518D (a) to its parental fibroblast line, 1518 (b).  A green horizontal line adjacent 
to a chromosome region indicates a copy number of more than 2; while a red horizontal line indicates a copy number of 
less than 2.  Vertical grey bars indicate loss of heterozygosity, except in the case of the X-chromosome, where grey 














4.2.2.5 In vitro differentiation from embryoid bodies 
To determine the differentiation capabilities of the iPSC lines generated in vitro, dissociated iPSCs 
were cultured in suspension to form embryoid bodies (EBs).  After 8 days in suspension culture, 
iPSCs formed ball-like structures (Fig. 16a).  Two of the iPSC lines (iPS George and 1519C) were 
then subjected to undirected differentiation, in which EBs were transferred to gelatin-coated plates 
and allowed to spontaneously differentiate for a further 8 days before RNA extraction. Reverse 
transcriptase PCR confirmed that these differentiated cells expressed paired box 6 (PAX6, a marker 
of ectoderm), microtubule-associated protein 2 (MAP2, ectoderm), Msh homeobox 1 (MSX1, 
mesoderm), forkhead box A2 (FOXA2, endoderm), and α-fetoprotein (AFP, endoderm), to varying 
degrees (Fig. 16b).  By contrast, the undifferentiated iPSC lines did not express these germ-layer 
markers (with the exception of MAP2, which was expressed at low levels in iPSCs, compared to 
EBs). 
 
EBs from a further two iPSC lines, iPS SC NHDF and 1519A, were subjected to directed 
differentiation into the three germ layers, as described in Section 2.9.6.4.  Immunocytochemistry was 
used to detect cells which stained positive for markers of the three embryonic germ layers: FOXA2 
and/or AFP (endoderm), α-sarcomeric actin and/or α-smooth muscle actin (mesoderm), and βIII-
tubulin (ectoderm).  EBs from both lines differentiated into a variety of cell types, representatives of 
which stained positive for all the aforementioned markers (Fig. 16c-h), indicating the ability of these 

































         
 
Figure 16 Embryoid body-mediated differentiation of SCA7 and control iPSCs. (a) Floating cultures of iPSCs at day 
8. (b) Reverse-transcriptase PCR analysis of germ layer markers in EBs from iPSC lines iPS George and 1519C indicate 
their ability to differentiate into all three germ layers. Immunostaining confirmed the ability of the iPSC line 1519A to 
differentiate into endoderm (c) and mesoderm (d).  Ectodermal differentiation was confirmed by the ability of the line to 
generate βIII-tubulin positive neurons (e) (see Chapter 5).  Similarly, the ability of iPS SC NHDF to differentiate into 
endoderm (f), mesoderm (g) and ectoderm (h) was assessed by immunostaining. FOXA2, Forkhead box protein A2; 
AFP: α-fetoprotein; ASA, α-sarcomeric actin; ASMA, α-smooth muscle actin.  Nuclei are stained with DAPI (blue). 
Scale bars: (a), 500µm; (c)-(h), 100µm.  Immunostaining images courtesy of Dr Janine Scholefield (c), (d) and Dr Sally 
Cowley/Ms Jane Vowles (f), (g), (h). 
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This study has demonstrated the generation of iPSCs from dermal fibroblasts of adult SCA7 patients 
by retroviral transduction with three reprogramming factors, namely pMXs-hOct3/4,-hSox2 and        
-hKlf4, in combination with the HDAC inhibitor, valproic acid.  The established iPSCs resemble 
human ESCs in several aspects, including morphology, proliferation, expression of cell surface 
markers and pluripotency genes, and capacity for in vitro differentiation.  This is only the second 
report of iPSC generation from SCA7 patients, and the first to demonstrate successful 
reprogramming using patient fibroblasts from the South African SCA7 cohort (Luo et al., 2012). 
 
4.3.1 Retrovirus-mediated reprogramming of fibroblasts to iPSCs 
The observed efficiency of reprogramming of SCA7 patient fibroblasts to iPSCs (~0.01%) is 
comparable to previous reports of retrovirus-mediated reprogramming of adult dermal fibroblasts 
(Takahashi et al., 2007).  This is, in part, a reflection of the probability of simultaneous transduction 
with all three retroviral vectors, a prerequisite for reprogramming to pluripotency (Takahashi et al., 
2007).  
 
The use of retroviral vectors for iPSC reprogramming represents a balance between efficiency, and 
safety concerns regarding genomic integration.  Numerous strategies to avoid viral integration have 
been tested (see Section 4.1.1), with some achieving enhanced reprogramming rates, while others 
demonstrate impractically low efficiencies.  The labour intensive nature of direct delivery of proteins 
or RNA, requiring repeated delivery of reprogramming factors, together with the technical demands 
associated with the preparation of modified Sendai virus vectors or synthesised RNA initially 
hindered the development of these methods (Okita and Yamanaka, 2011).  However, ongoing 
improvements in technology, together with recent evidence suggesting that integration events may 













methods which avoid genomic alterations (Liu et al., 2012).  Thus, future experiments are likely to 
employ a combination of methods to enhance efficiency while minimising the effects of integration, 
including p53 suppression, and the addition of small molecule enhancers of reprogramming, in 
addition to the HDAC inhibitor valproic acid used here (Okita and Yamanaka, 2011; Huangfu et al., 
2008).  Different factor combinations may also be employed to compensate for decreases in delivery 
efficiency, such as the substitution of oncogenic c-MYC with the more potent and specific L-MYC 
(Nakagawa et al., 2010).  Additional strategies, including anti-inflammatory modulation of the innate 
immune response (upregulated in response to viral transduction), preselection of cells expressing 
pluripotency-associated cell-surface antigens, and the activation of specific interaction pathways 
which amplify pluripotency signalling have also been suggested (Mah et al., 2011). 
 
Nonetheless, the primary factor influencing the choice of reprogramming method remains the 
downstream applications of the iPSCs generated.  As outlined in Table 3, the reproducibility and 
relative efficiency of retroviral reprogramming, in comparison to non-integrative methods, have 
made it the preferred method for generating iPSCs for in vitro disease modelling, in which 
integration-associated tumorigenesis is not a primary concern.   
  
4.3.2 Repression of transgene expression 
The multiple challenges associated with virus-mediated reprogramming have led to the establishment 
of criteria for the selection of reproducible, full reprogrammed pluripotent cell lines (Maherali and 
Hochedlinger, 2008).  Of these, the silencing of retroviral transgenes post-reprogramming is of 
particular importance, as even low levels of persistent transgene expression may affect the molecular 
signatures, differentiation behaviour and developmental potential of iPSCs (Stadtfeld et al., 2008).  
As such, only iPSCs which have upregulated endogenous markers of pluripotency in conjunction 













and Ellis, 2008; Okita et al., 2007).  Indeed, transgene silencing has been associated with an increase 
in germ-line competency (Okita 2007), while persistent transgene expression may be a risk factor for 
tumorigenicity (Okita et al., 2007) and genomic instability (Ramos-Mejia et al., 2010). 
 
In this study, four of the iPSC lines analysed demonstrated nearly complete silencing of all retroviral 
transgenes, approximately 10 passages post-reprogramming.  The remaining four lines tested (1519B 
and –C, and 1518A and –D) showed persistent expression of pMXs-hOct3/4, similar to previously-
described iPSC lines (Dimos et al., 2008; Yu et al., 2007).  This may have resulted from the specific 
integration of OCT4 transgenes into active loci in these clones, where the transgene expression level 
could be influenced by the flanking promoter regions, allowing for sustained expression.  Of greater 
importance is the confirmed silencing of the transgenes pMXs-hKlf4 and -hc-Myc (known 
oncogenes) in the iPSC lines into which they had been introduced, since their continuous ectopic 
expression may make cells more vulnerable to further oncogenic events, eventually leading to gross 
chromosomal abnormalities (Ramos-Mejia et al., 2010). 
 
Variation in transgene repression between iPSC clones is a well-documented phenomenon, with 
possible implications for the complete conversion of iPSCs to an ESC-like state (Lowry et al., 2008).  
However, results from continual culture of iPSCs suggest that reprogramming continues even after 
the establishment of iPSC colonies, resulting over time in a gene expression pattern more similar to 
ESCs than that of earlier passages (Okita and Yamanaka, 2011; Chin et al., 2009).  Thus, it seems 
likely that prolonged culture of these iPSC lines may result in silencing of even the OCT4 transgene.  
Nevertheless, the observation that persistent transgene expression does not appear to affect 
downstream differentiation events (Dimos et al., 2008), suggests that these lines, while unsuitable for 














The elimination of transgene expression remains a concern, however.  Future studies are therefore 
likely to involve either the generation of larger numbers of iPSC lines by retroviral transduction (in 
order to increase the statistical likelihood of generating transgene-free clones), or a switch to non-
integrating methods of reprogramming, such as those described in Section 4.1.1. 
 
4.3.3 Expression of pluripotency markers, and capacity for in vitro differentiation 
Similar to human ESCs, the iPSC lines generated here all showed robust expression of pluripotency-
associated genes and cell surface markers – the result of global epigenetic remodelling brought about 
by alterations in histone modification and CpG methylation patterns (Drews et al., 2012).  
Consequently, expression patterns of iPSCs more closely resembled that of the ESC positive control 
than those of their parental fibroblasts (Mah et al., 2011).   One exception was the expression of c-
MYC observed in the 1518 fibroblast line.  However, endogenous expression of c-MYC in fibroblasts 
has been previously reported (Dimos et al., 2008; Takahashi et al., 2007). 
 
In addition to the ESC-like patterns of gene expression, all the iPSC lines tested here were capable of 
embryoid body formation and differentiation into the three embryonic germ layers, a hallmark of 
pluripotency.  Results for two of the lines (iPS George and 1519C), obtained using reverse-
transcriptase PCR, suggested that the expression of germ layer markers was not uniform across all 
EBs – a fact which has been previously reported (Okita and Yamanaka, 2011; Yu et al., 2007).  
While expression of germ layer markers was generally not detected in undifferentiated iPSCs, both 
iPS George and 1519C showed some MAP2 expression.  This is of particular interest, since previous 
reports have shown a correlation between another ectodermal marker (PAX6) and a failure to 














Due to limited cell availability, not all cell lines were subjected to EB-mediated differentiation.  
However, as all of the SCA7 patient iPSC clones were generated in the same manner, those which 
passed all other tests of integrity and pluripotency, and could be successfully differentiated into 
neurons using the methods described in Section 2.10, were deemed fit for use for in vitro modelling 
of the disease. 
 
4.3.4 Genomic integrity of iPSCs 
The reprogramming process has been associated with a high mutation rate (Gore et al., 2011; 
Hussein et al., 2011), and recent findings indicate that the derivation of iPSCs may alter the integrity 
of the genome of the parental cells.  Indeed, the occurrence of chromosomal aberrations within 
human ESCs and iPSCs has been demonstrated by several groups, and it appears that certain types of 
aneuploidies (such as trisomy 12) may confer a proliferative advantage, by increasing the expression 
of pluripotency-associated genes located on the affected chromosomes, such as NANOG, or LIN28 
(Laurent et al., 2011; Mayshar et al., 2010). 
 
As the genomic integrity of iPSCs is a matter of critical importance for clinical applications, it is 
essential to address the biological and clinical relevance of such mutations (Drews et al., 2012).  To 
date, none of the chromosomal abnormalities detected has been found to severely compromise 
cellular functionality, suggesting that such aberrations may be transient (Pasi et al., 2011), 
particularly since several iPSC lines harbouring karyotypic variations have been shown to pass 
stringent tests of differentiation capacity (Boulting et al., 2011).  iPSCs derived from aged donors 
appear most prone to abnormalities.  However, these cells do not exhibit abnormally high levels of 
oxidative stress, DNA damage or apoptosis resistance, all hallmarks of cancer transformation 
(Prigione et al., 2011b).  In addition, the presence of mitochondrial mutational events does not 













Thus, despite the potential risks for clinical applications, the loss of nuclear and mitochondrial 
genome integrity detected in some iPSC lines does not appear to be associated with any particular 
cellular deficiency, indicating that reprogramming-related genomic alterations may not necessarily 
result in the acquisition of malignant features (Drews et al., 2012), although further detailed 
investigations will be required to distinguish harmless variations from those capable of impairing 
functionality and enhancing clinical risks. 
 
Although retrovirus-mediated reprogramming poses a significantly lower risk for aneuploidy 
compared to adenoviral transduction (Stadtfeld et al., 2008), the persistent expression of integrated 
transgenes post-reprogramming has been suggested to increase the likelihood of genomic instability 
(Ramos-Mejia et al., 2010).  To rule out this possibility, the genomic integrity of five of the iPSC 
lines generated here was assessed using the Infinium HD assay, on HumanCytoSNP-12v2.1 bead-
chips, with a further one line (iPS George) assessed using traditional G-banding karyotypic analysis.  
All of the lines assessed were deemed euploid and, while several small-scale changes were observed 
across all iPSCs, these did not differ significantly from the parental fibroblast karyotypes in each 
case, confirming the absence of gross chromosomal abnormalities.  No abnormalities were observed 
in mitochondrial DNA, which have been previously reported to occur in iPSCs (Prigione et al., 
2011a).   
 
Such a study is not without limitations, however.  Although SNP arrays such as the HumanCytoSNP-
12v2.1 used here offer enhanced resolution over traditional karyotyping methods, both approaches 
are limited to measuring changes in DNA content and chromosome morphology.  They therefore 
provide little data regarding the effects of such changes on global gene expression.  In addition, SNP 
arrays may fail to detect certain abnormalities, such as balanced translocations.  Thus, an alternative 













proposed, in order to identify clusters of genes with significantly elevated or reduced expression, 
which may be of clinical significance (Mayshar et al., 2010). 
 
Finally, it has been shown that long-term culture of iPSCs may lead to the stochastic acquisition of 
adaptive copy number aberrations, which confer a growth advantage (Mayshar et al., 2010).  It is 
therefore recommended that karyotypic analysis be periodically performed for all iPSCs intended for 
long term use, in order to ensure their continued genomic integrity. 
 
4.3.5 Fibroblasts as a source of primary cells 
Dermal fibroblasts remain the most common source of primary cells for reprogramming to 
pluripotency, accounting for 80% of the iPSC studies to date (González et al., 2011).  However, the 
requirement for skin biopsies and the need to expand fibroblasts for several passages in vitro to 
generate sufficient numbers of cells for reprogramming experiments present distinct disadvantages.  
Alternative sources of primary cells have therefore been proposed, including peripheral blood (Loh 
et al., 2009) and keratinocytes (Trond Aasen et al., 2008), each of which have advantages and 
limitations.   
 
Keratinocytes, which can be cultured and reprogrammed form a single plucked hair, offer a simple 
and accessible route to iPSC generation, avoiding the need for medical personnel and invasive 
procedures during their harvest (Trond Aasen et al., 2008).  In addition, the reprogramming of 
ectodermal keratinocytes has been found to be two-fold faster and up to 100-fold more efficient, 
when compared with dermal fibroblasts.  However, considerable more care is required when 
isolating, culturing and transducing cells, particularly since the growth and quality of hair follicles, 
and hence, of the keratinocytes themselves, are dependent on the age and medical condition of the 













and medical condition appear to have little bearing on the efficiency of reprogramming (Dimos et al., 
2008). 
 
The generation of iPSCs from human blood cells represents a novel method using easily accessible 
cells, which require little manipulation time in culture (Loh et al., 2009).  However, a study based on 
global gene expression, microRNA expression and histone modification data has highlighted the 
existence of residual gene expression patterns in iPSCs – a form of “epigenetic memory” – which 
may result from incomplete silencing of genes specific to the parental tissue of origin (Chin et al., 
2009).  As a result, iPSCs may preferentially differentiate back into the lineage from which they 
were originally derived, suggesting that ectodermal cells (such as fibroblasts) may be more suited to 
generating iPSCs for neurological diseases than mesoderm-derived blood cells (Ohi et al., 2011; 
Marchetto et al., 2009). 
 
4.3.6 Concluding remarks 
The generation of iPSCs from patient somatic cells has revolutionised the field of pluripotent cell 
technology, offering the opportunity to generate an unlimited source of patient-derived cells for 
disease modelling, drug screening and autologous transplantation therapies, while bypassing the 
ethical and host-rejection issues associated with classical ESC technology (Inoue, 2010; Abeliovich 
and Doege, 2009). 
 
This study has demonstrated the feasibility of generating iPSCs from the South African SCA7 patient 
cohort, through the transduction of patient dermal fibroblasts with retroviral vectors (Takahashi et 
al., 2007). The resulting iPSCs recapitulate many features of ESCs, and satisfy the criteria for the 
successful reprogramming of somatic cells to pluripotency (Ellis et al., 2009; Maherali and 













of endogenous pluripotency genes, ability to differentiate into the three embryonic germ layers, and 
karyotypic normality.   
 
Numerous challenges to iPSC technology remain to be addressed.  The process of reprogramming is 
relatively slow and inefficient, and the extent to which iPSCs can replace ESCs in every aspect is 
still a topic for debate.  Persistent expression of oncogenic transgenes may limit the transplantation 
potential of retrovirally reprogrammed iPSCs, while the presence of tumorigenic partially-
reprogrammed cells within an iPSC population may pose additional risks for cell-based therapies – 
an observation which has led to the exploration of alternative methods of reprogramming, which 
bypass iPSC intermediates altogether (Pang et al., 2011; Vierbuchen et al., 2010; Abeliovich and 
Doege, 2009).   
   
Nevertheless, the SCA7 iPSCs generated here serve as a starting point for differentiation into a 
variety of disease-associated cell types, including neurons, providing an ideal model in which to 














Chapter 5 Identification of a Transcriptional Phenotype in an     
iPSC-derived Model of SCA7 
5.1 Introduction 
The unique characteristics of iPSCs suggest they are likely to become a powerful tool for biomedical 
research, as well as a source for cell-replacement therapies (Inoue, 2010; Soldner et al., 2009). 
Although the realization of iPSC-based therapies is still in its very early stages, the possibility of in 
vitro modelling of human disease may make patient-specific iPSCs immediately valuable, 
particularly for diseases affecting the CNS (Soldner et al., 2009). 
 
5.1.1 iPSC-derived models of neurodegenerative disease 
In addition to the studies of ALS and SMA described in Section 1.5.2.1 (Dimos et al., 2008; Ebert et 
al., 2008), neurons derived from iPSCs have been used to model a variety of other neurodegenerative 
disorders (Table 5), including Parkinson’s disease (Soldner et al., 2009) and several of the polyQ 
diseases.  The generation of SCA3 patient neurons from iPSCs was first reported in 2011 by Koch et 
al.  In response to L-glutamate-induced excitation, these neurons undergo calcium-dependent 
proteolysis of Ataxin-3, triggering aggregation of the disease-causing protein.  This aggregation, 
which was also found to depend on functional sodium and potassium channels, as well as ionotropic 
and voltage-gated calcium channels, could be abolished by calpain inhibition, confirming the key 
role of this protease in Ataxin-3 cleavage.  Furthermore, aggregation was not observed in iPSCs, 
fibroblasts or glia generated by similar protocols, providing a possible explanation for the neuron-
specific phenotype observed in SCA3 patients.  The proteolytic liberation of highly aggregation-
prone polyQ fragments had been previously proposed as a critical step in the formation of early 
aggregation intermediates, although the precise pathogenic mechanism of disease initiation had 













using patient iPSC-derived neurons for the study of aberrant protein processing associated with late-
onset neurodegenerative diseases (Koch et al., 2011).   
 
It is interesting to note, however, that the aggregation phenotype observed in these neurons was not 
associated with the formation of NIs or macroaggregates, or with manifestations of acute cellular 
toxicity, but rather with the formation of SDS-insoluble microaggregates, which could only be 
detected by western blot.  These observations are not entirely unexpected, as inclusion formation and 
neuronal death are generally viewed as phenomena of late-stage disease, being exacerbated by an 
age-related decline in protein homeostasis (Hartl et al., 2011).  The findings of this study therefore 
support the view that early aggregation of polyQ fragments is not necessarily associated with acute 
toxicity, since neurons appear capable of coping, at least temporarily, with the burden of 
accumulated polyQ material (Koch et al., 2011). 
 
A number of recent studies using iPSCs derived from HD patients have demonstrated phenotypes 
including elevated lysosomal activity, mitochondrial deficits, decreased BDNF expression, and 
altered TGFβ and cadherin signalling (An et al., 2012; Camnasio et al., 2012).  A study of NSCs 
derived from 14 HD iPSC lines by the HD iPSC Consortium (2012), revealed a further 1601 genes 
which were significantly differentially expressed when compared to controls, including those 
involved in signalling, cell cycle, axonal guidance, and neuronal development.  In addition, 
differentiated HD neural cells demonstrated disease-associated changes in electrophysiology, cell 
adhesion, metabolism and cell death, many of which were CAG repeat-length dependent (The HD 
iPSC Consortium, 2012).  Of interest, neither the HD nor SCA3 patient derived iPSCs showed 
significant increases in the disease-causing CAG repeat length after reprogramming, prolonged 













The recent generation of βIII-tubulin-positive neurons from iPSCs of a single Chinese SCA7 patient 
has paved the way for similar investigations in other population groups (Luo et al., 2012).  To date, 
however, a disease phenotype in SCA7 iPSC-derived neurons remains to be identified. 
Table 5 Examples of successful iPSC-based modelling of neurodegenerative disorders 
Disease Molecular defect Cells derived 
from iPSCs 





Mutations in SMN1 Astrocytes, 
neurons, mature 
motor neurons 
Yes (lack of SMN1 expression, 
selective death of motor 
neurons) 
(Ebert et al., 
2008) 
ALS Mutation in SOD1 Motor neurons Yes (elevated TDP-43 protein 
levels, decreased survival, 
increased vulnerability to PI3K 
inhibition)* 
(Bilican et al., 
2012; Dimos et 
al., 2008) 




No (Soldner et al., 





Mutation in LRRK2 Ventral midbrain 
dopaminergic 
neurons 
Yes (impaired autophagy) (Sánchez-Danés 




APP duplication Neurons Yes (elevated amyloid-β
levels, increased numbers of
endosomes)
(Israel et al., 
2012) 
Huntington’s disease CAG expansion in 
HTT 
Neurons Yes (increased lysosomal 
activity, mitochondrial and 
signalling deficits, alterations 
in transcription, 
electrophysiology, cell 
adhesion, metabolism and cell 
death) 
(An et al., 2012; 
Camnasio et al., 
2012; The HD 
iPSC Consortium, 
2012) 





Partial (low levels of FXN 
mRNA) 
(Liu et al., 2011) 
SCA3 CAG expansion in 
ataxin-3 
Neurons Yes (excitation-induced 
aggregation of Ataxin-3) 
(Koch et al., 
2011) 
SCA7 CAG expansion in 
ataxin-7 
Neurons Not investigated (Luo et al., 2012) 
*Dimos et al. (2008) did not demonstrate a disease-associated phenotype.  Adapted by permission from Journal of













5.1.2 Advantages and limitations of iPSC-based models  
The study by Ebert and colleagues in 2008 was the first to demonstrate the potential of human iPSCs 
to model the specific pathology observed in genetically inherited disease (SMA), suggesting that 
iPSC-derived models may be a promising resource for the study of disease mechanisms, screening 
novel drugs and developing new therapies (Ebert et al., 2008).  Importantly, this study confirmed that 
the generation of iPSCs had no significant effect on critical gene expression profiles or alternative 
splicing events of disease-relevant genes.  
 
Previous efforts to understand mechanisms of neurodegenerative disease in human tissues have often 
relied on fibroblasts, or other readily-available cultured cell lines. While these models certainly have 
value (see Chapter 3), one of the most intriguing aspects of many neurodegenerative diseases is that 
mutations in ubiquitously- (or at least, widely-) expressed genes can lead to the specific degradation 
of subpopulations of neurons. This suggests that the unique anatomy and physiology of these 
neurons may underlie their vulnerability to the disease process (Ebert et al., 2008).  Thus, the use of 
human neurons carrying the disease-causing mutation, generated from a virtually limitless source of 
iPSCs, should help to clarify the role of these genes in disease initiation and progression. 
 
The limitations of existing animal models in the study of neurodegeneration and therapeutic 
development have bee  extensively discussed (Section 1.5.1).  Among these, the absence of 
midbrain substantia nigra dopamine neuron degeneration in mouse models of familial Parkinson’s 
disease (Abeliovich and Doege, 2009), and the absence of SMN2 expression in models of SMA 
(Ebert et al., 2008) are just two examples of the failure of such models to recapitulate key 
phenotypes – a possible consequence of species-specific aspects of these diseases.   
 
Neurons differentiated from patient iPSCs offer a unique compromise, providing a relatively 













(fibroblasts, in most cases), which carry the disease-causing mutation, as well as the patient’s full 
genetic background, and can be manipulated with relative ease for both cellular and biochemical 
applications in vitro.  Although the derivation of disease-specific iPSC-based systems for 
neurodegenerative diseases is becoming more commonplace, there is a definite need to establish and 
evaluate such models in diverse population groups, particularly those in which polyQ diseases occur 
at an unusually high frequency, to provide insights which only patient biological material can offer.  
These include investigations of potential modifiers of disease onset and progression, and methods of 
evaluating the efficacy of population-specific therapies, such as the allele-specific RNAi (Scholefield 
et al., 2009). 
 
Whether or not typical neurodegenerative disease traits can be observed in the context of iPSC-based 
culture models of these disorders remains to be determined.  At the molecular level – for instance, in 
the case of disease-associated gene- or protein expression analyses – it is possible that iPSC-derived 
neuronal cultures may recapitulate patient phenotypes.  However, for late-onset neurodegenerative 
diseases, the likelihood of iPSC-derived models showing typical patient brain pathology (for 
example, Parkinson’s disease-associated Lewy bodies) has been met with scepticism (Abeliovich and 
Doege, 2009), despite the promising results obtained in models of (childhood onset) SMA (Ebert et 
al., 2008).  It is possible that the phenotypes of adult-onset conditions, such as Parkinson’s disease 
and ALS, may never be fully recapitulated under basal cell culture conditions, but may require the 
addition of neural stressors such as reactive oxygen species, pro-inflammatory factors or even toxins 
in order to manifest (Soldner et al., 2009).   
 
In addition to their role as disease models, iPSC-derived neurons have been proposed as a source for 
autologous transplantation, mitigating concerns regarding immune rejection, while circumventing the 
ethical, political and logistical roadblocks previously associated with human ESCs.  Promising 













symptoms of rats with Parkinson’s disease or stroke have provided strong impetus for the continuing 
investigation of the feasibility of cell-based iPSC therapies (Oki et al., 2012; Wernig et al., 2008).    
However, numerous barriers to the use of iPSC-derived cells for transplantation remain to be 
addressed, including the risk of cancer posed by the persistent expression of oncogenes such as c-
MYC (Dimos et al., 2008; Okita et al., 2007), or by retroviral integration into host genome; the 
formation of correct synaptic connections in vivo; and the potential of iPSC-derived therapeutics to 
recapitulate patient’s disease process, due to their inherent genetic propensity.  It is therefore likely 
that iPSC-derived models will be confined to in vitro applications until more robust and controlled 
methods of reprogramming have been developed (Dimos et al., 2008; Stadtfeld et al., 2008). 
 
5.1.3 Neuronal differentiation from iPSCs 
The process of in vitro differentiation from human iPSCs has been shown to follow developmental 
principles, albeit with variable potency.  Indeed, the order and timing of neurogenesis and 
gliogenesis in human iPSC differentiation strongly resemble those same processes in human ESCs 
and normal brain development (Hu et al., 2010b). 
 
Most protocols employed to date follow the same basic steps (Table 6).  These include the separation 
of iPSC colonies from their feeder fibroblast layer, culture in suspension to form spherical 
aggregates (EBs or neurospheres), and selection for neural precursors, by the addition of growth 
factors (such as FGF, and other lineage-specific combinations) to the culture medium. In some cases, 
an intermediate neuroepithelial differentiation step is employed, in which cells are cultured for up to 
8 days, until the formation of neural tube-like “rosettes”.  Terminal differentiation is induced by 
culture on a laminin or polyornithine substrate, following the withdrawal of growth factors (Hu et al., 
2010b; Koch et al., 2009; Soldner et al., 2009).  Neurons, which stain positive for the early neuronal 













after seven to eight weeks (Hu et al., 2010b).  Glial cells, which stain positive for glial fibrillary 
acidic protein (GFAP), are also frequently observed (Hu et al., 2010b). 
 
To realise the full potential of iPSCs for the production of neural cells, however, the development of 
improved differentiation protocols will be required, to eliminate the use of undefined factors 
(produced by stromal feeder cells), the heterogeneous nature of EB-mediated differentiation, and the 
low yield associated with protocols based on the selective survival of neural progenitors (Chambers 
et al., 2009).  Several strategies have therefore been suggested to improve the timing and efficiency 
of differentiation.  Among these, the inhibition of SMAD signalling by the bone morphogenetic 
protein (BMP) inhibitor, Noggin, has been shown to induce rapid and uniform neural conversion of 
pluripotent cells, without the need for EB formation or stromal co-culture.  Noggin, which shows 
neural-inducing properties in both frog (Smith and Harland, 1992) and mammalian (Valenzuela et 
al., 1995) models, represses the endogenous BMP signals which drive trophoblast fates, as well as 
repressing endodermal differentiation.  Treatment with Noggin has been shown to greatly shorten the 
differentiation period required for the generation of neuronal subtypes (to approximately 19 days, as 
compared to up to 46 days for stromal feeder-mediated differentiation), while enhancing 
differentiation efficiency by up to 70% when used in combination with a second SMAD inhibitor, 
SB431542 (Chambers et al., 2009). 
 
Although human iPSCs utilise the same transcriptional network to generate neuronal cells over the 
same developmental time course as ESCs, the efficiency of differentiation from iPSCs is 
significantly reduced, and there is a marked increase in the variability between lines compared to 
ESC-mediated differentiation.  These observations are consistent across iPSC lines, and appear to be 
independent of the set of reprogramming factors used, as well as the presence or absence of 


















Methods Factors Duration*             Purification 
method 
Validation method 
Pomp et al., 
2008;   





stromal cells (PA6, 










factors    
42-46 days Mechanical 
passage 
Immunostaining for 





Hu et al., 
2010b;   
Koch 2009; 
Zhang et al., 
2001 
Suspension culture 
as EBs, adherent 








FGF, EGF >31 days Enrichment for 
neuroepithelial 








grafting of precursors 























FGF,   
TGF-β 
inhibitor 
13 days None Immunostaining for 
PAX6, differentiation 
into neural crest and 
neuronal subtypes 
Pang et al., 
2011; 
Vierbuchen 










12 days FACS Immunostaining for 





* Approximate time from ESCs/iPSC culture to first identifiable neurons. ** Optional step omitted from some protocols. 
 
To this end, recent studies have examined the possibility of direct differentiation from terminally 
differentiated cells, bypassing the pluripotent intermediate stage altogether (Yang et al., 2011).  













Ascl1 and Myt1l) to directly induce the formation of neuronal cells from mouse fibroblasts, yielding 
cells which exhibit both molecular and functional properties of neurons (Vierbuchen et al., 2010).  
The conversion rate from mouse embryonic fibroblasts (approximately 20% over two weeks) is 
substantially faster and more efficient that the rate of iPSC formation, suggesting that direct 
differentiation may represent an improvement over traditional differentiation methods (Yang et al., 
2011).  These results have subsequently been replicated in human fibroblasts, with the addition of 
NeuroD1 (Pang et al., 2011); although the longer maturation times (five to six weeks) and reduced 
efficiency (2-4%) indicate the need for additional improvements to this protocol (Yang et al., 2011).  
Additional questions remaining to be addressed include the requirement for an intermediate neural 
progenitor state, the versatility of the induced neurons (iNs) to differentiate into a variety of different 
subtypes, the degree to which the epigenetic landscape is remodelled towards a neuronal pattern and, 
crucially, whether iN cells can integrate functionally into the brain (Yang et al., 2011).  Although the 
elimination of pluripotent intermediates from the neuronal differentiation process offers a number of 
advantages, bypassing the line-to-line variation associated with iPSCs, and reducing the risk of 
tumour formation upon transplantation, the potential for expansion offered by iPSCs remains a major 
advantage of traditional methods of differentiation, suggesting that iN-based methods are unlikely to 
completely replace the use of iPSCs, at least in the near future (Yang et al., 2011). 
 
The protocol employed in this study was based on the method originally described by Dottori and 
Pera in 2008, for neuronal differentiation from ESCs (Dottori and Pera, 2008).  This method was 
selected based on its relative simplicity, efficiency, and short duration, allowing for the rapid 
generation of neurons from several different iPSC lines in parallel.  Treatment of ESC colonies with 
Noggin for 14 days resulted in the induction of neural stem cells (NSCs), which express 
neuroectodermal markers, including Sox2, Pax6, and Nestin (Pera et al., 2004). Following Noggin 
treatment, NSCs could be mechanically dissected from colonies, and cultured in suspension in the 













further differentiated in vitro to yield either neurons or glia. The efficiency of differentiation was 
assessed by immunocytochemical staining for early neuronal (βIII-tubulin) and glial (GFAP) 
markers, following guidelines previously described by Yang et al. (2011).  The transplantation of 
neurospheres derived from Noggin-treated human ESCs into the brains of Parkinsonian rodents has 
been previously shown to result in their integration and differentiation into neural and glial cells 
(Ben-Hur et al., 2004).  This neural induction protocol is thus both highly efficient and extremely 
useful for downstream applications. 
 
5.1.4 A cellular phenotype in SCA7 iPSCs and iPSC-derived neurons 
The role of transcriptional dysregulation in the early stages of polyQ pathogenesis has been 
extensively discussed (see Section 1.2.3).  Several studies have examined transcriptional phenotypes 
in peripheral cell and animal models of SCA7 in particular. To date, however, no disease-associated 
phenotype has been identified in SCA7 iPSCs or iPSC-derived neurons.  This is a crucial step in the 
evaluation of these cell lines as models for evaluating disease pathogenesis and therapies, 
particularly due to the concerns associated with the ability of iPSC-derived models to recapitulate 
phenotypes of adult-onset conditions (Section 5.1.2).  As transcriptional dysregulation represents one 
of the earliest manifestations of polyQ disease, preceding the onset of clinical symptoms, it seems 
likely that such a phenotype may be detectable in the early developmental stages represented by 
iPSCs and iPSC-derived neurons. 
 
To this end, the expression of a set of candidate transcripts, previously shown to be dysregulated in 
the context of SCA7 disease models, was evaluated in these cells.  These included the genes 
encoding heat shock proteins, an RNA chaperone, and the ubiquitin carboxy-terminal hydrolase L1 
(UCHL1), assessed in SCA7 fibroblasts (Chapter 3).  An additional eight genes were evaluated, 













signalling, all of which had previously been shown to be differentially expressed in SCA7 disease 
models (Chou et al., 2010; Wang et al., 2010; Tsai et al., 2005; Palhan et al., 2005), with some 
showing dysregulated expression across several polyQ models (Luthi-Carter et al., 2002).   
 
5.1.5 Aims 
The aims of the experiments described in this chapter were as follows: 
1. To establish and characterise SCA7 patient and control iPSC-derived neuronal lines from 
iPSC lines (which had been generated as described in Chapter 4), 
















5.2.1 Neuronal differentiation of iPSCs  
Neuronal differentiation was performed as previously described (Dottori and Pera, 2008), using two 
control (iPS SC NHDF and iPS George) and three SCA7 iPSC lines (1518D, 1519A and 1519C), all 
of which had been extensively characterised (see Chapter 4).  Multiple neuronal lines were generated 
from each iPSC line, to account for variability between differentiation experiments.  iPSC colonies 
were treated with the BMP antagonist Noggin for 14 days (Fig. 17a), followed by dissociation and 
culture in suspension in the presence of bFGF and EGF, to produce neurospheres (Fig. 17b). Single 
neurospheres were transferred onto a poly-D-lysine/laminin substrate in the absence of growth 
factors, and allowed to differentiate for one to three weeks prior to RNA isolation and imaging.  
After approximately 5 days in culture, neuron-like outgrowths were observed (Fig. 17c), which 
stained positive for the neuronal marker, βIII-tubulin (Fig. 17d-o). 
 
Despite following a protocol intended to favour neuronal growth and differentiation, both control and 
SCA7 iPSC-derived neuronal cultures also contained small numbers of GFAP-positive glial cells 
(Fig. 17d-i).  The ratio of neurons:glia did not differ between control (Fig. 17d-f) and SCA7 (Fig. 
17g-i) iPSC-derived neurons, and was sufficiently high to allow for the conclusion that neurons 
constituted the majority of the cell population at the one-, two- and three-week time points. 
 
Purkinje cells are among the neuronal subtypes most severely affected by SCA7 (Garden and La 
Spada, 2008; Einum et al., 2001).  To investigate the presence of GABAergic neurons, the lineage 
from which Purkinje cells are derived, levels of GABA expression were ascertained in iPSC-derived 
neuronal populations at one-, two- and three weeks post-differentation, by means of immunostaining 
(Fig. 17j-o).  Very little GABA expression was detected after one week of differentiation (Fig. 17j, 
m).  However, after two weeks of growth, both control (Fig. 17k) and SCA7 (Fig. 17n) neurons 













difference in the number of GABA-positive processes was detected amongst the SCA7 iPSC-derived 
neurons, when compared to controls, although fluctuations in the total number of neuronal 












Figure 17 Neuronal differentiation from iPSCs (next page). (a) iPSC colony cultured on iMEF feeders for 14 days 
without passage, in the presence of the BMP antagonist, Noggin. (b) Colonies were dissected and cultured in suspension 
in the presence of bFGF and EGF, to form neurospheres, three-dimensional balls of cells consisting of neuronal 
precursors. (c) Within five days of plating onto a poly-D-lysine/laminin substrate, neurospheres (NS) produced neuronal-
type projections.  The presence of a small proportion of glia within the iPSC-derived neuronal cultures is evident at one 
week, two weeks and three weeks post differentiation, in both control (d-f, respectively) and SCA7-derived cultures (g-i, 
respectively).  Virtually no GABA-positive projections were present in control (j) or SCA7 (m) iPSC-derived neurons at 
one week post differentiation.  However, after two weeks, the presence of putative GABAergic neurons was confirmed 
by the detection of long, GABA-positive projections in both the control (k) and SCA7 (n) neuronal populations 
(indicated by white arrowheads). After three weeks, staining for GABA (indicated by white arrowheads) was not 
significantly different in controls (l) relative to SCA7 patient-derived neurons (o). Red: βIII-tubulin. Green: (d-i), GFAP, 






































a   b    c 
d   e f 
g h i 
j k  l 
m n  o 





























































5.2.2 CAG repeat length  
In order to confirm the presence of a pathologically-expanded ataxin-7 CAG repeat in the iPSCs and 
iPSC-derived neurons generated from SCA7 patient fibroblasts, the genomic region surrounding the 
CAG repeat was amplified by PCR, and subjected to agarose gel electrophoresis (Fig. 18).  The 
approximate lengths of the CAG repeats in SCA7 fibroblasts, iPSCs and iPSC-derived neurons, 
determined by automated fluorescent genotyping, are listed in Table 7. 
       
 
Figure 18 ataxin-7 CAG repeat lengths in SCA7 iPSCs and iPSC-derived neurons.  PCR-amplified genomic DNA 
containing the ataxin-7 CAG repeat was subjected to electrophoresis on a 2% (w/v) agarose gel containing 500ng/ml 
ethidium bromide. Relative sizes were approximated by comparison to the Gene Ruler 100bp DNA Ladder Plus 
Improved (Fermentas) (MWM). N1, 2 and 3, neurons at 1, 2 and 3 weeks post-differentiation, respectively. 
 
The length of the normal CAG repeat did not appear to fluctuate during reprogramming or neuronal 
differentiation, a finding corroborated by the results obtained from the control iPSC and neuronal 
lines (data not shown).  However, an increase of three to four CAG repeats was observed when 
comparing two of the SCA7 iPSC lines (at passage 8-10) with their parental fibroblast lines.  
Compared to the iPSCs from which they were derived, neuronal lines showed no difference in the 
length of the expanded CAG repeat, when assayed at one, two and three weeks post-differentiation.  
The lengths of the expanded alleles in the patient fibroblasts are slightly shorter than those quoted in 













blood; possibly as a result of tissue-specific differences in CAG repeat length stability (Cannella et 
al., 2009; Veitch et al., 2007). 
Table 7 Normal and expanded ataxin-7 CAG repeat lengths in SCA7 iPSCs and iPSC-derived neurons. 




Neurons                                                 
CAG repeat length 
1 week* 2 weeks 3 weeks 
1518 9/40 1518D 9/43 N/D N/D N/D 
1519 10/47 1519A N/D 10/47 10/47 10/47 
1519C 10/51 10/51 10/51 10/51 
Lengths are listed as normal allele/expanded allele. N/D: not determined. *Weeks post-differentiation. 
 
5.2.3 Expression of Ataxin-7  
The expression, localization and aggregation patterns of the disease-causing protein, Ataxin-7, were 
evaluated in control and SCA7 iPSC-derived neurons by means of immunofluorescence.  Both 
control (Fig. 19a-c) and SCA7 (Fig. 19d-f) neurons showed predominant nuclear expression of 
Ataxin-7, as has been previously reported (Einum et al., 2001; Cancel et al., 2000).  Of interest, 
Ataxin-7 nuclear staining highlighted the presence of non-neuronal cells in several of the lines – 
possibly a result of incomplete differentiation.  However, since these cells express Ataxin-7 (albeit at 
lower levels when compared to βIII-tubulin-positive cells), they were considered to contribute to, 
rather than detract from, the results detailed in Section 5.2.5. 
 
After three weeks of differentiation, both patient- (Fig. 19g), and control-derived neurons (Fig. 19h) 
showed diffuse nuclear staining of Ataxin-7.  No Ataxin-7-positive NIs or macroaggregates could be 
detected in SCA7 patient-derived iPSCs, even at high magnification (Fig. 19g), up to six weeks post-




















Figure 19 iPSC-derived neurons express Ataxin-7. Both control- and patient iPSC-derived neurons show 
predominantly nuclear localization of Ataxin-7 (green) after two to three weeks in culture. (a)-(c), control neurons (iPS 
George); (d)-(f), SCA7 patient neurons (1519A or C). At higher magnification, no NIs could be detected in SCA7 patient 
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5.2.4 Transcriptional phenotype in iPSCs  
In order to evaluate differences in gene expression between SCA7 patient and control iPSCs, 12 
candidate transcripts were selected, based on their relevance to known polyQ disease pathways.  
These included the genes whose expression had previously been evaluated in SCA7 and control 
fibroblast lines – namely, HSP27, -70, -105, DNAJA1, RBM3 and UCHL1 – as well as genes 
encoding a component of the STAGA complex (KAT2A), a proapoptotic protein (BAX), a growth 
factor (IGFBP5), a protein involved in chromatin phosphorylation (SNRK), and two genes encoding 
proteins involved in neuronal differentiation (Bex1 and Olig1).  All of these genes had previously 
been shown to be differentially expressed in SCA7 disease models (Chou et al., 2010; Wang et al., 
2010; Palhan et al., 2005; Tsai et al., 2005), with some showing dysregulated expression across 
several polyQ models (Luthi-Carter et al., 2002). 
 
When expression was compared across two control iPSC lines (SC NHDF and George) and three 
SCA7 iPSC lines (1518D, and 1519A and -C), all of which had been extensively characterised, a 
significant decrease in expression of KAT2A (p=0.03), was observed in SCA7 iPSCs relative to 
controls (Fig. 20).  Levels of IGFBP5 were found to be approximately three-fold higher in SCA7 
iPSCs compared to controls, although this result was not statistically significant.  No significant 
changes in any of the remaining genes were observed.  However, there did appear to be a trend 
towards increased DNAJA1 expression in patient iPSCs, correlating with the increase in DNAJA1 





























Figure 20 Transcriptional changes in SCA7 patient iPSCs.  Expression of endogenous transcripts in SCA7 iPSCs 
relative to controls is shown, normalised to β-Actin. Values are mean ± SEM. Control iPSCs, n = 2, SCA7 iPSCs, n = 3. 
UCHL1, Ubiquitin carboxy-terminal hydrolase LI; DNAJA1 (HSP40), DNAJ homolog, subfamily A, member 1; HSP-, 
heat shock protein -27; -70; -105; RBM3, RNA-binding motif protein 3; Olig1, Olig1 bHLH protein; Bex1, Brain-
expressed X-linked 1; BAX, BCL2-associated X protein; KAT2A, K (lysine) acetyltransferase 2A; SNRK, SNF related 
kinase; IGFBP5, insulin-like growth factor binding protein 5. * indicates a p value < 0.05. 
 
5.2.5 Transcriptional phenotype in iPSC-derived neurons 
Differences in gene expression between SCA7 patient and control iPSC-derived neurons were also 
investigated.  In addition to the candidate transcripts evaluated in iPSCs, expression of a further three 
genes was assessed.  Two of these – solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 6 (SLC17A6), encoding a vesicular glutamate transporter; and glutamate 
receptor, ionotropic, AMPA2 (GRIA2) – have been previously shown to be dysregulated in the 
cerebellum of SCA7 mice (Chou et al., 2010).  The third gene included was ataxin-7, encoding the 
disease-causing protein, whose expression has been shown to depend to some degree on the length of 













Multiple neuronal lines were used, which had been differentiated from five iPSC lines – two 
controls, iPS SC NHDF and iPS George; and three SCA7 patient lines, 1518D, 1519A and 1519C.  
Expression of the fifteen candidate genes was assessed in all of the lines at one and three weeks post-
differentiation.  No significant differences in expression were observed between any of the 1518D-
derived neuronal lines and the controls at either the one or three week time points (Fig. 21 and 22). 
 
At one week post-differentiation (Fig. 21), an approximate two-fold increase in HSP27 expression 
was observed in the 1519-derived neurons, when compared to controls (p=0.01), although this trend 
was not sustained at three weeks post-differentiation (Fig. 22).   
 
Also at one-week post-differentiation, a significant difference in GRIA2 expression between 1518D-
derived and 1519-derived neurons was observed, with 1518D-derived neurons showing slightly 
elevated GRIA2 expression relative to controls, while 1519-derived neurons showed significantly 
decreased expression levels relative to both controls and 1518D-derived neurons (p=0.03).  By three 
weeks post-differentiation, GRIA2 expression in 1519-derived neurons had fallen to one-third of the 
expression levels observed in controls (p=0.03).  A two-fold reduction in GRIA2 expression was 
observed 1518D-derived neurons relative to controls at the same time point, although this result was 
not statistically significant. 
 
A 2.3-fold increase in ataxin-7 expression was observed at one-week post-differentiation in 1519-
derived neurons, as compared to controls (p=0.004).  Ataxin-7 expression 1518D-derived neurons 
was 1.6-fold higher than controls at the same time point, although this change was not significant.  
By three weeks post-differentiation, ataxin-7 expression in neurons from both SCA7 patients had 














Several non-significant trends were observed at the one week time point in SCA7 patient-derived 
neurons versus controls, including decreased levels of UCHL1 and SLC17A6 expression, and 
marginally elevated levels of the heat shock protein genes HSP70 (1519), HSP105 (1518), and the 
growth factor IGFBP5 (1519).  A four-fold elevation of Olig1 in was observed in 1518D-derived 












Figure 21 Transcriptional changes in SCA7 iPSC-derived neurons one week post-differentiation. Expression of 
endogenous transcripts in SCA7 iPSC-derived neurons relative to controls is shown, normalised to β-Actin. Values are 
mean ± SEM. Control iPSC-derived neuronal lines, n = 6, 1518D iPSC-derived neuronal lines, n = 3, 1519 iPSC-derived 
neuronal lines n = 6. UCHL1, Ubiquitin carboxy-terminal hydrolase LI; DNAJA1 (HSP40), DNAJ homolog, subfamily 
A, member 1; HSP-, heat shock protein -27; -70; -105; GRIA2, glutamate receptor, ionotropic, AMPA2;  RBM3, RNA-
binding motif protein 3; SLC17A6, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), 
member 6; Atxn7, ataxin-7; Bex1, Brain-expressed X-linked 1; IGFBP5, insulin-like growth factor binding protein 5; 
KAT2A, K (lysine) acetyltransferase 2A; BAX, BCL2-associated X protein; SNRK, SNF related kinase; Olig1, Olig1 














A 1.3-fold increase in DNAJA1 expression was observed in 1519-derived neurons, relative to 
controls at three weeks post-differentiation (p=0.01).  This corresponds with previously-published 
reports, as well as with the results obtained in SCA7 fibroblasts described in Chapter 3, and the non-
significant trend observed in SCA7 patient-derived iPSCs. 
 
Several additional non-significant trends were observed at three weeks post-differentiation, including 
decreased UCHL1 (in both 1518D- and 1519-derived neurons), IGFBP5 (1518D) and Olig1 (1519) 
expression; and elevated HSP27 (1519), HSP105 (1519) and BAX (1518).  An approximate 1.7-fold 
increase in SLC17A6 expression in 1519-derived neurons relative to controls was also observed, 
although this was not deemed to be significant. 
 
In order to track changes in expression of the various genes over a three-week time course, an 
intermediate time point (two weeks) was included.  Given the lack of statistically significant results 
for 1518D-derived neurons at the one- and three-week time points, the detailed time-course analysis 
was limited to a comparison between 1519-derived neurons and control lines.  These data revealed a 
further three significant results (p<0.05) – at two weeks post-differentiation, 1.2-fold increases in 
DNAJA1 and HSP105 expression, and a 2-fold decrease in GRIA2 expression were observed in 
1519-derived neurons compared to controls (Fig. 23a-c). 
 
Trends in expression of two additional genes, SLC17A6 and Olig1 were of interest, although not 
significant.  In the case of SLC17A6, expression increased over time in 1519-derived neurons, but 
decreased over the same three week period in control neurons.  Thus, while 1519-derived neurons 
displayed deficient SLC17A6 expression at one week post-differentiation, the same neurons showed 
abnormally elevated expression of the gene by the three-week time point (Fig. 23d).  The opposite 













expression at early time points, with expression falling below the levels of that of control neurons, by 














Figure 22 Transcriptional changes in SCA7 iPSC-derived neurons three weeks post-differentiation. Expression of 
endogenous transcripts in SCA7 iPSC-derived neurons relative to controls is shown, normalised to β-Actin. Values are 
mean ± SEM. Control iPSC-derived neurons, n = 6, 1518D iPSC-derived neurons, n = 3, 1519 iPSC-derived neurons n = 
6. UCHL1, Ubiquitin carboxy-terminal hydrolase LI; DNAJA1 (HSP40), DNAJ homolog, subfamily A, member 1; HSP-, 
heat shock protein -27; -70; -105; GRIA2, glutamate receptor, ionotropic, AMPA2;  RBM3, RNA-binding motif protein 
3; SLC17A6, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6; Atxn7, ataxin-7; 
Bex1, Brain-expressed X-linked 1; IGFBP5, insulin-like growth factor binding protein 5; KAT2A, K (lysine) 
acetyltransferase 2A; BAX, BCL2-associated X protein; SNRK, SNF related kinase; Olig1, Olig1 bHLH protein.              






































Figure 23 Transcriptional changes in SCA7 iPSC-derived neurons over time.  Expression of endogenous transcripts 
in SCA7 iPSC-derived neurons (1519) and controls are shown for each time point, normalised to β-Actin. Values are 
mean ± SEM. Control iPSC-derived neurons, n = 6, SCA7 (patient 1519) iPSC-derived neurons, n = 6.  Time post-
differentiation (in weeks) is indicated on the x-axis. (a) DNAJA1 (b) HSP105 (c) GRIA2 (d) SLC17A6 (e) Olig1.              

















This study has demonstrated the feasibility of differentiating SCA7 patient iPSCs into neurons, 
which express neuronal markers including βIII-tubulin and GABA.  Moreover, both iPSCs and 
iPSC-derived neurons display changes in expression of key transcripts, previously implicated in the 
pathogenesis of polyQ disease, suggesting that iPSC-derived cells may serve as useful models of 
neurodegenerative disease progression, for future studies.  This is the first report of the development 
of iPSC-derived neurons from the South African SCA7 patient cohort.  It is also the first study to 
identify a transcriptional phenotype in these cells. 
 
5.3.1 Neuronal differentiation from iPSCs 
Based on the criteria outlined by Yang et al. in 2011, both control and SCA7 patient iPSCs appeared 
capable of robust, reproducible differentiation towards neuronal fates, as demonstrated by βIII-
tubulin positive staining at one, two and three weeks post differentiation.  The presence of a small 
population of cells which did not express βIII-tubulin was occasionally detected; indicative of minor 
variations in differentiation efficiency between iPSC lines, as has been previously described (Hu et 
al., 2010b).  The Yang et al. guidelines, first proposed to standardise the generation of iNs via direct 
differentiation from fibroblasts, list the following criteria for successful neuronal differentiation, in 
increasing order of stringency: development of characteristic neuronal morphology, expression of 
multiple neuronal markers (for example, βIII-tubulin, MAP2, NeuN, Neurofilament and Synapsin), 
development of membrane potential, including membrane voltage and current responses, and 
demonstration of synaptic competence, as determined by the presence of spontaneous and evoked 
pre- and postsynaptic responses (Yang et al., 2011).  Given the aims of this proof-of-principle study, 
which sought to compare SCA7 and control iPSCs in vitro, in order to evaluate differences in 
transcriptional regulation, emphasis was placed on the first two criteria, which have been previously 













No significant differences in morphology or propensity for βIII-tubulin expression were observed 
when comparing neurons derived from SCA7 patient iPSCs with those derived from controls.  This 
contradicts a previous report of ESCs expressing expanded CAG repeats, which demonstrated 
aberrant neuronal differentiation, decreased survival, and the formation of dystrophic neurites, 
similar to pathological abnormalities observed in several polyQ diseases (Lorincz et al., 2004; 
DiFiglia et al., 1997; Burright et al., 1995).  These results suggested that the expression of proteins 
harbouring CAG repeat expansions may impair the ability of pluripotent cells to generate functional 
neurons (Lorincz et al., 2004).  However, more recent studies of polyQ and other neurodegenerative 
diseases have demonstrated that this is not the case.  Indeed, reports of neuronal differentiation in 
polyQ disease (Camnasio et al., 2012; Koch et al., 2011) and Parkinson’s disease (Soldner et al., 
2009), among others, have found no difference in differentiation potential between patient and 
control iPSCs, suggesting that pathogenesis may result from the degeneration of neurons at advanced 
stages of disease progression, rather than from aberrant differentiation during development. 
 
The neurons primarily affected in SCA7 are the cerebellar Purkinje cells (Garden and La Spada, 
2008; Einum et al., 2001).  However, at the time of experimental design, only one protocol existed 
for the differentiation of Purkinje cells, from mouse ESCs (Tao et al., 2010).  (A more 
straightforward protocol for EB-mediated differentiation of cerebellar neurons from human and 
mouse ESCs has subsequently been published (Erceg et al. 2012).)  The complexity of the method 
described by Tao et al., which requires co-culture with dissociated cerebellar material harvested from 
mice at postnatal day 6-8, precluded its use in this proof-of-principle study.  Thus, the simplified 
general neuronal differentiation method described by Dottori and Pera (2008) was selected.   
 
This protocol, which was adapted as per the author’s recommendations to favour the production of 
neurons, nevertheless produced a small population of contaminating GFAP-positive glial cells.  The 













established (Garden and La Spada, 2012; Inoue, 2010).  Indeed, the expression of mutant polyQ 
protein in the glia of transgenic mice has been shown to result in non-cell-autonomous Purkinje cell 
degeneration (Custer et al., 2006).  Thus, the presence of glial cells within the differentiated neuronal 
population was deemed to be an advantage in assessing the overall disease-associated phenotype. 
 
Further characterization of the general neuronal population produced from SCA7 and control iPSCs 
revealed the presence of putative GABAergic neurons, the lineage from which cerebellar Purkinje 
cells are derived.  The strong propensity for in vitro differentiated neurons to acquire an interneuron-
like phenotype, with co-expression of GABA and the GABA-producing enzyme, glutamic acid 
decarboxylase (GAD67) has been previously described (Koch et al., 2009).  Despite some line-to-
line variation, no significant difference in the ability to generate GABA-positive processes could be 
detected between SCA7 and control iPSC-derived neurons, suggesting that the presence of mutant 
ataxin-7 does not affect the development of Purkinje cells, at least at early stages of neuronal 
differentiation.  It should, however, be noted that the protocol employed for neuronal differentiation 
relied on the generation of neurosphere intermediates – inherently heterogeneous structures whose 
size, number and morphology proved difficult to standardise across lines, making cross-line 
comparisons challenging.   
 
5.3.2 CAG repeat length 
The CAG repeat encoding the polyQ tract in disease-causing proteins such as ataxin-7 is by nature 
unstable, with repeat lengths above the pathogenic threshold showing a propensity to expand during 
vertical transmission from parent to child (Monckton et al., 1999).  A high degree of somatic 
instability has also been reported in transgenic mouse models and autopsied brain samples from HD 
and SCA7 patients (Dragileva et al., 2009; Gonitel et al., 2008; Kennedy et al., 2003), while in a 












following neural differentiation (Niclis et al., 2009), although this has not been replicated in other 
ESC lines (Seriola et al., 2011).   
It is therefore surprising to note that iPSCs derived from the somatic cells of several polyQ disease 
patients, including those with SCA3 and HD, show remarkable CAG repeat stability up to 40 
passages post-reprogramming (Camnasio et al., 2012; Koch et al., 2011).  This stability has also been 
shown to be maintained over several weeks of neuronal differentiation (Koch et al., 2011).  In terms 
of triplet repeat disorders, only Friedreich’s ataxia has shown disease-associated repeat instability in 
patient iPSCs over time – a phenomenon believed to result from the particular structure and length of 
the GAA∙TTC repeat (Ku et al., 2010). 
In this study, the disease-causing CAG repeat in ataxin-7 was shown to expand by between three and
four repeats during the reprogramming process from fibroblasts to iPSCs. This instability was 
limited to the mutant allele, and was not observed in control iPSCs, suggesting that the mutant allele 
is more prone to expansion, as has been previously reported (Monckton et al., 1999). No changes in 
CAG repeat length were observed during the process of neuronal differentiation from iPSCs. The
expansion of the CAG repeat in iPSC reprogramming but not differentiation may reflect the high rate
of cell division during the derivation of iPSCs, in comparison to post-mitotic neurons (Yoon et al., 
2003). Alternatively, the integration of retroviral transgenes has been shown to affect genomic
stability, possibly resulting in mutations in already unstable regions of the genome (Ramos-Mejia et
al., 2010). Despite the relative stability observed in HD and SCA3, the expansion of the CAG repeat
tract in SCA7 iPSCs was not entirely unexpected, as the ataxin-7 repeat tract has previously been
identified as the most expansion-prone of all the polyQ diseases (Monckton et al., 1999).  
It is important to note, however, that an error margin of three CAG repeats is considered acceptable 













in this study result simply from the limitations of the fluorescent genotyping technique employed to 
determine repeat length. Of critical importance to this study, no contractions or large-scale 
expansions were observed, which may have resulted in a different phenotype than that predicted by 
the diagnostic test results for the SCA7 patients. 
 
5.3.3 Ataxin-7 expression and localization 
Wildtype Ataxin-7 is widely expressed in the brain, retina, and peripheral tissues (Jonasson et al., 
2002; Einum et al., 2001; Cancel et al., 2000).  Within the CNS, expression is preferentially 
neuronal, although low levels of Ataxin-7 have also been detected in non-neuronal cells, including 
astrocytes (Cancel et al., 2000).  In normal human brains, Ataxin-7 is localised to the cell bodies and 
processes of neurons, as well as the nucleus (Cancel et al., 2000).  Subcellular localization varies 
according to cell type, patient age and polyQ repeat length (Jonasson et al., 2002; Einum et al., 2001; 
Cancel et al., 2000), with longer polyQ repeats showing a tendency to inhibit the cytoplasmic 
trafficking of the protein (Taylor et al., 2006).  
 
The formation of nuclear inclusions (NIs), aggregates of mutant protein which sequester crucial 
cellular components including molecular chaperones and transcription factors, is a pathological 
hallmark of many polyQ diseases (see Section 1.1.3). In SCA7, the presence of intra- and perinuclear 
aggregates of Ataxin-7 has been confirmed in studies of cell models and human brain tissue, 
particularly in cases in which truncated, polyQ-containing fragments of the protein are expressed 
(Zander et al., 2001).   Indeed, caspase-7-mediated cleavage of Ataxin-7, yielding fragments which 
demonstrate enhanced nuclear localisation and increasing tendency towards aggregation (Taylor et 
al., 2006), has been demonstrated to modulate toxicity in SCA7 (Young et al., 2007; Garden et al., 













of aggregates in unaffected tissues (Ansorge et al., 2004; Jonasson et al., 2002; Lindenberg et al., 
2000; Holmberg et al., 1998), and the lack of NIs observed in some cases (Einum et al., 2001).   
 
Both the SCA7 and control iPSC-derived neurons generated in this study showed predominantly 
nuclear localisation of Ataxin-7, as has been previously observed (Jonasson et al., 2002; Einum et al., 
2001).  Despite reported differences in localisation between SCA7 patients with different CAG 
repeat lengths, and different ages of onset, no difference in subcellular compartmentalisation of 
Ataxin-7 was observed between the two SCA7 patients in this study, corresponding to previously 
published reports (Jonasson et al., 2002; Einum et al., 2001).  This suggests that iPSC-derived 
neurons represent an early stage of development, rather than recapitulating the age or disease stage of 
the patient from which the primary cells were derived.   
 
No NIs or macroaggregates of Ataxin-7 were detected in SCA7 patient iPSC-derived neurons, up to 
six weeks post-differentiation.  It may be argued that aggregation of Ataxin-7 obscures epitopes 
required for antibody recognition, resulting in selective immunostaining of unbound wildtype 
protein.  However, this is unlikely to be the case, since the antibody used for Ataxin-7 detection in 
this study has been previously shown to label Ataxin-7-containing NIs in patient brains (Jonasson et 
al., 2002).   
 
Previous studies employing similar models for the study of neurodegenerative disease have raised 
concerns regarding the relevance of modelling adolescent- and adult-onset diseases over the short 
lifespan of cultured neurons (Soldner et al., 2009).  Indeed, pathological hallmarks of disease such as 
the formation of NIs may take decades to manifest, requiring the gradual accumulation of toxic 
proteins as a result of age-dependent deficiencies in protein homeostasis (Hartl et al., 2011).  
Although some studies suggest that NIs may be detected at earlier stages, the major determinants of 













polyQ-containing protein (Miller et al., 2010; Arrasate et al., 2004).   Thus, a cell line derived from 
an individual expressing endogenous (low) levels of a moderately-expanded Ataxin-7 protein may be 
less likely to demonstrate an observable cellular phenotype. 
 
The propensity for NI formation has also been shown to vary extensively between cell types (Cancel 
et al., 2000).  Thus, it may be that the neuronal subtypes generated in this study are less prone to 
aggregation, although more extensive characterisation of the neuronal population generated will be 
necessary in order to confirm this.  Alternatively, the aggregation of mutant protein may require an 
exogenous trigger, such as exposure to oxidative stress or neurotoxins.  The recent study of SCA3 
iPSC-derived neurons by Koch et al. supports this hypothesis, suggesting that excitation-induced 
calcium influx is required for proteolytic cleavage and aggregation of Ataxin-3 (Koch et al., 2011). 
 
Of interest, no inclusion bodies were detected by epifluorescence staining in the SCA3 iPSC-derived 
neurons described by Koch et al.  Instead, the SDS-insoluble Ataxin-3-containing fragments detected 
by western blot were deduced to be microaggregates.  These minute aggregates, whose presence 
precedes the formation of larger NIs, have been detected in numerous models of polyQ disease, 
including SCA1 and SCA7 (Latouche et al., 2007; Michalik et al., 2003; Michalik and Van 
Broeckhoven, 2003; Yoo et al., 2003; Watase et al., 2002), where they represent an early stage of 
pathology.  Thus, a lack of microscopically-detectable aggregates does not preclude the formation of 
pathological microaggregates.  Further studies involving the detection of Ataxin-7 protein by western 
blot should help to clarify the presence of these structures in the SCA7 iPSC-derived neurons 














5.3.4 Transcriptional alterations in iPSCs and iPSC-derived neurons 
The role of transcriptional dysregulation the polyQ diseases has been extensively documented, 
particularly in cell and animal models of SCA7 (Chou et al., 2010; Zijlstra et al., 2010; Abou-
Sleymane et al., 2006; Tsai et al., 2005; Yoo et al., 2003; La Spada et al., 2001).  The identification 
of gene expression changes which precede the onset of symptoms suggests strongly that alterations 
in transcription may be among the earliest manifestations of disease (Helmlinger et al., 2006a).  
Thus, it makes sense to use gene expression changes as a tool to identify a disease-associated 
phenotype in cells representing early stages of development.   
 
A recent study by Feyeux et al. succeeded in identifying early transcriptional changes linked to 
naturally-occurring HD mutations in human ESCs, and ESC-derived neural stem cells (NSCs) 
(Feyeux et al., 2012).  Using multiple ESC lines derived from human blastocysts diagnosed as HTT 
mutation carriers by pre-implantation genetic diagnosis, the study aimed to investigate differences in 
gene expression at early stages of development, by means of differential transcriptomics.  Statistical 
refinement of whole genome expression data revealed a total of seven up- or downregulated genes in 
HD cells, including genes implicated in disease-associated pathways such as mitochondrial function.  
Of note, no statistically significant correlation was observed between differentially expressed 
transcripts in patient autopsied brain samples (representing end-stage disease), and the 
presymptomatic state represented by ESCs and NSCs (Feyeux et al., 2012).  Nonetheless, this study 
provided convincing evidence that a disease-associated phenotype may be identified in pluripotent 
cells and/or early-stage neurons.  This is supported by recent findings by the HD iPSC Consortium 
(2012), who used HD iPSC-derived neural stem cells to identify disease-associated patterns of 
transcriptional dysregulation. 
 
In order to investigate transcriptional alterations in the SCA7 iPSCs and iPSC-derived neurons 













demonstrated (Sopher et al., 2011; Chou et al., 2010; Wang et al., 2010; Palhan et al., 2005; Tsai et 
al., 2005; Luthi-Carter et al., 2002).  These included genes encoding heat shock proteins, an RNA 
binding protein, a growth factor and a deubiquitinating enzyme, as well as genes involved in 
transcriptional regulation, apoptosis, chromatin phosphorylation, neuronal differentiation and 
signalling.  Of these 15, only three genes showed no notable changes in expression between wildtype 
and SCA7 iPSCs and iPSC-derived neurons over three weeks of differentiation – the RNA chaperone 
RBM3 (Chou et al., 2010), SNRK, encoding a protein involved in chromatin phosphorylation (Luthi-
Carter et al., 2002), and Bex1, an interactor of the p75 neurotrophin receptor, which regulates 
neurotrophin signalling and neuronal differentiation (Vilar et al., 2006).  The remaining 12 genes 
demonstrated either significant alterations in expression or notable trends over time.  A summary of 
the transcriptional changes observed in fibroblasts (Chapter 3), iPSCs and iPSC-derived neurons can 
be found in Table 8. 
Table 8 Summary of transcriptional changes identified in SCA7 patient-derived fibroblasts, iPSCs and 
iPSC-derived neurons, relative to controls 
Gene  Published  
Data* 





  UCHL1  ↓ ↓ NS (↓) (↓) Deubiquitinating enzyme 
  DNAJA1  ↑, ↓ ↑ (↑) NS   ↑ HSP/Chaperone 
  Hsp70  ↓ NS NS (↑) NS HSP/Chaperone 
  Hsp27  ↓ NS NS ↑ (↑) HSP/Chaperone 
  HSP105  ↑, ↓ NS NS (↑) (↑) HSP/Chaperone 
  GRIA2  ↑ - - (↓) ↓ AMPA receptor  
  RBM3  ↑ NS NS NS NS RNA chaperone  
 SLC17A6  ↓ - - (↓) (↑) Glutamate transport  
  Olig1  ↓ - NS (↑) (↓) Oligodendrocyte myelination  
  ataxin-7  ↑ - NS   ↑ (↑) Component of STAGA  
  Bex1  ↑ - NS NS NS Neuronal differentiation  
  IGFBP5  ↓ - (↑) (↑) (↓) Growth factor 
  KAT2A  ? - ↓ NS NS Component of STAGA  
  BAX  ↑ - NS NS (↑) Apoptosis 
  SNRK  ↓ -    NS NS NS Chromatin phosphorylation  
*Sopher et al., 2011; Chou et al., 2010; Wang et al., 2010; Palhan et al., 2005; Tsai et al., 2005; Luthi-Carter et al., 2002 
**Results for neurons derived from iPSCs of one or both SCA7 patients 
Key: ↑, significantly upregulated (p<0.05); ↓, significantly downregulated (p<0.05); (↑) or (↓), trends towards up- or 














KAT2A encodes the protein Gcn5, the histone acetyltransferase (HAT) component of the STAGA 
transcription coactivator complex (Strom et al., 2005; Martinez et al., 2001).  The evolutionarily 
conserved role of STAGA in transcriptional regulation has been shown to be mediated by two 
histone-modifying activities – histone acetyltransferase (HAT) via Gcn5 (Martinez et al., 2001), and 
deubiquitination via Usp22 (Zhao et al., 2008b). Ataxin-7 is a component of the deubiquitination 
module of STAGA, where it appears to anchor this module to the main complex (Köhler et al., 
2008).  Since Gcn5 interacts directly with the zinc-binding motif of Ataxin-7 (Helmlinger et al., 
2004a), a loss of Gcn5 function may result in the displacement of the deubiquitination submodule 
from STAGA, compromising its enzymatic functions (Atanassov et al., 2009). 
 
The interaction of Gcn5 with Ataxin-7 is required for STAGA-mediated histone H3 acetylation, and 
for the activation of CRX-dependent retinal genes (Helmlinger et al., 2006a; Helmlinger et al., 
2006c; Helmlinger et al., 2004a), both of which have been shown to be inhibited in a dominant 
negative fashion by the incorporation of mutant Ataxin-7 into the STAGA complex (Helmlinger et 
al., 2006a; Helmlinger et al., 2006c; McMahon et al., 2005; Palhan et al., 2005).  Indeed, evidence 
from a SCA7 knock-in mouse model, in which transcriptional downregulation was shown to be an 
early event leading to photoreceptor dysfunction, retinal degeneration and visual impairment (Yoo et 
al., 2003), appears consistent with a decrease in STAGA transcriptional coactivation in the presence 
of mutant Ataxin-7 (Chen et al., 2012).  In direct contrast to these results, however, Helmlinger et al. 
reported the isolation of STAGA complexes from SCA7 mouse models which exhibited normal 
levels of HAT activity (Helmlinger et al., 2006a).  Moreover, they observed increased recruitment of 
STAGA to target promoters in the presence of mutant Ataxin-7, resulting in histone H3 
hyperacetylation.  In this model, the wildtype functions of Ataxin-7 and STAGA (including Gcn5) 














Previous studies of Gcn5 function have demonstrated the importance of its importance in mouse 
embryo survival and development, including neural tube closure and anterior-posterior patterning 
(Lin et al., 2008; Bu et al., 2007; Xu et al., 2000).  A recent study by Chen et al. sought to further 
investigate the importance of Gcn5 and STAGA function in the development of SCA7 by examining 
the effects of Gcn5 mutations in SCA7 transgenic mice (Chen et al., 2012). Their results indicated 
that partial loss of Gcn5 function led to accelerated neuronal dysfunction and pathology, although 
deletion of Gcn5 in Purkinje cells was not sufficient to induce severe ataxia in the presence of 
wildtype Ataxin-7. Of interest, the accelerated pathogenesis observed in SCA7 mouse retinal cells 
was not accompanied by expression changes in known Ataxin-7 target genes, suggesting the 
involvement of non-transcriptional functions of STAGA. 
 
Thus, it would appear that a loss of Gcn5 function may contribute to SCA7 pathogenesis (Chen et al., 
2012).  In line with these observations, results from this study indicate significant downregulation of 
KAT2A expression in SCA7 iPSCs, relative to controls.  Altered KAT2A expression could result in a 
derangement in the composition and/or function of STAGA in patient iPSCs, supporting the 
hypothesis that a loss of Gcn5 expression may contribute to the pathogenesis of SCA7, at least in the 
early stages of development.   
 
A decrease in KAT2A in SCA7 iPSCs may also reflect global deficiencies in HAT activity, with 
possible implications for the effectiveness of reprogramming, given previous reports of the 
interaction between Gcn5 and c-Myc, a key pluripotency protein (Takahashi et al., 2007).  This 
hypothesis is less likely, since no obvious differences in reprogramming efficiency, genomic 
integrity or pluripotency could be detected between SCA7 iPSCs and controls (see Chapter 4).  
However, genome-wide expression analysis may be necessary to further investigate the contribution 













Knockout of Gcn5 has been shown to inhibit neuronal differentiation in vivo (Martínez-Cerdeño et 
al., 2012).  However, no significant differences in expression were detected between SCA7 and 
control iPSC-derived neuronal lines in this study.  Indeed, KAT2A expression appeared marginally 
higher in the SCA7 neuronal lines, potentially due to compensatory upregulation in the presence of 
mutant Ataxin-7, a phenomenon previously described in a SCA7 mouse model (Palhan et al., 2005).   
Despite extensive evidence for the role of KAT2A/Gcn5 deficiency in the exacerbation of SCA7
pathogenesis, a causative link between mutant Ataxin-7 expression and decreased KAT2A mRNA is 
difficult to establish. Indeed, the current understanding of STAGA complex composition implies
that any effect of polyQ-expanded Ataxin-7 on Gcn5 is likely only to be observed at the protein level 
– the result of aberrant interactions between components of the complex. The observation that 
RNAi-mediated knockdown of Ataxin-7 in HEK293 cells leads to a concomitant reduction in Gcn5
levels suggests the possibility of a feedback loop, which may be perturbed in the presence of mutant
Ataxin-7 (Palhan et al., 2005).  However, such speculations remain to be verified.
The role of the heat shock response (HSR) in the pathogenesis and treatment of polyQ diseases is 
well documented. Aggregates of mutant polyQ proteins have been shown to recruit heat shock
proteins (HSPs) (such as HSP40 and HSP70) (Zander et al., 2001; Chai et al., 1999a; Chai et al.,
1999b; García-Mata et al., 1999; Cummings et al., 1998), while exogenous overexpression of several
HSPs, including HSP27 and HSP104 has been shown to suppress neurotoxicity in HD mouse and rat 
models (Perrin et al., 2007).
Induction of the HSR, in order to promote mutant polyQ protein folding and prevent aggregation, has 
been observed in the CNS of presymptomatic animal models of disease, and in patient peripheral 













of genes encoding numerous heat shock proteins, including HSP27, HSP105 and HSP40 (DNAJA1) 
should be significantly elevated in SCA7 iPSC-derived neurons compared to controls, at various time 
points during differentiation.  These results correlate with previous reports of early-stage 
transcriptional changes in SCA7 mice cerebella, as well observations in SCA3 patient fibroblasts 
(Chou et al., 2010; Zijlstra et al., 2010), iPSC-derived neurons from patients with neurodegenerative 
disease (Byers et al., 2011), and SCA7 patient fibroblasts (as reported in Chapter 3 of this study). 
 
Of interest, only DNAJA1 (HSP40)  showed an increase in expression over the three time points 
evaluated, with the remaining heat shock proteins showing a gradual decline in expression over time.  
This corresponds with previous reports of a biphasic nature of the HSR in polyQ diseases, in which 
an initial increase in HSR components at early stages of disease is followed by progressive 
impairment of HSP gene transcription – the result of an accumulation of toxic mutant Ataxin-7 
(Chou et al., 2010), as well as possible epigenetic silencing of the HSP genes (Labbadia et al., 2011).  
Indeed, downregulation of HSP expression is a common hallmark of late-stage polyQ pathogenesis, 
having been identified in affected neurons in HD, SBMA, SCA3 and SCA17 transgenic mice (Chou 
et al., 2010; Chou et al., 2008; Katsuno et al., 2005; Hay et al., 2004).  Investigation of HSP gene 
expression at later time points is likely to clarify whether or not this phenomenon can be observed in 
SCA7 iPSC-derived neurons. 
 
In contrast to the results obtained from iPSC-derived neurons, SCA7 iPSCs showed no significant 
induction of HSP gene expression.  Similar to LCLs, the rapid rate of cell division associated with 
iPSCs suggests that these cells are capable of efficient protein turnover, making them far less 
susceptible to mutant Ataxin-7 accumulation than post-mitotic neurons; thus reducing the need for 














The only gene to show consistent downregulation in SCA7 iPSC-derived neurons across all three 
differentiation time points was GRIA2, encoding the glutamate receptor, ionotropic, AMPA2 
(GluR2).  GluR2 functions as a major subunit of glutamate AMPA receptors expressed in cerebellar 
Purkinje and granule neurons (Häausser and Roth, 1997), where it controls calcium permeability of 
AMPA receptors (Bai and Wong-Riley, 2003). 
 
A previous study of SCA7 transgenic mice revealed elevated levels of GluR2 mRNA at advanced 
stages of disease (Chou et al., 2010).  Since excitotoxicity, caused by glutamate receptor 
overactivation, has been proposed to contribute to SCA7 pathogenesis (Bauer and Nukina, 2009), it 
was hypothesised that GluR2 overexpression might lead to cerebellar malfunction through 
dysregulated glutamatergic transmission (Chou et al., 2010).  By contrast, decreased GluR2 
expression has been associated with disease progression in other neurodegenerative diseases, 
including Alzheimer’s disease (Courtney et al., 2010) and ALS (Cozzolino et al., 2008). 
 
GluR2 expression has been shown to be restricted to particular neuronal subtypes, with the highest 
levels observed in pyramidal neurons (Bai and Wong-Riley, 2003).  In addition, GluR2 expression 
has been found to increase during development, in cultured murine cortical neurons (Jensen et al., 
2001). Both mRNA and protein levels of GluR2 are also tightly controlled by neuronal activity, with 
decreased activity inducing a significant decrease in GluR2 expression (Bai and Wong-Riley, 2003).  
The decrease in GRIA2 (GluR2) expression observed in the SCA7 iPSC-derived neurons generated 
in this study may thus result from aberrant development and maturation, leading to decreased 
neuronal activity in comparison to neurons generated from control iPSCs.  Alternatively, a failure of 
SCA7 iPSCs to generate particular neuronal lineages, associated with high levels of GluR2 
expression, could also account for the low levels of GluR2.  Further studies may therefore be 
required to determine both the extent to which neuronal electrophysiology is impaired in SCA7 












determine whether mutant Ataxin-7 has any effect on the development and maturation of these 
neurons. 
The final gene to show a statistically significant change in expression was the disease-causing gene
itself, ataxin-7. An approximate two-fold increase in ataxin-7 expression was observed in SCA7
iPSC-derived neurons in comparison to controls, one week post-differentiation. The role of the
Ataxin-7 protein as a core component of the STAGA/TFTC transcriptional coactivator complexes 
has already been extensively discussed (see Section 1.1.4). In addition, the deleterious effects of
mutant Ataxin-7 expression on cellular function suggest that increased expression levels may
exacerbate SCA7 pathology (Yoo et al., 2003). A recent study by Sopher et al. examined the 
modulation of Ataxin-7 expression by the transcriptional regulator CTCF, via the promotion of a
convergently transcribed, antisense noncoding RNA, termed SCAANT1, suggesting that this may
represent a novel mechanism for the epigenetic regulation of ataxin-7 gene expression. Of critical 
importance to this study, Sopher et al. identified a reduction in SCAANT1 promoter activity
associated with expansion of the ataxin-7 CAG repeat tract. The resultant reduction in SCAANT1 
expression leads to derepression of the ataxin-7 alternative promoter, significantly boosting the
levels of ataxin-7, creating a feed forward effect which agonises the SCA7 disease pathway by
promoting increased production of mutant Ataxin-7 protein (Sopher et al., 2011).
Thus, an increase in CAG repeat length should correlate with an increase in ataxin-7 expression, as is 
the case in SCA7 iPSC-derived neurons one week post-differentiation. However, a subsequent 
decrease in ataxin-7 expression was observed at the two- and three week time points, suggesting that 
Ataxin-7 upregulation may not be sustained.  It may therefore be of interest to quantify SCAANT1 
expression in these neurons, to determine the influence of this noncoding RNA on the levels of 













In addition to the statistically significant changes in gene expression described above, several 
interesting non-significant trends were observed.  These included decreased expression of the 
deubiquitinating enzyme UCHL1 in SCA7 iPSC-derived neurons at one week and three weeks post 
differentiation.  This trend corresponds to changes previously reported in SCA7 transgenic mice 
(Chou et al., 2010), as well as the results obtained for SCA7 fibroblasts in this study (Chapter 3).  A 
non-significant increase in BAX, which encodes a proapoptotic protein previously shown to be 
upregulated in the cerebellar and inferior olivary neurons of SCA7 transgenic mice (Wang et al., 
2010), was also observed, in SCA7 neurons at three weeks post differentiation. 
 
Although no significant differences in Olig1 expression were observed between SCA7 and control 
iPSC-derived neurons, an interesting trend emerged over the three week time course.  At one week 
post-differentiation, Olig1 expression appeared marginally higher in patient neurons (particularly 
those derived from the older of the two patients, 1518), although this was followed by a consistent 
decrease in expression over the following two weeks.  By contrast, control iPSC-derived neurons 
showed a gradual increase in Olig1 expression over time, with the result that control neurons 
appeared to express marginally higher levels of Olig1 than their patient-derived counterparts by three 
weeks post-differentiation.   
 
Olig1 encodes a basic helix-loop-helix transcription factor which has been shown to play an essential 
role in oligodendrocyte myelinogenesis, through the regulation of transcription of several major 
myelin-specific genes (Xin et al., 2005).  A study of Ataxin-7-Q52 transgenic mice demonstrated 
significantly decreased levels of Olig1 mRNA and protein at both early (six months of age) and late 
(10-11 months of age) stages of disease.  In the 10-11 month-old mice, which displayed pronounced 
ataxic symptoms, this decrease was associated with the presence of loose and poorly compacted 
myelin sheaths in the cerebellar white matter, consistent with the hypothesis that Olig1 












2010).  The decrease in cerebellar mRNA levels of Olig1 in 6 month-old mice, which preceded the 
onset of disease symptoms, suggested that Olig1 downregulation may play an important role in 
initiating the pathological processes of SCA7 (Chou et al., 2010).   
Olig1, together with Olig2, has been shown to play a role in motor neuron and oligodendrocyte
progression (Zhou and Anderson, 2002).  Thus, the gradual decrease in Olig1 expression over time in 
SCA7 iPSC-derived neurons may reflect a gradual decrease in the potential of these cells to generate
certain neuronal and glial lineages, or to attain developmental maturity. More extensive
characterisation of the composition of the neuronal populations generated from SCA7 and control
iPSCs may thus be required, in order to identify particular lineages whose development may be
affected by the differences in Olig1 expression over time.
A non-significant increase in the growth factor gene, IGFBP5, was also observed in SCA7 iPSCs
and iPSC-derived neurons versus controls. Insulin-like growth factor binding proteins (IGFBPs) 
function in the transport and modulation of activity of insulin-like growth factors (IGFs) (Jones and
Clemmons, 1995). IGFBP5 in particular, has been shown to stimulate the phosphorylation of the
IGFBP5-receptor, activating its serine/threonine kinase activity (Andress, 1998). The expression of
IGFBP5 has been previously found to be decreased in mouse models of several of the polyQ
diseases, including DRPLA, HD, SCA7 and SBMA (Luthi-Carter et al., 2002). Robust
downregulation of IGFBP5 has also been described in a mouse model of SCA1, with both SCA1 and 
SCA7 mice demonstrating a non-cell-autonomous decrease in IGFBP5 expression in granule
neurons, concomitant with the activation of the IGF pathway and the type I IGF receptor on Purkinje
cells (Gatchel et al., 2008). Since IGFBP5 downregulation is common across a number of polyQ
diseases, in some cases in presymptomatic stages, it is more likely to be part of a general response to 













The increased expression observed in this study was therefore unexpected.  Indeed, only one 
previous report provides some supporting evidence for this finding – the discovery of abnormally 
high levels of IGFBP5 in the granule neurons of ataxic, “weaver” mice (Zhong et al., 2005).  The 
aberrant increase in IGFBP5 expression, which precedes the demise of these neurons, is thought to 
result in a blockade of IGF-I activity.  Since IGF-I is essential for the survival and differentiation of 
cerebellar neurons, reduced IGF-I availability resulting from excess IGFBP5 was deduced to 
accelerate the rate of apoptosis of granule neurons in this model.  Elevated IGFBP5 in SCA7 iPSCs 
and iPSC-derived neurons may thus reflect an early predisposition towards degeneration, although 
these results should be treated with caution, given their lack of statistical significance. 
Finally, a gradual increase in SLC17A6 in SCA7 iPSC-derived neurons was observed over three
weeks of differentiation, in contrast to the gradual decline in expression of that gene over the same 
period in control iPSC-derived neurons. SLC17A6 encodes the vesicular glutamate transporter 2
(VGLUT2), required for vesicular glutamate release from cerebellar glutamatergic neurons (Hioki et 
al., 2003). Downregulated mRNA expression of VGLUT2, observed in both early and late stages of
disease progression in SCA7 transgenic mice, has been proposed to contribute to dysregulated 
glutamatergic transmission and consequently, cerebellar malfunction (Chou et al., 2010). By
contrast, increased VGLUT2 xpression has been described in the putamen of Parkinson’s disease
patient brains (Kashani et al., 2007).
The fraction of VGLUT2-positive neurons generated by neuronal differentiation from ESCs is small, 
but increases over time (Koch et al., 2009).  Thus it may be that the differing trends in VGLUT2 
expression between SCA7 and control neurons described here merely represent a bias towards the 
development of different neuronal lineages over time.  Further analysis is complicated by a limited 













neurons at three weeks post-differentiation, and conclusions should be drawn with caution, given the 
lack of statistical significance of the results. 
 
In general, similar trends were observed across all patient-derived neurons, relative to controls, 
although neurons derived from the iPSC line 1518D (generated from the SCA7 patient carrying the 
shorter CAG repeat tract, consisting of 42 CAG repeats) tended to display a milder transcriptional 
phenotype.  This may be attributed to the differences in CAG repeat lengths between the two 
individuals, since longer CAG repeat tracts have been associated with more rapid and severe 
phenotypes (Lebre and Brice, 2003).  Of crucial importance, the age and stage of disease (patient 
1518 is the older and more advanced case of the two patients in this study) did not appear to 
influence the transcriptional changes observed in iPSC-derived neurons, suggesting that markers of 
disease progression, such as the epigenetic alterations proposed to affect the HSR, may be “reset” 
during iPSC reprogramming (Labbadia et al., 2011; Takahashi et al., 2007).   
 
This epigenetic remodelling may also account for the lack of statistically significant disease-
associated transcriptional alterations in SCA7 patient iPSCs, although trends in expression of certain 
genes (such as DNAJA1), which correspond to those identified in patient fibroblasts, support the 
assertion that iPSCs may retain the epigenetic memory of the somatic cells from which they were 
derived (Kim et al., 2010). 
 
5.3.5 The value of iPSC-derived models of SCA7 in the South African population 
This is the first record of iPSC-derived neurons derived from South African SCA7 patients.  The 
generation of patient-specific, disease-relevant cell types is particularly important in 
neurodegenerative diseases; as such cells provide a unique model in which to evaluate disease 












models.  In addition, the use of cells containing the patient’s own genetic background offers the 
opportunity to investigate potential modifiers of disease onset and progression (Bilen and Bonini, 
2007; Marsh and Thompson, 2006).   
Perhaps most importantly to the South African context, iPSC-derived neurons provide the first 
opportunity to evaluate the efficacy of the allele-specific RNAi-based therapy developed by 
Scholefield et al. (2009), in disease-affected cells.  Current efforts have now shifted to the 
identification of a mechanism for the efficient delivery of the gene silencing effector into post-
mitotic neurons, which have thus far proven refractory to transfection. 
5.3.6 Concluding remarks 
This study has shown that iPSCs, derived from two South African SCA7 patients, are capable of
differentiation into neuronal cells, exhibiting characteristic neuronal morphology and expressing the
neuronal marker βIII-tubulin. No differences in differentiation efficiency, Ataxin-7 expression or
localization were observed between SCA7 and control iPSC lines. Furthermore, no significant
differences in the ability of SCA7 iPSCs to generate GABAergic neurons, the precursors of
cerebellar Purkinje cells, could be detected.
Although the aggregation of mutant protein is generally viewed as a defining feature of polyQ 
disease, the lack of observable aggregates in the SCA7 neurons generated here was not entirely 
unexpected, given the early stage of differentiation assessed.  These findings strongly suggest that 
certain early markers of pathogenesis, such as alterations in gene transcription, may precede the 
formation of detectable aggregates, although further studies of protein expression may be necessary 












However, the identification of additional phenotypic markers, in the form of alterations in 
transcription, suggests that these cells may still be useful for investigating pathogenesis and 
evaluating therapies.  Significant differences in expression of HSPs, as well as genes involved in 
neuronal differentiation, transcriptional regulation and glutamatergic signalling were observed in 
both SCA7 iPSCs and iPSC-derived neurons relative to controls, suggesting that these key genes, 
previously implicated in polyQ toxicity in cell and animal models, may indeed play a role at the 
earliest stages of development of disease. 
 
Despite these promising results, a number of limitations remain to be addressed.  The general 
neuronal protocol used for this study generates a wide variety of neuronal as well as a small 
population of glia.  This heterogeneity may result in a dilution of disease-specific effects, since the 
cell types present do not necessarily represent those most vulnerable to disease changes.  Further 
analysis of gene expression and electrophysiology will therefore be required to fully elucidate the 
relative compositions of control and SCA7 iPSC-derived populations, in order to understand their 
contribution to the disease phenotype, as well as to identify possible disease-associated deficiencies 
in neuronal subtype specification and maturation.   
 
The question of whether iPSC-derived neurons will ever fully recapitulate the phenotype of a late-
onset, neurodegenerative disease has been plagued with controversy.  A number of mechanisms have 
been proposed to improve these models, including the culture of neurons over longer time points, 
and the introduction of cell stressors (Wichterle and Przedborski, 2010), both of which would add 
value to the current study.  Concerns as to whether the “age” of patient-derived neurons more closely 
reflects the age of the patient from which the fibroblasts of origin were derived, or the embryonic 
state of the iPSCs from which they were differentiated are also of critical importance.  Based on 












in iPSC-derived models from patients with an earlier age of onset, such as patient 1519 in this study 
(Ebert et al., 2008). 
 
Finally, the extensive variations in gene expression and differentiation potential observed between 
iPSC lines, both here and in previous studies (Hu et al., 2010b), motivate strongly for the inclusion 
of additional patient iPSC lines, particularly from the older patient (1518) to further clarify the role 
of the transcriptional alterations described here in the development and progression of SCA7. 
 
Despite these limitations, however, the results of this study provide the first evidence for the 
differentiation of neurons from iPSCs generated from the South African SCA7 patient cohort, paving 














Chapter 6 Discussion 
This study sought to evaluate novel cell models for SCA7, a dominantly-inherited polyQ 
neurodegenerative disease characterised by cerebellar ataxia and macular degeneration, which is 
caused by the expansion of an unstable CAG repeat tract within the ataxin-7 gene (Lebre and Brice, 
2003).  As with many inherited neurodegenerative conditions, research into SCA7 pathogenesis and 
therapy has been hindered by the lack of readily-available (CNS-derived) biological material.  This 
has led to the development of numerous cellular and animal models, in an attempt to recapitulate the 
main features of the disease (Ingram et al., 2011; Zander et al., 2001).  Despite the invaluable 
insights gained from these models, the inherent challenges associated with modelling human 
neurodegenerative diseases in animals suggest that their applications may be limited. 
 
Attention has thus turned to the use of patient-derived cells as models of disease.  Non-neuronal 
cells, including fibroblasts and lymphoblasts have previously been suggested as useful models for 
investigating pathogenesis and screening therapeutic modalities (Tsai et al., 2005; Garden et al., 
2002).   More recently, advances in pluripotent stem cell technology have given rise to a multitude of 
iPSC-derived models for the study of human disease, offering the opportunity (in theory, at least) for 
differentiation into any affected cell type (Rajamohan et al., 2012).  This study therefore examined 
the feasibility of using patient-derived peripheral cells (dermal fibroblasts), as well as iPSCs and 
iPSC-derived neurons as models for the study of SCA7 pathogenesis and therapy.  Each of these cell 
types has both advantages and disadvantages – fibroblasts, for example, are easily accessible, but are 
not derived from disease-affected tissue; while iPSC-derived neurons are difficult to culture, but 
more closely represent the disease state.  Nonetheless, results indicate that all three cell models may 













6.1 Generation of SCA7 iPSC-based disease models 
A number of iPSC-based models of neurodegenerative disease have been described (Koch et al., 
2011; Zhang et al., 2010; Ebert et al., 2008; Dimos et al., 2008).  However, the only published record 
of SCA7 iPSCs to date is based on a single Chinese patient, with adult onset of disease symptoms 
(Luo et al., 2012).  The current study has demonstrated the successful reprogramming of dermal 
fibroblasts from two South African SCA7 patients (one with presumed adolescent onset, and one 
with adult onset of disease) to pluripotency, using retroviral vectors (Takahashi et al., 2007).  Of the 
iPSC lines generated, two SCA7 (and two control) lines passed the stringent tests for pluripotency 
outlined by Maherali and Hochedlinger (2008), including the development of ESC-like 
morphological characteristics, suppression of retroviral transgenes, expression of endogenous 
pluripotency genes and cell surface markers of pluripotency, karyotypic normality, and the ability to 
differentiate into cells from each of the three embryonic germ layers. A further one patient line, 
1518D, passed all the tests but one, having not been evaluated for EB-mediated in vitro germ layer 
differentiation (although its ability to generate ectodermal cells was confirmed by successful 
neuronal differentiation). 
 
This represents a significant improvement over the previous SCA7 iPSC study by Luo et al. (2012), 
as it offers the first opportunity for comparison between patients, and for comparison between 
multiple iPSC lines generated from the same patient.  In addition, the difference in CAG repeat 
length, age of onset and stage of disease progression between the two patients may allow for future 
investigations into the influence of these factors on cellular phenotype.  However, given the observed 
variation between iPSC lines (Hu et al., 2010b), it is likely that additional iPSC lines, generated from 
these and other SCA7 patients, may be required to differentiate between disease-specific phenotypic 













The inclusion of a control iPSC line (iPS SC NHDF) generated using five retroviral reprogramming 
factors (as opposed to the remaining control and patient iPSC lines, generated using a three-factor 
combination) represents a potential source of controversy.  On the one hand, cells reprogrammed 
using a larger pool of viral vectors are at greater risk of insertional mutagenesis, and have an 
increased propensity for genomic instability and tumorigenesis, particularly where the 
reprogramming factors include the oncogene, c-MYC, as was the case in this study (Okita et al., 
2007).  However, it may also be argued that increasing the number of retroviral vectors used in 
reprogramming enhances the efficiency of the process, leading to a greater number of fully 
reprogrammed clones (Liao et al., 2008).  Most pertinent to this study are questions regarding the 
differential effect of multiple retroviral insertions on the expression profile of iPSCs (Liu et al., 
2012).  However, the lack of observable variation between iPSCs and neurons derived from iPS SC 
NHDF and those derived from the three-factor control iPSC line (iPS George) suggested that 
variations in the reprogramming protocols between these lines did not affect the results obtained.  
Nevertheless, future studies would benefit from the inclusion of additional control iPSC lines 
generated using the three-factor combination of pMXs-hOct3/4, pMXs-hSox2 and pMXs-hKlf4, 
together with VPA, in order to minimise the potential for variation between lines. 
 
To this end, the Division of Human Genetics at UCT has established fibroblast cell lines from a 
further four consented SCA7 patients, with varying CAG repeat lengths, during the course of 2012.  
Future work will focus on the reprogramming of these fibroblasts to iPSCs, and the characterisation 
of all iPSC lines generated, including outstanding iPSC lines from the current study, in order to 
establish a more comprehensive resource for the study of SCA7 in the South African population. 
 
Although concerns have been raised regarding the safety and viability of retrovirally-reprogrammed 
iPSCs for downstream applications, this study observed no effects of viral integration on either the 











lines tested here showed silencing of the retroviral transgenes (with the exception of pMXs-hOct3/4) 
at 10 passages post-reprogramming.  This is significant, as persistent transgene expression has been 
shown to affect the molecular signatures, differentiation behaviour and developmental potential of 
iPSCs (Stadtfeld et al., 2008)  Taking into account the most likely application of these lines, as 
vehicles for in vitro disease modelling and therapeutic screening rather than autologous 
transplantation, the efficiency of retroviral reprogramming may be considered to outweigh the 
potential harms, at least in the context of the current study (González et al., 2011).  Nonetheless, the 
incorporation of non-integrating methods into future iPSC reprogramming experiments may be of 
benefit, in order to minimise potentially deleterious effects.  
Neurons derived from iPSCs have been used to model a variety of neurodegenerative disorders,
including Parkinson’s disease (Soldner et al., 2009) and several of the polyQ diseases (Camnasio et 
al., 2012; Koch et al., 2011). In order to generate disease-relevant cells from the SCA7 iPSC lines 
generated here, a general neuronal protocol was followed (Dottori and Pera, 2008). Despite previous 
reports suggesting that CAG expansions may hinder neuronal differentiation (Lorincz et al., 2004), 
no obvious differences in the number or morphology of βIII-tubulin positive neuronal cells were
observed between SCA7 and control iPSC lines. The same was true of the small proportions of
GFAP-positive glial cells and GABA-positive, putative GABAergic cells produced over three weeks 
of differentiation. These results confirm the ability of SCA7 and control iPSCs to generate neuronal
cells with equal efficiency, corresponding to results of studies of other polyQ diseases (Koch et al.,
2011; Camnasio et al., 2012).
Despite these promising results, there are several limitations to the current study, which future work 
will seek to address.  The neuronal differentiation protocol described by Dottori and Pera (2008) 
served the purpose of this study, offering a relatively simple, rapid and robust means of generating a 












in the developing brain.  Immunostaining for GFAP and GABA provided some information as to the 
types of cells generated by each iPSC line.  However, further comparisons of the neuronal 
populations generated by SCA7 and control iPSCs are recommended, to rule out the possibility of 
disease-associated deficiencies in composition and maturation which may affect the gene expression 
profile.  Future studies should therefore expand the panel of antibodies used in immunostaining to 
include markers of different neuronal and glial subtypes, such as tyrosine hydroxylase (dopaminergic 
neurons), vesicular glutamate transporters (glutamatergic neurons) or GalC (oligodendrocytes). 
 
This study focused on the generation of cells displaying neuronal morphology and expressing 
markers of early neuronal differentiation, but did not investigate the functionality of the neurons 
generated.  Since defects in signalling leading to excitotoxicity have been previously implicated in 
SCA7 pathogenesis, future studies may involve a comparison of the development of membrane 
potentials and synaptic connections in patient versus control iPSC-derived neurons, using 
electrophysiological tools.  Synaptic competence has previously been proposed as a defining feature 
of neuronal maturation in vitro (Yang et al., 2011); thus, such a study should also provide insight into 
the presence of any disease-associated developmental defects. 
 
The ability of iPSC-derived neurons to fully recapitulate the phenotype of neurodegenerative 
diseases remains a subject of controversy, particularly since the age of neurons in culture is difficult 
to approximate.  It may be argued that the time period used in this study was not sufficient to 
produce phenotypes reminiscent of end-stage disease.  Future studies will therefore evaluate the 
differentiation and gene expression of iPSC-derived neurons following longer periods of culture, and 
may also include treatment with environmental stressors such as reactive oxygen species, designed to 













6.2 Identification of a disease-relevant phenotype in patient-derived cells 
The mechanisms underlying polyQ pathogenesis are complex, involving a combination of protein 
aggregation, impairment of protein clearance pathways, aberrant protein-protein interactions, post-
translational modifications and defects in mitochondrial energy metabolism (Watson and Wood, 
2012).  Although the formation of nuclear inclusions of mutant protein was once considered a 
hallmark of polyQ pathology, results from this study and others (Einum et al. 2001) suggest that 
Ataxin-7 aggregation is not a prerequisite for SCA7 pathogenesis, at least in immature neurons 
equivalent to early stages of disease progression. 
 
Transcriptional dysregulation has been proposed as a common early feature of polyQ diseases 
(Helmlinger et al., 2006b).  In SCA7 in particular, the role of the disease-causing protein, Ataxin-7, 
in the TFTC and STAGA transcriptional co-activator complexes has highlighted the role of 
transcriptional alterations in the development and progression of disease (Helmlinger et al., 2006a; 
Palhan et al., 2005).  These transcriptional changes in response to mutant polyQ protein expression 
are not limited to disease-affected tissues, having previously been demonstrated in peripheral cells 
(Tsai et al., 2005). 
 
Transcriptional alterations were thus chosen as a measure of the polyQ disease phenotype in the 
SCA7 patient-derived cell models investigated in this study.  Using a candidate gene approach, 
significant differences in expression levels of genes involved in the heat shock response, UPS and 
glutamatergic transmission were detected between SCA7 and control fibroblasts, iPSCs and iPSC-
derived neurons, further emphasising the known role of these pathways in polyQ pathogenesis.  One 
gene in particular, DNAJA1, encoding the heat shock protein DnaJA1, was found to be upregulated 
in SCA7 fibroblasts and iPSC-derived neurons, emphasising the global role of the HSR in the 
response to cellular stress caused by misfolding of mutant Ataxin-7.  The remaining genes showed 












expression profiles, mutant protein turnover and cell-type susceptibility.  Despite these differences, 
the observed trends corresponded for the most part to results previously obtained in cell and animal 
models of SCA7 (Chou et al. 2010; Tsai et al., 2005), suggesting that the patient-derived models 
evaluated here may be similarly used to provide insights into the molecular pathogenesis of the 
disease.   
 
This is the first study to report a transcriptional phenotype in SCA7 patient fibroblasts, iPSCs and 
iPSC-derived neurons, easily-accessible cell types which may readily be used for disease modelling 
and therapeutic screening.  In addition, the appearance of transcriptional changes in SCA7 iPSC-
derived neurons as early as one week post differentiation, prior to the observable aggregation of 
mutant Ataxin-7, confirms the role of transcriptional changes as an early marker of disease 
progression.  Furthermore, the identification of differentially expressed transcripts in “unaffected” 
cell types such as cultured fibroblasts suggests that the deleterious effects of mutant Ataxin-7 are 
widespread, with significant clinical pathology developing only in those cells which are particularly 
susceptible to accumulation of the polyQ-expanded protein.  The diverse range of differentially 
expressed transcripts identified in SCA7 patient-derived cells suggests strongly that alterations in 
transcription result from both the accumulation of mutant protein (leading to manifestations of 
cellular stress, such as impairment of the UPS and upregulation of the HSR); and its effects on 
transcriptional regulation via the TFTC/STAGA complex, resulting in more general dysregulation of 
gene expression (Helmlinger et al., 2006a). 
 
The results of this investigation have thus provided a number of valuable insights into the role of 
gene expression changes in the development of SCA7.  Nonetheless, several questions remain, which 
future studies should aim to address.  Since the pattern of disease-associated alterations in gene 
expression has been shown to change with disease progression and advancing age, evaluation of 












advantageous.  By the same token, derivation of neurons from iPSCs from patients with longer CAG 
repeat tracts, associated with more rapid progression and greater disease severity (Lebre and Brice, 
2003), may provide additional insights. 
 
The candidate gene approach, favoured in this proof-of-principle study, detects only a fraction of the 
potential gene expression changes between SCA7 and control lines, and offers no information 
regarding the effects of these changes on alterations in protein levels.  Future studies may therefore 
involve whole-genome expression analyses, in order to capture the full extent of transcriptional 
dysregulation in SCA7 disease models.  Such studies will require the derivation of many more iPSC 
lines, from a larger patient cohort, as well as further optimisation of the neuronal differentiation 
protocol, in order to minimise inter- and intra-individual sample variation, so that true disease-
associated transcriptional changes can be identified.  This is likely to include efforts to standardise 
the number, size and density of both iPSC colonies and neurospheres used in differentiation, as well 
as the use of alternative protocols which employ more defined intermediate steps and generate a 
more homogeneous neuronal population, such as those proposed by Koch et al. (2009) or Erceg et al. 
(2012).  In addition, validation of the results obtained here, together with the results of future array-
type studies, at the protein level should aid in understanding their pathological significance.  Further 
investigations into the role of TFTC/STAGA in regulating the differentially expressed transcripts 
identified here would also be of value. 
 
A final caveat of the present investigation, which deserves some scrutiny, is the use of related SCA7 
patients.  The study of affected family members (in this case, a mother and son) provides a degree of 
genetic homogeneity which may be advantageous.  However, the possibility exists that some of the 
gene expression changes, attributed here to the presence of the mutant protein, may result instead 
from family-specific, or even population-group specific variations.  The results obtained from RNAi-












case.  However, the incorporation of additional SCA7 patients, together with age-, ethnicity- and sex-
matched controls would provide further proof of the disease-associated nature of these transcriptional 
changes; particularly in light of the recent discovery of X chromosome-associated epigenetic 
variability of female iPSC lines, which may influence stability and gene expression patterns 
(Anguera et al., 2012).  To date, the size of the cohort has been hindered by a lack of access to 
consenting individuals.  However, recent advances in patient recruitment at UCT (mentioned in 
Section 6.1) should aid in the expansion of the patient and control cohorts, setting the scene for 
larger, more comprehensive future studies of gene expression, electrophysiology and cellular 
pathology, similar to the recent report on CAG repeat-associated phenotypes in iPSCs by the HD 
iPSC Consortium (2012). 
 
6.3 SCA7 patient-derived cells as a model for evaluating RNAi-based therapy 
The toxic gain-of-function nature of the polyQ expansion mutation, together with the complexity of 
the pathogenic pathway described above, make diseases such as SCA7 ideal candidates for gene 
silencing therapies which target and suppress pr duction of the mutant protein upstream of its 
deleterious effects. In particular, the high frequency and heterozygosity of a disease-linked SNP in 
the South African SCA7 patient population have led to the design of RNAi effectors for this cohort 
(Scholefield et al., 2009).  The extensive pre-clinical validation required by such therapies is often 
hindered by a lack of suitable disease models; thus, the three patient-derived cell models of SCA7 
described here were intended not only for the study of pathogenesis, but also as vehicles for the in 
vitro evaluation of previously-developed RNAi therapies, with a view to developing alternative 
therapies for SCA7 in the future. 
 
Results obtained from RNAi experiments in SCA7 fibroblasts were promising, confirming the ability 












allele-specificity of siR-P16, which discriminates between wildtype and mutant copies of the ataxin-
7 transcript based on the genotype of the disease-linked SNP (Scholefield et al., 2009).  Although 
similar results have been obtained for other polyQ diseases using patient fibroblasts (Fiszer et al., 
2011; Hu et al., 2011; Hu et al., 2010a; Hu et al., 2009b; Lombardi et al., 2009; Van Bilsen et al., 
2008), this is the first report confirming allele-specific silencing of ataxin-7 in patient-derived cells. 
 
This is also the first report of the amelioration of a transcriptional phenotype in patient cells, 
following RNAi-mediated gene silencing, with knockdown of ataxin-7 resulting in restoration of 
disease-associated aberrations in DNAJA1 and UCHL1 expression to approximately normal levels.  
This is not only a significant proof-of-principle of the utility of transcriptional alterations as a marker 
for therapeutic efficacy, but also provides strong evidence for the disease-associated nature of the 
changes in gene expression, since ataxin-7 silencing does not produce a similar effect on DNAJA1 or 
UCHL1 levels in controls. 
 
A number of issues remain to be addressed, however, in the progression of such RNAi therapies 
towards pre-clinical trials.  Among these are questions of dosage and off-target effects, highlighted 
by the dose-dependent nature of DNAJA1 restoration, and the differing effects of allele-specific and 
non-allele-specific siRNAs on UCHL1 expression at high doses.  Of concern for future allele-
specific therapies is the finding that restoration of DNAJA1 levels towards normal occurs only at a 
concentration at which the allele-specific effect of siR-P16 is no longer observed.  In addition, the 
relationship between wildtype ataxin-7 expression and UCHL1 levels, implied by the results 
obtained from non-allele-specific silencing of ataxin-7 in both SCA7 patient and control fibroblasts, 
merits further investigation.  As such, more detailed dose titrations of siR-P16 may be required prior 
to clinical application, to achieve a compromise between allele-specificity and phenotypic 











immunoprecipitation or DNA footprinting studies to identify possible interactions between Ataxin-7 
and/or STAGA/TFTC and the UCHL1 promoter, are also potential avenues for future investigations.  
Evaluation of siRNA efficacy at the level of mutant protein aggregation is currently hindered by the 
absence of detectable protein aggregates in the SCA7 patient cells investigated here.  However, the 
recent study of SCA3 iPSC-derived neurons by Koch et al. (2011) suggests that western blotting may 
serve as an alternative to microscopy for the measurement of aggregation.  Future studies may 
therefore involve the validation of ataxin-7 silencing, restoration of DNAJA1 and UCHL1 
expression, and reduction of mutant protein aggregation at the protein level, by means of western 
blot analysis. 
Finally, since this report reflects only the results obtained from SCA7 patient cultured fibroblasts,
current and future work will focus on evaluating the effects of ataxin-7 gene silencing in iPSCs and 
iPSC-derived neurons. Postmitotic neurons are known to be sensitive to cytotoxicity and are
notoriously difficult to transfect, requiring more complex procedures than the electroporation 
described here, such as those mediated by lentiviruses or magnetic nanobeads (Fallini et al., 2010).
iPSCs, by contrast, are far more amenable to lipid-mediated transfection (Ma et al., 2012; Chatterjee
et al., 2011). A more straightforward approach may therefore be to introduce the RNAi effector into 
patient-derived iPSC lines prior to neuronal differentiation, although this would require a more
sustainable method of knockdown than short-lived siRNA molecules. The effects of ataxin-7
suppression could then be measured in comparison to both control lines, and untransfected patient
neurons. It should, however, be noted that this approach, while valuable, would may not provide
sufficient insight into the efficacy of RNAi-mediated silencing of ataxin-7 in end-stage disease, in 
which accumulation of the mutant protein results in neuronal dysfunction. A combinatorial approach 












6.4 Concluding remarks 
This project sought to establish and evaluate patient-derived cell models of SCA7, for use in the 
investigation of SCA7 pathogenesis and therapy.  Three patient-derived cell types (fibroblasts, iPSCs 
and iPSC derived neurons) were found to exhibit disease-associated changes in transcripts previously 
implicated in SCA7 pathogenesis, providing insights into disease progression.  Furthermore, the 
evaluation of RNAi-based therapy in SCA7 fibroblasts demonstrated the ability of an allele-specific 
siRNA, designed specifically for the South African patient population, to selectively silence mutant 
ataxin-7, leading to the restoration of the transcriptional phenotype described above. 
 
Taken together, these results suggest that patient fibroblasts, iPSCs and iPSC-derived neurons may 
serve as novel, disease-relevant models for the study of SCA7 in the South African patient cohort; 
representing a significant advance in the study of this debilitating neurodegenerative disease in a 
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Appendix 1 Ethics approval and patient consent forms 
A1.1 Confirmation of ethics approval  
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A1.2 Example of an information sheet and consent form 
Information Sheet 
What is this study about? 
There have been several methods developed to study neurodegenerative diseases, however, none of 
these include looking at the full complement of human genes in cells that are directly affected by the 
disease, such as nerve cells, which are ultimately destroyed during the course of these inherited 
conditions. The research approach for this project revolves around the acquisition and culturing of 
cells from patients and their unaffected family members that have a neurodegenerative condition so 
we can both gain a better understanding in the laboratory of what goes wrong in the disease at a 
cellular level, and also to develop effective therapies in the laboratory.  
Requirements of the participant: 
You have been asked to participate in this study, because a member (or members) of your family
have been diagnosed with Spinocerebellar Ataxia type 7 (SCA7). The study will require the use of
your DNA and RNA, which contain the genetic material required for your cells to work normally.
Both DNA and RNA may be isolated from the white blood cells in your blood, and/or from skin cells
(called fibroblasts). There are no more risks involved in this process than there would be for a
standard blood-taking procedure and a skin punch biopsy.  
Ideally, we would like to obtain both a blood and a skin sample from you.  However, since the skin 
punch biopsy is a more invasive procedure, and may cause discomfort, you may choose to participate 
in this study by donation of a blood sample only.  You will need to indicate your preference on the 













Any information given by you will remain strictly confidential.  Your samples will be assigned an 
anonymous code, known only to the investigators working on the project. 
 
Voluntary participation 
Please be aware that your participation in the study is entirely voluntary and that you are free to 
refuse to participate or to withdraw from the study at any time. This study is being conducted 
according to the principles of the Declaration of Helsinki (2008), which looks after the interest of the 
participants. In addition, you will not be paid for taking part in this study, nor will there be any cost 
on your part. 
 
Benefits of the Study 
This study is purely for research purposes, and offers no direct benefit to you or your family, at this 
stage.  However, in the long term, your participation in this study may allow us to find out more 
about the cause of SCA7, particularly due to the familial aspect of the disease.  This may help us to 
























I, ______________________________________________________, have read and understand the 
patient information sheet attached. 
 
I hereby agree to participate in this study, and I give my voluntary and informed consent to donate 
my blood/skin cells/hair (for keratinocytes isolated from plucked hair) (DELETE WHERE NOT 
APPLICABLE) to be cultured/immortalised, in order to provide a constant source of biological 
material for research into the disease-causing mechanism of Spinocerebellar Ataxia type 7 (SCA7) in 
my family.  I understand that my samples will be allocated an anonymous code, and that my 
information will be treated with strict confidentiality.  I also understand that I may refuse to 
participate or to withdraw from this study at any time.  
 
The details of this study have been explained to me in a language that I understand and my questions 
have been answered by _____________________________ DATE:___________ 
Patient Signature: __________________________________________________ 
Witnessed Consent: ________________________________________________ 
Date: ___________________________________________________________ 
 
This protocol has been approved by the Department of Clinical Laboratory Sciences Research 
Committee as well as the UCT Research Ethics Committee of the Faculty of Health Sciences at 
UCT. 





Principal Investigator: Professor Jacquie Greenberg            +27 21 406 6299 
 













Appendix 2 General cell culture protocols 
A2.1 Reagents for general cell culture  
General cell culture medium 
500ml   DMEM  
50ml   FCS (Life Technologies) 
5ml   100X Antibiotic/antimycotic (Life Technologies) 
 
Freezing medium 
20% (v/v) FCS (Life Technologies) 
10% (v/v) Dimethyl Sulphoxide (DMSO) (Sigma-Aldrich) 
70% (v/v) DMEM (Life Technologies) 
 
A2.2 Thawing cells  
 Thaw cryopreserved cells rapidly at 37°C  
 Add cells to 4ml prewarmed DMEM + 10% FCS + 1X antibiotic/antimycotic 
 Centrifuge at 1000-1500rpm for 4-5min in a standard benchtop centrifuge 
 Remove supernatant and reconstitute in prewarmed DMEM+10%FCS+1X 
antibiotic/antimycotic, and add to T25-T75 flask (use approximately 1x10
6
 cells for T75 and 
300 000 cells for T25) 
 
A2.3 Passaging cells  
 Aspirate medium and rinse with 10ml PBS 
 Aspirate PBS and add 2-3ml TrypLE (Life Technologies) 












 Wash flask with DMEM + 10% FCS + 1X antibiotic/antimycotic and decant into a sterile 
centrifuge tube 
 Centrifuge at 1000-1500rpm for 4-5min in a standard benchtop centrifuge 
 Aspirate supernatant and resuspend cell pellet in an appropriate amount of fresh 
DMEM+10% FCS + 1X antibiotic/antimycotic to give the desired ratio for passaging into a 
new flask (usually 1:4). 
 
A2.4 Cryopreservation of cell stocks  



















Appendix 3 General laboratory reagents and protocols 
A3.1 Primers for CAG repeat length determination and SNP genotyping  
Feature Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Atxn7 (CAG)n                  
(Dorschner et al., 2002) 
*ATTGTAGGAGCGGAAAGAATG CCAGCATCACTTCAGGAC 
rs3774729 AATGAACTGCCTGTCAACTC GCTCACAGTCCATTTCCTAC 
Key: HEX fluorescent labelling is indicated by an asterisk (*) 
 
A3.2 Gene Ruler 100bp DNA Ladder Plus Improved (Fermentas) 


















A3.3 Standard PCR reaction mix  
Reagent Final Concentration/Amount 
GoTaq Buffer (Promega) 1x 
dNTPs (Bioline, Michigan, USA) 200µM 
Forward Primer 0.4 µM 
Reverse Primer 0.4 µM 
GoTaq DNA Polymerase (Promega) 0.5U 
Template DNA 100ng 
 
Made up to a final volume of 25µl with sterile distilled water. 
A3.4 Standard PCR cycling conditions  
1. 95°C for 5min 
2. 95°C for 30 seconds 
Ta for 30 seconds 
72°C for 30 seconds 
3. 72°C for 7min 
Perform 30 cycles of Step 2. 
A3.5 siRNA sequences 
siRNA Sense Sequence (5’-3’) 
siR-atxn-7 GCG TTA CTG TGG ATC TTT C tt 
siR-p16 GCC ATG AAC AAT GTT CAT A tt 















A3.6 Primers for qPCR 
Gene Name Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ataxin-7 GCCAGCCGTGAACAATGTC TTCCTCCCCGTGCTATTTTCA 
ataxin-7 A allele CAAAGTGCCAGCCAT TAGCAAGCAGTTCAGACC 
ataxin-7 G allele CAAAGTGCCAGCCG TAGCAAGCAGTTCAGACC 
BAX AAAGATGGTCACGGTCTGC GCTGGACATTGGACTTCCTC 
BEX1 GGAGGAGACTACAAGGATAGG TCCTTTTCTTCATTTTCTTGGTT 
DNAJA1 AAAGGAGGAGAACAGGCAATTAA TAGGGTTACTGAGAGCTGATGT 
GRIA2 CTATGGCATCGCAACACCTAA GTCCTTGGCTCCACATTCAC 
HSP27 ACGAGCTGACGGTCAAGAC GGGGGCAGCGTGTATTTCC 
HSP70 ATGGAATCTATAAGCAGGATCT CACATACAGAAACTTGATAAGC 
HSP105 CCCGTCAGTCATATCATTTGGA AATCTTTTGAAGTTAGACACCGTATT 
IGFBP5 CTTCATCCCGTACTTGTCCAC TGTACCTGCCCAATTGTGAC 
KAT2A CTTCAGGTGGTTCATCAGGT CATCTGCTTCCGCATGTTTC 
OLIG1 GTTTGGAGAGCTGTATTTAAGACT TTCTAAGAAACCCCCAGGATTTA 
RBM3 CCTGGAGGGTATGGATATGGATA TGTCTCATTTCAGTTGTCATAATTGT 
SLC17A6 TCAACTACGACAGTGAGAAAGAT GAATAGCCAACGACCAGGAG 
SNRK GCCCACACACCAACATGA CTTGCATATTCCGCTCCAGA 
UCHL1 TGAAGCAGACCATTGGGAAT TGTTTCAGAACTGATCCATCCT 
 
 
A3.7 Buffers for immunostaining  
FACS buffer 
0.01% (w/v)  Sodium azide NaN3 
1% (v/v)  FCS (Life Technologies) 
10μg/ml   Human IgG1 
Dissolved in PBS 
 
4% FACS Fix (protect from light) 
4ml   36% formaldehyde 












A3.8 Antibodies for immunofluorescence 
Primary Antibodies 
Epitope Species Source Dilution/ 
Concentration 
Application 
Oct3/4 Rat R&D Systems 0.1mg/ml Viral titre/transduction of 
fibroblasts 
Oct4 Rabbit Abcam 1:200 Pluripotency marker 
Nanog Rabbit Abcam 1:200 Pluripotency marker 
Tra-1-60*  Millipore 1:200 Pluripotency marker 
Alpha 1 Fetoprotein Mouse Abcam 1:50 In vitro differentiation 
Alpha smooth muscle actin Mouse Abcam 1:100 In vitro differentiation 
Forkhead box protein A2 
(FOXA2) 
Rabbit Abcam 1:1000 In vitro differentiation 
Alpha Sarcomeric actin Rabbit Abcam 1:100 In vitro differentiation 
βIII-tubulin  Mouse Covance 1:500 Neuronal Differentiation 
Gamma-Aminobutyric acid  
(GABA) 
Rabbit Sigma-Aldrich 1:500 Neuronal Differentiation 
Glial Fibrillary Acidic Protein 
(GFAP) 
Rabbit Dako 1:500 Neuronal Differentiation 
Ataxin-7 Rabbit Gift of Ana-Lena Strom 
(Stockholm University) 
1:100 Neuronal Differentiation 
*AlexaFluor 488 conjugated 
 
Secondary Antibodies 
Antibody Fluorescent Label Source Dilution 
Goat anti-mouse AlexaFluor 594 Invitrogen 1:100-1:500 
Goat anti-rabbit AlexaFluor 488 Invitrogen 1:100-1:500 














Appendix 4 iPSC culture reagents and protocols 
A4.1 Media and reagents for iPSC culture  
Plat-GP culture medium 
450ml  DMEM (Life Technologies) 
50ml  FCS (Life Technologies) 
5ml  Antibiotic/antimycotic (Life Technologies) 
500µl  Blasticidin (Sigma-Aldrich) 
 
Filter (0.22μm) before use. 
 
MEF medium 
500ml   Advanced DMEM (Life Technologies)  
50ml   FCS (Life Technologies) 
5ml   GlutaMAX (Life Technologies) 
500µl  β-mercaptoethanol (Sigma-Aldrich) 
 
iMEF Freezing medium 
10% (v/v) DMSO (Sigma-Aldrich) 
10% (v/v) Advanced DMEM (Life Technologies) 
80% (v/v) FCS (Life Technologies) 
 
mTeSR Medium  
400ml   mTeSR 1 Basal Medium (Stem Cell Technologies) 














huESC Culture Medium 
 
400ml  Knockout (KO) DMEM (Life Technologies) 
100ml  KO Serum Replacement (Life Technologies) 
5ml  Non-essential Amino Acids (Life Technologies) 
3.5µl  β-mercaptoethanol (Sigma-Aldrich) 
2.5ml  GlutaMAX (Life Technologies) 
5ml  Antibiotic/antimycotic (Life Technologies) 
500µl  bFGF (Stock 10µg/ml) (R&D Systems) 
 
Filter (0.22μm) before use 
 
EB Medium (Barcelona Stem Cell Bank) 
500ml  KO DMEM (Life Technologies) 
5ml  GlutaMAX (Life Technologies) 
5ml  Non-essential amino acids (Life Technologies) 
500µl  β-mercaptoethanol (Sigma-Aldrich) 
50ml  FCS (Life Technologies) 























A4.2 Inactivation of mouse embryonic fibroblasts  
Mouse embryonic fibroblasts (MEFs) are cryopreserved at passage 0-1 after harvesting from 
Pathology Oxford outbred (PO) mice embryos at 12.5 days.  
 
Day 1:   
 Thaw MEFs and resuspend in 10ml PBS 
 Centrifuge at 1500rpm in a standard benchtop centrifuge 
 Discard supernatant, resuspend in 30ml MEF medium and seed into a T175 flask. 
 
Day 4:   
 Split MEFs when they are ~80% confluent into 3 T175 flasks (=p2).   
(Remove medium, rinse with 10ml PBS, add 2ml TrypLE, incubate at 37
o
C for about 5min or 
until cells have detached, add MEF medium and divide into 3 new flasks.) 
 
Day 6:   
 Split again when 80% confluent as described above, into 12 T175 flasks (=p3) 
 
Day 7 or 8:  
 Resuspend 2mg of Mitomycin C (Sigma-Aldrich) in sterile distilled water to give a 1mg/ml 
stock, and allow to dissolve overnight at 4°C. 
 
Day 9:   
 Dilute Mitomycin C to a final concentration of 10µg/ml in MEF medium.  
 Remove MEF medium from cells, add 20ml of Mitomycin C solution per flask and incubate 














 Harvest cells by removing medium, washing with 10ml PBS, adding 3ml TrypLE and 
incubating for 5min at 37
o
C.   
 Remove cells into PBS (12ml per flask), pool, count and centrifuge at 1500rpm in a standard 
benchtop centrifuge.  
 Resuspend pellet in iMEF freezing medium, and aliquot into precooled cryovials for 
cryopreservation. 
 
The expected yield is 10-20 x 10
6
 cells per flask. 
 
A4.3 Preparation of iMEF feeder layer for iPSC culture  
Gelatin-coated plates 
 Add approximately 4ml EmbryoMax ES Cell Qualified 0.1% Gelatin Solution (Millipore) to 
10cm plate (1ml per well of 6-well plate/10ml to T175 flask) 
 Incubate at 37°C for 30min 
 Remove gelatin, allow plates to dry (Drying is not essential – plates can be used immediately 
after gelatin has been aspirated if necessary) 
 
Preparation of iMEF feeder layer 
 Thaw the appropriate volume of cryopreserved iMEFs (approximately 5x105 cells/well of a 
6-well plate) as described in A2.2, resuspending the cell pellet in DMEM + 10% FCS + 1% 
antibiotic/antimycotic 
 Seed iMEFs onto gelatin-coated plates and incubate overnight at 37°C, 5% CO2 
 Approximately 5 hours before passaging/seeding iPSCs, aspirate plating medium from 
iMEFs, rinse three times with PBS to remove all traces of serum, and add an equal volume of 












A4.4 Preparation of iMEF-conditioned huESC medium  
Day 1:  
 Seed iMEFs at 10x106 cells per T175 flask, in 25ml DMEM+10% FCS+1X 
antibiotic/antimycotic. 
Day 2: 
 Aspirate culture medium from iMEFs. 
 Wash iMEFs three times with PBS. 
 Replace medium with 20ml huESC medium (without bFGF). 
Day 3: 
 Remove huESC medium from iMEFs and add bFGF to a final concentration of 10ng/ml 
 Filter using 0.22µm filter (Millipore). 
 Add 20ml huESC medium (without bFGF) to iMEFs to repeat procedure the following day. 
Conditioned medium may be harvested for up to 10 days, and can be stored at -20°C for later use.  
 
A4.5 Transition of iPSCs from iMEF feeders to feeder-free culture conditions  
It takes 3 passages to eliminate all iMEFs and for the iPSCs to be fully adapted to mTeSR medium.  
 Begin with one well of a 6-well plate of iPSCs that have been cultured for 6 days on iMEFs. 
 Passage the cells, as described in A4.6, and transfer all the cells to one matrigel-coated well 
 Feed as per A4.6. 
 The cells should become confluent in a few days, and can then be split 1:2  
 The next (third) passage, a few days later, is 1:4  












A4.6 Maintenance of iPSCs on Matrigel (BD Biosciences)  
 Warm TrypLE (Life Technologies) to 37oC in a water bath.  
 Discard supernatant from confluent iPSCs and wash with 1ml of PBS. 
 Add 1ml TrypLE to each well. 
 Incubate for 5min at 37oC until the cells have just begun to lift off plate 
 Harvest cells from each well into a conical tube with 9ml of sterile PBS, and mix. 
 Remove 10μl for cell count and centrifuge remaining cell suspension for 5min at 1500rpm 
using a standard benchtop centrifuge. 
 Discard supernatant and resuspend cells to concentration of 2.5 x 105/ml in mTeSR medium 
(Stem Cell Technologies).  Antibiotic/antimycotic may be added to the medium if desired. 
 Add Rho-kinase inhibitor (Y-27632) (Sigma-Aldrich) to give a final concentration of 10μM.   
 Add 2ml of cells in mTeSR medium to each matrigel-coated well (5 x 105 cells/well).  
 Incubate at 37oC, 5% CO2.  
 Change medium completely every day. 
 Cells may be passaged again once they became confluent (approximately every 5 – 7 days). 
 
A4.7 Primers to test expression of endogenous pluripotency genes 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
OCT3/4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCAACCAGTTGCCCCAAAC 
SOX2 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG 
NODAL GGGCAAGAGGCACCGTCGACATCA GGGACTCGGTGGGGCTGGTAACGTTTC 














A4.8 Primers to test expression of viral transgenes  
Transgene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
pMXs-hc-MYC  CAACAACCGAAAATGCACCAGCCCCAG TTATCGTCGACCACTGTGCTGCTG 
pMXs-hKLF4 ACGATCGTGGCCCCGGAAAAGGACC TTATCGTCGACCACTGTGCTGCTG 
pMXs-hOCT3/4 CCCCAGGGCCCCATTTTGGTACC TTATCGTCGACCACTGTGCTGCTG 
pMXs-hSOX2  GGCACCCCTGGCATGGCTCTTGGCTC TTATCGTCGACCACTGTGCTGCTG 
 
A4.9 Primers to test in vitro differentiation from EBs  
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 




























Appendix 5 Reagents and protocols for neuronal differentiation 
A5.1 Media for neuronal differentiation 
Supplemented Neurobasal medium A (NBM) 
500ml  Neurobasal-A Medium (Life Technologies) 
2% (v/v) B-27 Supplement (Life Technologies) 
1% (v/v) Insulin-Transferrin-Selenium-A (Life Technologies) 
1% (v/v) N2 Supplement (Life Technologies) 
2mM  GlutaMAX (Life Technologies) 
0.5% (v/v) Antibiotic/antimycotic (Life Technologies) 
 
For neurosphere formation add: 
10ng/ml EGF (Millipore) 
10ng/ml  bFGF (R&D Systems) 
 
A5.2 Preparation of non-adherent cell culture plates  
 Prepare 120mg/ml poly 2-hydroxyethyl methacrylate (poly-HEMA) (Sigma-Aldrich) solution 
in 95% ethanol, stirring overnight to dissolve 
 Filter using 0.22µm syringe-driven filter (Millipore) 
 Coat wells with poly-HEMA solution (50µl per well of a 96-well plate) 
 Allow poly-HEMA to evaporate at room temperature for approximately 3hrs 
 Rehydrate surface with supplemented neurobasal medium without EGF and bFGF for at least 
15min at 37°C 
 Aspirate and add supplemented neurobasal medium with EGF and bFGF, and return to 37°C 












A5.3 Preparation of poly-D-lysine and laminin-coated plates  
 Prepare 10µg/ml poly-D-lysine (Sigma-Aldrich) in PBS 
 Coat wells with poly-D-lysine solution (0.5ml per well of a 24-well plate) and incubate at 
room temperature for at least 30min, under UV light 
 Aspirate solution and wash three times with PBS.  Air dry. 
 Coat plates with 5µg/ml natural mouse laminin (Sigma-Aldrich) in PBS (0.5ml per well of a 
24-well plate) and incubate at 37°C for 60min 
 Remove laminin solution and wash three times with PBS 
 Add supplemented neurobasal medium without EGF or bFGF and return to the 37°C 













Appendix 6 Genomic integrity of iPSCs 
A6.1 Karyograms of 1519 fibroblasts (a), and the derived iPSC lines 1519A (b) 
and 1519C (c) 
 
























A6.2 Karyograms of SC Con fibroblasts (a), and the derived iPSC line iPS SC NHDF 
(b)  
a b 
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